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A B S T R A C T
Background
Tinea capitis is a common contagious fungal infection of the scalp in children. Systemic therapy is required for treatment and to prevent
spread. This is an update of the original Cochrane review.
Objectives
To assess the effects of systemic antifungal drugs for tinea capitis in children.
Search methods
We updated our searches of the following databases to November 2015: the Cochrane Skin Group Specialised Register, CENTRAL
(2015, Issue 10), MEDLINE (from 1946), EMBASE (from 1974), LILACS (from 1982), and CINAHL (from 1981). We searched
five trial registers and checked the reference lists of studies for references to relevant randomised controlled trials (RCTs). We obtained
unpublished, ongoing trials and grey literature via correspondence with experts in the field and from pharmaceutical companies.
Selection criteria
RCTs of systemic antifungal therapy in children with normal immunity under the age of 18 with tinea capitis confirmed by microscopy,
growth of fungi (dermatophytes) in culture or both.
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
We included 25 studies (N = 4449); 4 studies (N = 2637) were new to this update.
Terbinafine for four weeks and griseofulvin for eight weeks showed similar efficacy for the primary outcome of complete (i.e. clinical
and mycological) cure in three studies involving 328 participants with Trichophyton species infections (84.2% versus 79.0%; risk ratio
(RR) 1.06, 95% confidence interval (CI) 0.98 to 1.15; low quality evidence).
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Complete cure with itraconazole (two to six weeks) and griseofulvin (six weeks) was similar in two studies (83.6% versus 91.0%; RR
0.92, 95% CI 0.81 to 1.05; N = 134; very low quality evidence). In two studies, there was no difference between itraconazole and
terbinafine for two to three weeks treatment (73.8% versus 78.8%; RR 0.93, 95% CI 0.72 to 1.19; N = 160; low quality evidence). In
three studies, there was a similar proportion achieving complete cured with two to four weeks of fluconazole or six weeks of griseofulvin
(41.4% versus 52.7%; RR 0.92, 95% CI 0.81 to 1.05; N = 615; moderate quality evidence). Current evidence for ketoconazole
versus griseofulvin was limited. One study favoured griseofulvin (12 weeks) because ketoconazole (12 weeks) appeared less effective for
complete cure (RR 0.76, 95% CI 0.62 to 0.94; low quality evidence). However, their effects appeared to be similar when the treatment
lasted 26 weeks (RR 0.95, 95% CI 0.83 to 1.07; low quality evidence). Another study indicated that complete cure was similar for
ketoconazole (12 weeks) and griseofulvin (12 weeks) (RR 0.89, 95% CI 0.57 to 1.39; low quality evidence). For one trial, there was no
significant difference for complete cure between fluconazole (for two to three weeks) and terbinafine (for two to three weeks) (82.0%
versus 94.0%; RR 0.87, 95%CI 0.75 to 1.01; N = 100; low quality evidence). For complete cure, we did not find a significant difference
between fluconazole (for two to three weeks) and itraconazole (for two to three weeks) (82.0% versus 82.0%; RR 1.00, 95% CI 0.83
to 1.20; low quality evidence).
This update provides new data: in children with Microsporum infections, a meta-analysis of two studies found that the complete cure
was lower for terbinafine (6 weeks) than for griseofulvin (6-12 weeks) (34.7% versus 50.9%; RR 0.68, 95% CI 0.53 to 0.86; N =
334; moderate quality evidence). In the original review, there was no significant difference in complete cure between terbinafine (four
weeks) and griseofulvin (eight weeks) in children withMicrosporum infections in one small study (27.2% versus 60.0%; RR 0.45, 95%
CI 0.15 to 1.35; N = 21; low quality evidence).
One study provides new evidence that terbinafine and griseofulvin for six weeks show similar efficacy (49.5% versus 37.8%; RR 1.18,
95% CI 0.74 to 1.88; N = 1006; low quality evidence). However, in children infected with T. tonsurans, terbinafine was better than
griseofulvin (52.1% versus 35.4%; RR 1.47, 95% CI 1.22 to 1.77; moderate quality evidence). For children infected with T. violaceum,
these two regimens have similar effects (41.3% versus 45.1%; RR 0.91, 95% CI 0.68 to 1.24; low quality evidence). Additionally, three
weeks of fluconazole was similar to six weeks of fluconazole in one study in 491 participants infected with T. tonsurans and M. canis
(30.2% versus 34.1%; RR 0.88, 95% CI 0.68 to 1.14; low quality evidence).
The frequency of adverse events attributed to the study drugs was similar for terbinafine and griseofulvin (9.2% versus 8.3%; RR 1.11,
95% CI 0.79 to 1.57; moderate quality evidence), and severe adverse events were rare (0.6% versus 0.6%; RR 0.97, 95% CI 0.24 to
3.88; moderate quality evidence). Adverse events for terbinafine, griseofulvin, itraconazole, ketoconazole, and fluconazole were all mild
and reversible.
All of the included studies were at either high or unclear risk of bias in at least one domain. Using GRADE to rate the overall quality
of the evidence, lower quality evidence resulted in lower confidence in the estimate of effect.
Authors’ conclusions
Newer treatments including terbinafine, itraconazole and fluconazole are at least similar to griseofulvin in children with tinea capitis
caused by Trichophyton species. Limited evidence suggests that terbinafine, itraconazole and fluconazole have similar effects, whereas
ketoconazole may be less effective than griseofulvin in children infected with Trichophyton. With some interventions the proportion
achieving complete clinical cure was in excess of 90% (e.g. one study of terbinafine or griseofulvin for Trichophyton infections), but in
many of the comparisons tested, the proportion cured was much lower.
New evidence from this update suggests that terbinafine is more effective than griseofulvin in children with T. tonsurans infection.
However, in children with Microsporum infections, new evidence suggests that the effect of griseofulvin is better than terbinafine.
We did not find any evidence to support a difference in terms of adherence between four weeks of terbinafine versus eight weeks of
griseofulvin. Not all treatments for tinea capitis are available in paediatric formulations but all have reasonable safety profiles.
P L A I N L A N G U A G E S U M M A R Y
Antifungal medicines for treating children with ringworm
Background
Tinea capitis, or ringworm, is a fungal infection of the scalp caused mainly by two species of fungi calledTrichophyton andMicrosporum.
It is common in children. Most fungal infections can be treated with antifungal creams applied directly to the skin (topical treatments).
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However, because the fungal infection is found at the root of the hair follicles, where topical treatments cannot reach, tinea capitis
always requires medication administered by mouth so that the treatment spreads throughout the entire body (systemic treatments).
There are several different types of antifungal medicines available.
Review question
Which antifungal medicine is best for treating ringworm on the scalp in children?
Study characteristics
In November 2015, we searched for studies that used the gold standard design for clinical trials (randomised controlled trials) of
antifungal treatments taken by mouth. We found 25 studies in which 4449 children under 18 years (4 studies with 2637 children were
new to this update) had taken part.
Key results
With respect to complete cure (both cure of the infection and visible cure (i.e. fungal and clinical cure) low to moderate quality evidence
suggests that newer treatments such as terbinafine, itraconazole and fluconazole are at least as good as griseofulvin, the usual treatment in
children with tinea capitis caused by Trichophyton infections. However, new evidence in this update suggests that terbinafine may have
better effects than griseofulvin for completely curing children with T. tonsurans infection. By contrast, in children with Microsporum
infections, new evidence seems to indicate that griseofulvin is more effective than terbinafine.
Terbinafine, itraconazole and fluconazole appear to have similar effects in terms of the proportion of participants achieving complete
cure, whereas ketoconazole appears to be less effective than griseofulvin for children with tinea capitis caused by Trichophyton species.
However, the quality of this evidence is low. With some interventions, the proportion with complete clinical cure was in excess of 90%
(e.g. one study of terbinafine versus griseofulvin for Trichophyton infections), but in many of the comparisons tested, the proportion
cured was much lower.
The included studies reported on negative side effects, whichwere similarlymild and reversible for terbinafine, griseofulvin, itraconazole,
ketoconazole and fluconazole. They included skin-specific effects such as itching as well as abdominal discomfort, headache and nausea.
Quality of the evidence
The quality of the evidence in this review was generally low to moderate, so further research is likely to have an important effect on our
confidence in these results. Some evidence was even of very low quality. We still need more and better evidence to help us understand
the effectiveness and adverse events of systemic antifungal drugs for tinea capitis in children.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Terbinafine versus griseofulvin for children with tinea capitis
Patient or population: children with t inea capit is
Intervention: terbinaf ine
Comparison: griseofulvin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Griseofulvin Terbinafine
Proportion of partic-
ipants with complete
cure
Follow-up: 6-24 weeks
790 per 1000 837 per 1000
(774 to 908)
RR 1.06
(0.98 to 1.15)
328
(3 studies)
⊕⊕©©
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This outcome was for
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Trichophyton,
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(1 study)
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This outcome was
for children infected
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treatment durat ion
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RR 1.47
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weeks) in Trichophy-
ton infect ions; medium
treatment durat ion
Proportion of partic-
ipants with complete
cure
Follow-up: 10 weeks
451 per 1000 411 per 1000
(307 to 560)
RR 0.91
(0.68 to 1.24)
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(1 study)
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This outcome was for
children infected with T.
violaceum
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treatment durat ion
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Severe adverse events
Follow-up: mean 10
weeks
6 per 1000 6 per 1000
(1 to 23)
RR 0.97
(0.24 to 3.88)
1549
(1 study)
⊕⊕⊕©
Moderatec
This outcome was for
children infected with
Trichophyton and Mi-
crosporum
Terbinaf ine (6 weeks)
versus griseofulvin (6
weeks), medium treat-
ment durat ion
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDowngraded one level because 1 of the 3 studies was at high risk of bias, the other two studies were at unclear risk of bias.
bDowngraded one level for imprecision because the 95% conf idence interval around the pooled ef fect includes both ’no ef fect ’
and ’appreciable benef it ’ (1.25).
cDowngraded one level because the study was at unclear risk of bias.
dDowngraded one level because I2 = 86% which indicated substant ial heterogeneity.
eDowngraded one level for imprecision because total number of events was less than 300.
f Downgraded one level because one of the two included studies was at high risk of bias.
gDowngraded one level because the study was at high risk of bias.
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B A C K G R O U N D
This is an updated version of an original Cochrane review
(Gonzalez 2007).
Description of the condition
Tinea capitis is the medical term for an infection of the scalp
(also known as scalp ringworm) involving the skin and the hair
(Higgins 2000). It is caused by fungi (dermatophytes), mainly by
Trichophyton or Microsporum species that invade the hair shaft (
Higgins 2000). The clinical hallmark is one ormore patches of hair
loss, sometimes with a black dot pattern (studded with broken-
off hairs), which may be accompanied by inflammation, scaling,
pustules and itching (Chan 2004; Higgins 2000).
Tinea capitis is uncommon in adults and is mostly seen in pre-
teen children from disadvantaged communities in countries of all
income levels (Chan 2004; Ginter-Hanselmayer 2007). Over the
past 30 years, the reported incidence of tinea capitis has increased
significantly, as travel and migration have been associated with
changes in epidemiology and in distribution of the species of fungi
that are likely to cause tinea capitis (Aly 1999).
There are several species of dermatophytes characteristically asso-
ciated with tinea capitis. Trichophyton infections are most com-
mon inCentral America, theUnited States and in parts ofWestern
Europe. Cases ofMicrosporum infections are mainly seen in South
America, Southern and Central Europe, Africa and the Middle
East (Havlickova 2008).
Tinea capitis is contagious and can be transmitted by humans,
animals or objects carrying the fungus (Yu 2005). Carrier states
also exist where the fungus is present on the scalp but there is no
clinical infection (Pomeranz 1999). Although it is not life-threat-
ening in people with normal immunity, if left untreated there may
be persistent symptoms (Elewski 2000). The inflammatory form,
kerion, can result in scarring alopaecia (hair loss), or permanent
baldness (Elewski 2000).
Physicians should confirm the clinical diagnosis by identifying the
presence of fungi within the hair shaft in hair samples viewed un-
der the microscope, by growing the fungus from such samples in
laboratory conditions (mycological diagnosis) or both (Higgins
2000). The main methods of collecting samples for microbiolog-
ical diagnosis involve either scraping or brushing the scalp and
plucking the affected hairs (Fuller 2003). Looking at the sample
under a microscope is the fastest way to diagnose the infection,
and if the result is positive, treatment can commence immediately
(Fuller 2003). However, sometimes this method indicates some-
one does not have the condition even if they actually do. Cultur-
ing the scrapings is more sensitive and allows accurate identifica-
tion of the organism involved; however, this method may take up
to four weeks to provide a result (Fuller 2003; Gupta 1999). A
Wood’s light (filtered ultraviolet light) can be used to detect infec-
tions that fluoresce under this type of light such as M. canis and
M. audouinii, but it is not helpful in diagnosing T. tonsurans tinea
capitis (Elewski 2000).
Description of the intervention
The primary aim of treatment for tinea capitis is to achieve com-
plete clinical (signs and symptoms) and mycological cure (culture
negative) as quickly as possible with minimal adverse events. Most
superficial fungal infections can be treated topically (treatment ap-
plied directly to the skin), but tinea capitis always requires systemic
medication (which spreads throughout the entire body) because
the fungal infection is found at the root of the hair follicles, where
topical agents cannot reach (Higgins 2000). Topical medications
are only used as adjuvant therapy alongside systemic treatments
(Higgins 2000).
Tinea capitis mainly occurs in children, and there are poten-
tial problems with persuading them to take their medicine (Hay
2006). Factors enhancing adherence include an acceptable taste
and a short course of therapy. The latter factor may be important
in reducing the risk of adverse events.
Griseofulvin has traditionally been themost widely prescribed and
commonly used antifungal treatment for tinea capitis in clinical
practice (Bennett 2000; Friedlander 2000). The paediatric dosage
of griseofulvin is 10 to 25 mg/kg/d for six to eight weeks (Blumer
1999). It is still a relatively inexpensive drug and has been used
as the standard to evaluate many newer agents (Blumer 1999).
However, it has a bitter, unpleasant taste and should be taken
with meals for one to two months, which may affect adherence in
children (Bennett 2000). The liquid form is not always available.
Physicians increasingly consider treating tinea capitis with newer
antifungal agents, such as ketoconazole, itraconazole, terbinafine
or fluconazole (Friedlander 2000; Gonzalez 2007), but there is
concern regarding the use of these drugs in children because of the
possibility of rare but potentially serious side effects, such as liver
toxicity or drug interaction (Blumer 1999). These newer agents
are also expensive, which is an important consideration given that
tinea capitis is endemic in some of the poorest communities in the
world.
How the intervention might work
The main mechanism of action of griseofulvin is binding and in-
activating the microtubular proteins that are essential for mitosis
(cell division), thus arresting cell division of the fungal cell. Grise-
ofulvin also inhibits nucleic acid synthesis and impairs synthesis
of the fungal cell wall (Fuller 2014).
The mechanism of action of terbinafine involves inhibition of
squalene epoxidase, which is a key enzyme in sterol biosynthesis
in the fungal cell. This causes a deficiency in ergosterol within the
fungal cell membrane, which results in damage to the fungi cell
membrane (Abdel-Rahman 2005).
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Themechanism of action of the azole antifungals (e.g. itraconazole
and fluconazole) is inhibition of the cytochrome P450-dependent
enzyme lanosterol 14-alpha-demethylase, which is essential for the
conversion of lanosterol to ergosterol. Disruptions in the synthesis
of ergosterol lead to damage in the cell membrane of fungi and
damage to the fungal cell (Zonios 2008).
Why it is important to do this review
There is a choice between several systemic antifungal drugs for
treating children with tinea capitis.
We wish to determine the comparative efficacy and safety profiles
for these drugs. Furthermore, because of the worldwide distribu-
tion of this infection and the responsiveness of fungal species to
different drugs, the cost implications may also be very important.
We are also interested in comparing different lengths of treatment,
because shorter courses of treatment, if effective, would be prefer-
able to prolonged therapy, which may increase the risk of adverse
events and the likelihood of non-adherence.
O B J E C T I V E S
To assess the effects of systemic antifungal drugs for tinea capitis
in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Children with normal immunity under the age of 18 years with
tinea capitis confirmed by microscopy, growth of dermatophytes
in culture or both.
Types of interventions
We considered studies of all regimens of any systemic antifungal
drug interventions for tinea capitis using the following compar-
isons.
• Any systemic treatment versus no treatment or placebo.
• Comparison of two or more systemic therapies.
• Comparison of different doses and regimens of the same
systemic therapy.
• Comparison of systemic versus topical therapies.
We anticipated that studies would not focus on some systemic an-
tifungal agents, such as amphotericin B, flucytosine, caspofungin
or miconazole, because of either a lack of antifungal spectrum of
activity or a lack of acceptable toxicity in this population.
Types of outcome measures
Primary outcomes
1. The proportion of participants with complete cure, i.e.,
clinical and mycological cure. We defined complete clinical cure
as resolution of itching and clinical signs, such as redness,
scaling, and oedema. We defined complete mycological cure as
negative results on microscopy, no growth in culture or both.
2. The frequency and type of adverse events.
Secondary outcomes
1. The proportion of participants with clinical cure only.
2. Measurement of recurrence of the condition after the end
of the intervention period.
3. Percentage of drop-outs as a surrogate for participant
adherence.
4. The time taken to cure.
Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
For this update, we revised all our search strategies in line with
current Skin Group practices.We searched the following databases
up to 23rd November 2015:
• The Cochrane Skin Group Specialised Register using the
search strategy in Appendix 1.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) 2015, Issue 10, in The Cochrane Library using the
strategy in Appendix 2.
• MEDLINE via Ovid (from 1946) using the strategy in
Appendix 3.
• EMBASE via Ovid (from 1974) using the strategy in
Appendix 4.
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 5.
• CINAHL via EBSCO (Cumulative Index to Nursing and
Allied Health Literature, from 1981) using the strategy in
Appendix 6.
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Trial registers
We searched the following trial registers up to 30th November
2015 using the strategy in Appendix 7.
• The ISRCTN registry (www.controlled-trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).
• The EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
Searching other resources
References from included studies
We handsearched the bibliographies of included and excluded
studies for further references to relevant trials.
Unpublished literature
We sought information on unpublished and ongoing trials as well
as grey literature via correspondence with authors of published
studies and pharmaceutical companies. We consulted the Ring-
worm Committee of the European Confederation ofMedical My-
cology with regard to unpublished data.
Conference proceedings
We stated in the protocol that we would search the conference
proceedings frommajor dermatology and mycology meetings. We
were unable to search proceedings from mycology meetings, and
we understand that the Cochrane Skin Group is searching some of
the major dermatology meetings. We will search mycology meet-
ing abstracts for an update of this review.
Adverse events
We asked pharmaceutical companies for surveillance data on ad-
verse events.
Data collection and analysis
Some parts of the ’Methods’ section of this review use text that
was originally published in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).We included ’Summary of
findings’ tables in our review to summarise the primary outcomes
and assessed the quality of the body of evidence using the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias).
Selection of studies
For the original review, two authors (GB and UG) checked titles
and abstracts identified from the searches. If study design was not
clear from the abstract, then two authors (GB and UG) indepen-
dently reviewed the full text of the study. The authors also de-
cided which trials met the inclusion criteria and resolved any dis-
agreement by discussion between the authors or referred to a third
author (JT) when necessary. We listed the excluded studies and
reasons for exclusion in the ’Characteristics of excluded studies’
tables.
In this update, two authors (XC and MY) independently selected
the studies using the samemethods as before.We resolved discrep-
ancies between XC and MY through discussion with XH.
Data extraction and management
For the previously published version of the review, at least two
authors (TS and UG) extracted data independently using a pre-
designed data extraction form.We extracted reported data for cure
rates for all evaluated drugs, payingparticular attention to the doses
and frequencies of treatment administration (including ’pulsed’
regimens: administering the drug in waves with drug-free inter-
vals). We used the extracted data to populate the Characteristics of
included studies table. We resolved disagreements by discussion,
and we attempted to obtain missing information from authors
whenever possible.
In this update, two authors (XC andMY) independently extracted
the information from the newly included studies, and another
author (MZ) checked and compared the data extraction forms.
Assessment of risk of bias in included studies
Two authors (MY and XC) independently assessed the quality of
included studies according to the methods recommended in Sec-
tions 8.9 to 8.15of theCochraneHandbook for Systematic Reviews of
Interventions (Higgins 2011). We resolved discrepancies between
MY and XC by consulting another author (MZ).
In addition, we considered the following factors in order to ad-
dress other potential biases: reporting of sample size calculation,
definition of inclusion and exclusion criteria, reporting of type of
fungi involved, baseline comparability and statement of funding
resources.
• Low risk of bias: study appears to be free of other sources of
bias.
• High risk of bias: had extreme baseline imbalance; has been
claimed to have been fraudulent.
• Unclear risk of bias: insufficient information to permit
judgement of ’high’ or ’low’; had some drawbacks in either of the
items listed above except for extreme baseline imbalance.
Measures of treatment effect
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Weexpressed dichotomous data, such as proportionof participants
achieving complete cure, as risk ratios (RR). We analysed these in
ReviewManager (RevMan) using theMantel-Haenszel test, unless
stated otherwise (Revman 2014). We reported all outcomes with
95% confidence intervals (CIs) if possible.
We reported data that could not be combined by meta-analyses
narratively. We expressed the time taken to cure as a mean.
Unit of analysis issues
We did not consider internally controlled trials, such as those with
cross-over and within-participant designs, because even with a
washout period, they are inappropriate designs for systemic treat-
ment (because effects of antifungal therapy may endure over the
washout period, as most participants would experience a cure or at
least some improvement in the first period of a cross-over study).
For RCTs withmultiple intervention groups, we combined groups
to a single pair-wise comparison or split the shared group into two
or more groups and included two or more independent compar-
isons, as recommended by Cochrane (Higgins 2011).
Dealing with missing data
We contacted the trial authors of Elewski 2008 and Foster 2005 by
email on 9 January 2015 to ask for for missing data; however, we
did not receive any response. For the previous version of the review,
we sent an email (when an email address was available) to authors
of published studies asking for unpublished, ongoing trials and
grey literature.We also consulted the RingwormCommittee of the
EuropeanConfederation ofMedicalMycology about unpublished
data. We did not receive any positive response.
Assessment of heterogeneity
We assessed statistical heterogeneity in the analyses results by in-
specting the forest plots to detect non-overlapping CIs, and by
implementing the I2 statistic (with a value of at least 50% being
interpreted as moderate to high levels of heterogeneity (Higgins
2011).
Assessment of reporting biases
We planned to perform funnel plots for publication bias if 10
or more studies contributed data. However, we could not carry
this out because of the small number of included studies for each
outcome.
Data synthesis
We used Revman 2014 to combine some outcomes. To estimate
differences between treatments, we pooled trials that evaluated
similar interventions using meta-analysis based on a random-ef-
fects model (Mantel-Haenszel method), if possible, to calculate a
weighted treatment effect across trials.
For each trial, we calculated complete cure at follow-up based on
the reported mycological and clinical results. Although we failed
to specify the acceptable window for the timing in the primary
outcome assessment in the original protocol, we decided during
the course of the review to combine studies that recorded primary
outcomes at 12 to 20 weeks on the basis that these are the range of
time periods that best reflect clinical decision-making in practice.
When necessary, we categorised the duration of treatment into
three groups.
• Short term (closest to 2 weeks, but between 1 and 4 weeks).
• Medium term (closest to 6 weeks, but between 5 and 8
weeks).
• Long term (closest to 12 weeks, but between 9 and 14
weeks).
Subgroup analysis and investigation of heterogeneity
In the original protocol we planned to perform subgroup analyses
where adequate information was given for severity of infection,
geographical setting of the trial, and dermatophyte species, whose
variation may play an important role in the response to treatment.
To explore reasons for heterogeneity in the review, we performed
subgroup analyses where the trial report gave adequate informa-
tion, based on dermatophyte species variation and duration of
treatment.
Sensitivity analysis
In the original protocol we planned to exclude some studies or
subgroups in sensitivity analyses, but we did not perform any
sensitivity analyses in this review.
R E S U L T S
Description of studies
Results of the search
The electronic database searches for this update yielded 85 stud-
ies after duplicates were removed. We discarded 79 studies after
screening titles and abstract and examined the full text of the re-
maining 6 records.We excluded two further studies (Koumantaki-
Mathioudaki 2005; Shemer 2013; see ’Characteristics of excluded
studies’), and we identified four new studies for inclusion in this
update (Deng 2011; Elewski 2008; Foster 2005; Khan 2011; see
’Characteristics of included studies’).Wedidnot identify any other
studies in our searches of ongoing trial registers or from other re-
sources.
The original review identified 21 trials of systemic treatments for
tinea capitis (Gonzalez 2007).
Please see Figure 1 for the study flow diagram.
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Figure 1. Study flow diagram.
Included studies
In total, we included 25 studies that randomised 4449 participants
(Characteristics of included studies). We found no other trials that
compared an active treatment to placebo. The trials compared dif-
ferent active treatments: either different drugs or different regi-
mens of the same drug.
Design
All included studies were parallel group RCTs. Ten of them had
a multi-arm design (Deng 2011; Foster 2005; Friedlander 2002;
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Gupta 2001;Haroon 1996; Kullavanijaya 1997; Lipozencic 2002;
Memisoglu 1999; Solomon 1997; Talarico Filho 1998).
Sample size
Only six studies reported a sample size calculation (Elewski
2008; Foster 2005; Fuller 2001, Khan 2011; Lipozencic 2002;
Ungpakorn 2004).
Regarding the sample size, we organised the studies into three
distinct groups.
• Nine studies were small (N < 50) (Cáceres-Ríos 2000;
Dastghaib 2005; Hamm 1999; López-Gómez 1994;
Martínez-Roig 1988; Rademaker 1998; Solomon 1997; Tanz
1985; Ungpakorn 2004).
• Eight studies were medium (N = 51 to 150) (Deng 2011;
Gan 1987; Jahangir 1998; Khan 2011; Kullavanijaya 1997;
Memisoglu 1999; Talarico Filho 1998; Tanz 1988).
• Eight studies were large (N > 150) (Elewski 2008; Foster
2005; Friedlander 2002; Fuller 2001; Gupta 2001; Haroon
1995; Haroon 1996; Lipozencic 2002).
Settings
The studies included in this review took place in many parts of
the world.
Eight took place in Asia: four in Pakistan (Haroon 1995; Haroon
1996; Jahangir 1998; Khan 2011); two in Thailand (Kullavanijaya
1997; Ungpakorn 2004); one in China (Deng 2011); and one in
Iran (Dastghaib 2005).
Five studies were carried out in Europe: one in Germany (Hamm
1999); one in Turkey (Memisoglu 1999); two in Spain (López-
Gómez 1994; Martínez-Roig 1988); and one in the UK (Fuller
2001).
Two studies were from South America (Cáceres-Ríos 2000;
Talarico Filho 1998), five were completed in North America
(Friedlander 2002; Gan 1987; Solomon 1997; Tanz 1985; Tanz
1988), and one study took place in New Zealand (Rademaker
1998).
Four of the studies were conducted in several locations: Gupta
2001 took place in the United States and South Africa; Lipozencic
2002, in Europe and South America; Elewski 2008 in the United
States, Peru, theUnitedKingdom, Egypt, Russia and South Africa;
and Foster 2005, in the United States, Guatemala, Chile, Costa
Rica and India.
Participants
With regard to age, most of the participants of included studies
were older than two years. Cáceres-Ríos 2000 and Talarico Filho
1998 included participants as young as one year. Another study
involved participants as young as six months of age (Gupta 2001).
The upper age limit in the majority of the trials was 16 years,
although Haroon 1995 included participants ranging in age from
2 to 65 years. In that trial, 94 of the 105 participants were under
12 years of age, so we assumed all the participants were under 16
years of age and therefore analysed the whole population. Three
other studies reported a total of four adults in their samples (
Kullavanijaya 1997; Lipozencic 2002; López-Gómez 1994).
Fungal type
Each of the 25 studies reported the types of fungi cultured; some
provided general percentages and reported exact proportions of
the types of fungi within each arm. The Trichophyton species pre-
dominated over Microsporum species. T. tonsurans and M. canis
were responsible for causing infection in the highest proportion
of participants. T. tonsurans was the most commonly identified
fungus in 11 studies (Cáceres-Ríos 2000; Elewski 2008; Foster
2005; Friedlander 2002; Fuller 2001; Gan 1987; Ginsburg 1987;
Khan 2011; Solomon 1997; Tanz 1985; Tanz 1988); T. violaceum
was the predominant fungus in four studies (Deng 2011; Haroon
1995; Haroon 1996; Jahangir 1998); in one study, the propor-
tions of M. canis and T. tonsurans were the same (Hamm 1999);
and M. canis was the main fungus in five trials (Lipozencic 2002;
López-Gómez 1994;Memisoglu 1999; Rademaker 1998; Talarico
Filho 1998). Three trials identified the causative fungi, but their
relative frequencies were not provided so it was impossible to de-
termine the frequencies: T. tonsurans and M. ferrugineum were
identified in one study (Kullavanijaya 1997), T. tonsurans and T.
violaceum in another (Gupta 2001), and T. mentagrophytes and
M. canis in a third study (Martínez-Roig 1988). In addition, one
study failed to classify the causative species of fungi (Memisoglu
1999).
Interventions
The standard dose for griseofulvin used in trials is generally 10 to
20 mg/kg/d or 125 mg/d in participants weighing 10 to 20 kg;
250 mg/d in those weighing from 20 to 40 kg and 500 mg/d for
those over 40 kg. Unless otherwise stated, the standard dosing for
terbinafine studies was 62.5 mg/d in participants weighing from
10 to 20 kg; 125 mg/d from 20 to 40 kg, and 250 mg/d over 40
kg.
In total, we studied five different antifungal agents: griseofulvin,
terbinafine, itraconazole, fluconazole and ketoconazole.
Comparisons
We evaluated a variety of regimens, including between-drug
and within-drug comparisons. We considered griseofulvin to
be the standard because it is the oldest agent, and 17 studies
used it as a control. Of the 25 included studies, 17 compared
griseofulvin as standard therapy with terbinafine (Cáceres-Ríos
2000; Deng 2011; Elewski 2008; Fuller 2001; Gupta 2001;
Haroon 1995; Khan 2011; Lipozencic 2002; Memisoglu 1999;
Rademaker 1998), itraconazole (Gupta 2001; López-Gómez
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1994;Memisoglu 1999), ketoconazole (Gan 1987;Martínez-Roig
1988; Tanz 1985; Tanz 1988), or fluconazole (Dastghaib 2005;
Foster 2005; Gupta 2001; Memisoglu 1999). Gupta 2001 and
Memisoglu 1999 compared griseofulvin, itraconazole andflucona-
zole.
Ten studies compared terbinafine versus griseofulvin (Cáceres-
Ríos 2000; Deng 2011; Elewski 2008; Fuller 2001; Gupta
2001;Haroon 1995; Khan 2011; Lipozencic 2002; Memisoglu
1999; Rademaker 1998), two versus itraconazole (Gupta 2001;
Memisoglu 1999) and two versus fluconazole (Gupta 2001;
Memisoglu 1999). Seven studies compared different treatment
duration regimens for terbinafine (Deng 2011; Friedlander 2002;
Hamm 1999; Haroon 1996; Kullavanijaya 1997; Lipozencic
2002; Talarico Filho 1998), and one compared different doses
(Ungpakorn 2004).
Three studies (Gupta 2001; López-Gómez 1994; Memisoglu
1999) compared itraconazole with other antifungals: three
with griseofulvin (Gupta 2001; López-Gómez 1994; Memisoglu
1999), two with terbinafine (Gupta 2001; Memisoglu 1999) and
two with fluconazole (Gupta 2001; Memisoglu 1999). Ketocona-
zole was compared with griseofulvin in four trials (Gan 1987;
Martínez-Roig 1988; Tanz 1985; Tanz 1988).
Five trials studied fluconazole (Dastghaib 2005; Foster 2005;
Gupta 2001; Memisoglu 1999; Solomon 1997); four with grise-
ofulvin (Dastghaib 2005; Foster 2005; Gupta 2001; Memisoglu
1999), two with terbinafine (Gupta 2001; Memisoglu 1999), two
with itraconazole (Gupta 2001; Memisoglu 1999), one by itself
with varying doses (Solomon 1997), and one by itself with differ-
ent durations of treatment (Foster 2005).
Outcomes
Primary outcomes
All but three studies reported the proportion of participants with
complete cure, which was our pre-specified primary outcome (
Martínez-Roig 1988; Rademaker 1998; Tanz 1985). Most of the
studies reported complete cure at 12 to 16weeks but three reported
at 8 weeks (Dastghaib 2005; Deng 2011; Gan 1987), one at 10
weeks (Elewski 2008), one at 2 weeks, 4 weeks, 8 weeks and one
year (Deng 2011), one at 3, 6 and 10 weeks (Foster 2005), one at
2, 4 and 6 weeks (Khan 2011), and two at 20 to 24 weeks (Fuller
2001; Ungpakorn 2004).
Three studies failed to report our other primary outcome: adverse
events (Gan 1987; Kullavanijaya 1997; Solomon 1997).
Secondary outcomes
Fourteen studies reported the proportion of participants with
clinical cure only, which was our first pre-specified secondary
outcome (Cáceres-Ríos 2000; Elewski 2008; Friedlander 2002;
Gupta 2001; Hamm 1999; Haroon 1996; Lipozencic 2002;
López-Gómez 1994; Martínez-Roig 1988; Memisoglu 1999;
Rademaker 1998; Solomon 1997; Talarico Filho 1998; Tanz
1988).
Only three studies reported recurrence of the condition after the
end of the intervention period, which was our second pre-speci-
fied secondary outcome (Martínez-Roig 1988; Rademaker 1998;
Solomon 1997).
Twelve studies reported the percentage of drop-outs as a surro-
gate for participant adherence, our third pre-specified secondary
outcome (Deng 2011; Friedlander 2002; Fuller 2001; Gan 1987;
Gupta 2001;Hamm1999; Lipozencic 2002; López-Gómez 1994;
Memisoglu 1999; Talarico Filho 1998; Tanz 1985; Tanz 1988).
Four studies reported the time taken to cure, our fourth pre-speci-
fied secondary outcome (Friedlander 2002; Gan 1987; Lipozencic
2002; Martínez-Roig 1988).
Follow-up
The follow-up period ranged from six weeks in Martínez-Roig
1988, Khan 2011 and Tanz 1985 to one year in Deng 2011.
Although most studies had a 12-week follow-up period, five tri-
als had longer follow-up periods ranging from 16 to 24 weeks
(Fuller 2001; Kullavanijaya 1997; Lipozencic 2002; Solomon
1997; Ungpakorn 2004). In addition, two trials had a 10-week
follow-up period (Elewski 2008; Foster 2005).
Other
Some of the studies did not provide detailed information on the
clinical setting or baseline characteristics of sex, age and infec-
tion severity, or they did not report the comparability between
arms or the duration of symptoms or signs. Rademaker 1998
did not compare the baseline characteristics at all, and two trials
did not report the information on comparability (Martínez-Roig
1988; Solomon 1997). Finally, only five trials reported informa-
tion about the severity of the infection (Cáceres-Ríos 2000; Deng
2011; Elewski 2008; Gupta 2001; Tanz 1985). For the 25 studies,
themost common reason for excluding a participant from the trial
was treatment with any antifungal agent within one month prior
to entering the trial.
Excluded studies
We provide details of the excluded studies in the ’Characteristics
of excluded studies’ table.
In this update, we excluded Koumantaki-Mathioudaki 2005 and
Shemer 2013 because we found that neither of them were RCTs
after reading the full texts.
The original review excluded 3 of the initial 24 trials of systemic
treatments for tinea capitis because they evaluated the therapy
for the inflammatory component (kerion) caused by tinea capitis
infection (Ginsburg 1987; Honig 1994; Hussain 1999).
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Studies awaiting classification
One trial reported in a conference paper appeared to meet the
inclusion criteria, but as we could not obtain further informa-
tion, we could neither include or exclude it (Pather 2006). See
Characteristics of studies awaiting classification.
Risk of bias in included studies
Please see Figure 2 for our judgements about each ’Risk of bias’
itempresented as percentages across all included studies and Figure
3 for the judgements about each domain for all the included stud-
ies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation
All included studies stated or implied that treatment allocation
was randomised; however, there were only four studies that re-
ported an adequate generation method of randomisation: two
used a computer-generated random number table (Fuller 2001;
Martínez-Roig 1988), and two used a table of random numbers
(Elewski 2008; Gan 1987).
Allocation concealment
Only two studies reported adequate allocation concealment (
Elewski 2008; Foster 2005).
Blinding
Performance bias
Five included studies reported that participants or personnel were
not blinded; therefore, we judged these studies to be at high risk
of performance bias (Dastghaib 2005; Fuller 2001; Gan 1987;
Rademaker 1998; Talarico Filho 1998).
We judged the other 20 studies as being at unclear risk of per-
formance bias, either because they did not report blinding of
participants or personnel (Hamm 1999; Haroon 1995; Jahangir
1998; Khan 2011), or because they did not describe the method
of blinding (Deng 2011; Elewski 2008; Foster 2005; Friedlander
2002; Gupta 2001; Haroon 1995; Haroon 1996; Kullavanijaya
1997; Lipozencic 2002; López-Gómez 1994; Martínez-Roig
1988; Memisoglu 1999; Solomon 1997; Tanz 1985; Tanz 1988;
Ungpakorn 2004).
Detection bias
Five included studies reported that outcome assessors were not
blinded; therefore, we judged these studies to be at high risk of
detection bias (Deng 2011; Fuller 2001; Gan 1987; Rademaker
1998; Talarico Filho 1998).
We deemed the other 20 studies to be at unclear risk of detection
bias, either because they did not report blinding of outcome as-
sessors (Cáceres-Ríos 2000; Hamm 1999; Jahangir 1998; Khan
2011), or because they did not describe the method of blind-
ing (Dastghaib 2005; Elewski 2008; Foster 2005; Friedlander
2002; Gupta 2001; Haroon 1995; Haroon 1996; Kullavanijaya
1997; Lipozencic 2002; López-Gómez 1994; Martínez-Roig
1988; Memisoglu 1999; Solomon 1997; Tanz 1985; Tanz 1988;
Ungpakorn 2004).
Incomplete outcome data
Overall, after randomising 4449 people, 471 participants (10.6%)
were lost. Only six studies performed intention-to-treat (ITT)
analyses (Elewski 2008; Foster 2005; Friedlander 2002; Fuller
2001; Lipozencic 2002; Talarico Filho 1998).
We considered 14 studies to be at low risk of attrition bias be-
cause either less than 10% of participants dropped out, or be-
cause the drop-outs were between 10% and 20% but balanced in
numbers across intervention groups (Cáceres-Ríos 2000; Elewski
2008; Foster 2005; Gupta 2001; Hamm 1999; Haroon 1995;
Haroon 1996; Jahangir 1998; Khan 2011; Kullavanijaya 1997;
López-Gómez 1994; Martínez-Roig 1988; Talarico Filho 1998;
Ungpakorn 2004).
We judged 10 studies to be at high risk of attrition bias because
either more than 20% of participants dropped out, whether ITT
analysiswas performedor not (Friedlander 2002; Fuller 2001;Gan
1987; Lipozencic 2002; Solomon 1997; Tanz 1985; Tanz 1988),
or the drop-outs were between 10%and 20%but ITT analysis was
not performed (Dastghaib 2005; Deng 2011; Memisoglu 1999).
Rademaker 1998 was at unclear risk of attrition bias, as it did not
provide sufficient information on drop-outs to make a judgement.
Selective reporting
All included studies reported findings on all outcomes listed in
the ’Methods’ section; therefore, we judged all included studies as
being at low risk of reporting bias. However, we did not have access
to the original study protocols in any of the included studies.
Other potential sources of bias
Ninteen of the 25 included studies did not report the method
of sample size calculation (Cáceres-Ríos 2000; Dastghaib 2005;
Deng 2011; Friedlander 2002; Gan 1987; Gupta 2001; Hamm
1999; Haroon 1995; Haroon 1996; Jahangir 1998; Kullavanijaya
1997; López-Gómez 1994; Martínez-Roig 1988; Memisoglu
1999;Rademaker 1998; Solomon1997;Talarico Filho 1998;Tanz
1985; Tanz 1988).
Nine studies did not report the funding sources (Dastghaib 2005;
Friedlander 2002; Gan 1987; Gupta 2001; Jahangir 1998; Khan
2011; Memisoglu 1999; Rademaker 1998; Solomon 1997).
Three studies did not report their inclusion or exclusion criteria
(Hamm 1999; Kullavanijaya 1997; Rademaker 1998); two other
studies did not report baseline comparability (Khan 2011; Tanz
1988). However, whether these factors introduced bias to the re-
sults remained unclear. We therefore judged these studies as being
at unclear risk of other bias.
In addition, all but two of the included studies reported the
proportion of different types of fungi (Kullavanijaya 1997;
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Martínez-Roig 1988).Most included studies recruited children in-
fected with both Trichophyton and Microsporum. Lipozencic 2002
and Ungpakorn 2004 only recruited children infected with Mi-
crosporum, while Friedlander 2002, Gupta 2001, Jahangir 1998
and Solomon 1997 only recruited children infected with Tri-
chophyton. Tanz 1985 recruited children infected with Trichophy-
ton,Scopulariopsis,Penicillium and unidentified fungus. We list the
details of type of fungi in each study in the ’Characteristics of
included studies’ tables.
Effects of interventions
See: Summary of findings for the main comparison Complete
cure and adverse events for terbinafine versus griseofulvin in
children with tinea capitis; Summary of findings 2 Complete
cure for itraconazole versus griseofulvin in children infected
with Trichophyton and Microsporum; Summary of findings 3
Complete cure for itraconazole versus terbinafine in children
infected with Trichophyton; Summary of findings 4 Complete
cure for ketoconazole versus griseofulvin in children infected
with Trichophyton; Summary of findings 5 Complete cure for
fluconazole versus griseofulvin in children with tinea capitis;
Summary of findings 6 Complete cure for fluconazole versus
terbinafine in children infected with Trichophyton; Summary of
findings 7 Complete cure for fluconazole versus itraconazole in
children infected with Trichophyton; Summary of findings 8
Complete cure for different durations of fluconazole in children
infected with T. tonsurans and M. canis
Numbers given show the total numbers of participants included
in the analysis. When it was possible to calculate an effect size,
we reported this with the 95% confidence interval (CI). We used
the P value of 0.05 as the cutoff value to determine statistical
significance; when P values were below this threshold, we stated
whether the result favoured the intervention group or the control
condition. In the text below, we report an I² statistical value for
heterogeneity as moderate or high if it exceeds 50%.
We have presented the results for our pre-specified outcomes below
under the following 13 comparisons.
1. Terbinafine versus griseofulvin (short treatment duration).
2. Terbinafine versus griseofulvin in Trichophyton infections
(medium treatment duration).
3. Terbinafine (medium- and long-term treatment) versus
griseofulvin in Microsporum infections.
4. Terbinafine short- versus long-term.
5. Terbinafine standard dose compared to terbinafine double
dose.
6. Itraconazole versus griseofulvin.
7. Itraconazole versus terbinafine.
8. Ketoconazole versus griseofulvin.
9. Fluconazole versus griseofulvin.
10. Fluconazole versus terbinafine.
11. Fluconazole versus itraconazole.
12. Fluconazole dosages (1.5, 3.0 and 6.0 mg/kg/d).
13. Treatment durations of fluconazole (short-term versus
medium-term).
We have summarised the results of included studies that we could
not combine inmeta-analyses because of differences between stud-
ies in terms of design. We present the results of studies that could
not be pooled inmeta-analyses using data and information derived
from the reports of individual studies.
We produced eight ’Summary of findings’ tables for the first pri-
mary outcome of complete clinical cure (Summary of findings
for the main comparison; Summary of findings 2; Summary
of findings 3; Summary of findings 4; Summary of findings 5;
Summary of findings 6; Summary of findings 7; Summary of
findings 8). In Summary of findings for the main comparison we
also reported our primary outcome of adverse events.
1. Terbinafine (2 to 4 weeks) versus griseofulvin (6 to
8 weeks); short treatment duration; 6 to 24 weeks
follow-up
Eight studies assessed the efficacy of terbinafine used in the short-
term for 2 to 4 weeks as compared to griseofulvin (used for 8
weeks) (Cáceres-Ríos 2000;Deng 2011; Fuller 2001;Gupta 2001;
Haroon 1995; Khan 2011; Memisoglu 1999; Rademaker 1998).
Primary outcomes
Complete cure, i.e. clinical and mycological cure, at 12 to 24
weeks follow-up
Five studies reported on complete cure (Cáceres-Ríos 2000; Fuller
2001; Gupta 2001;Haroon 1995;Memisoglu 1999). This update
did not identify any new studies addressing this outcome.
A pooled analysis of the five studies found that the difference in the
proportion of participants with complete cure between four weeks
of terbinafine and eight weeks of griseofulvin was not statistically
significant (73.6% versus 68.4%; RR 1.08, 95% CI 0.94 to 1.24;
Analysis 1.1).
Trichophyton infections
Three studies included participants with Trichophyton infections (
Fuller 2001; Gupta 2001;Haroon 1995). Haroon 1995 compared
terbinafine for 4weekswith 10mg/kg/d of griseofulvin for 8weeks
in 105 participants, of whom87.6%hadT. violaceum tinea capitis.
The proportion of participants with complete cure at week 12 was
93% (52/56) in the terbinafine group and 80% (39/49) in the
griseofulvin group (RR 1.17, 95% CI 0.99 to 1.37; Analysis 1.1).
Fuller 2001 recruited 210 participants and included 147 in the
ITT analyses. Trichophyton infection accounted for 84.4% of the
terbinafine group (N=65) and 82.9%of the griseofulvin group (N
= 58). At 24 weeks, the proportion of participants with complete
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cure was 69.2% (45/65) in the terbinafine group and 67.2% (39/
58) in the griseofulvin group (RR1.03, 95%0.81 to 1.31; Analysis
1.1)
Gupta 2001 compared 50 participants in each treatment group
with infections caused by T. tonsurans and T. violaceum. In this
trial, administration of terbinafine for 2 to 3 weeks was compared
with microsize griseofulvin 20 mg/kg for 6 weeks. The proportion
of participants with complete cure at week 12 was 94% (47/50)
for the terbinafine group and 92% (46/50) for the griseofulvin
treated group (RR 1.02, 95% CI 0.92 to 1.14; Analysis 1.1).
In the pooled analysis of 328 participants with a confirmed Tri-
chophyton infection, terbinafine for four weeks and griseofulvin
for 8 weeks showed similar efficacy in three studies (84.2% ver-
sus 79.0%; RR 1.06 95% CI 0.98 to 1.15; low quality evidence;
Analysis 1.1; Fuller 2001; Gupta 2001; Haroon 1995; Summary
of findings for the main comparison).
Microsporum infections
In Fuller 2001, the proportion of the 21 children with Microspo-
rum infections who achieved complete cure in the terbinafine (for
fourweeks) group and the griseofulvin (for eightweeks) groupwere
27.2% (3/11) and 60.0% (6/10), respectively (RR 0.45, 95% CI
0.15 to 1.35; N = 21; low quality evidence; Analysis 1.1; Summary
of findings for the main comparison).
Mixed Trichophyton and Microsporum infections
Cáceres-Ríos 2000 and Memisoglu 1999 included participants
with Trichophyton and Microsporum infections but did not report
results separately. In Memisoglu 1999, complete cure at the final
follow-up visit (week 12) was 39% (15/39) for the group treated
with four weeks of terbinafine compared with 44% (17/39) in
the group treated with eight weeks of ultra microsized griseoful-
vin (RR 0.88, 95% CI 0.52 to 1.50; Analysis 1.1). There was a
similar proportion of participants with complete cure within the
subgroups infected with M. canis (48% of participants) and Tri-
chophyton species according to the principal investigators of that
study. The other study, Cáceres-Ríos 2000, evaluated terbinafine
for four weeks versus microsized griseofulvin for 8 weeks in 50
participants from Peru and found a significant increase in com-
plete cure with terbinafine (76%; 19/25) compared to griseofulvin
(44%; 11/25) measured at 12 weeks (RR 1.73, 95% CI 1.05 to
2.83; Analysis 1.1). The causative organisms were T. tonsurans and
M. canis, at 74% and 26%, respectively.
A pooled analysis of the two studies showed no significant differ-
ence between the groups (53.1% versus 43.8%; RR 1.24, 95% CI
0.64 to 2.42; Analysis 1.1).
Adverse events
Seven studies reported this outcome (Cáceres-Ríos 2000; Deng
2011; Fuller 2001; Gupta 2001; Haroon 1995; Khan 2011;
Memisoglu 1999), of which two were new studies added in this
update (Deng 2011; Khan 2011).
Khan 2011 reported that the incidence of adverse events was com-
parable between the two groups, with none of participants show-
ing serious side effects, except for nausea and mild abdominal dis-
comfort. Deng 2011 reported one case of vomiting in the griseo-
fulvin group and no side effects in the terbinafine group.
Drug-related adverse events
In the open study (Fuller 2001), 36 participants in the terbinafine
group reported 57 adverse events (pruritus, urticaria, skin scaling),
and 4 participants withdrew from the study due to adverse events
(vomiting, dizziness, urticaria and weight loss). A total of 52 ad-
verse events, predominantly abdominal discomfort and vomiting,
were detected in 27 participants in the griseofulvin group, and
1 participant withdrew from the study due to abdominal pain,
headache and vomiting.Therewas no significant difference regard-
ing adverse events that might be attributed to either of the study
drugs in the terbinafine (26/77) or griseofulvin (17/70) group
(33.8% versus 24.3%, RR 1.39, 95% CI 0.83 to 2.34; Analysis
1.2).
Some studies reported good tolerability for terbinafine because
there were no or few adverse events, and these had either an
uncertain or no relationship to the treatment (Cáceres-Ríos
2000; Haroon 1995). Haroon 1995 reported tonsillitis, cuta-
neous infestations, raised hepatic enzymes, raised triglycerides and
eosinophilia, and Memisoglu 1999 reported mild elevated triglyc-
erides, with an uncertain relationship to the drug. The follow-
ing adverse events were reported less commonly and may not
have been caused by griseofulvin: skin infections, skin infestations,
elevated hepatic enzymes, elevated serum triglycerides, elevated
serum uric acid, anaemia, eosinophilia, leucocytosis and granulo-
cytopenia (Haroon 1995;Memisoglu 1999).Gupta 2001 reported
three gastric problems and three cases of nausea in the griseofulvin
group. Griseofulvin was associated with a small number of adverse
events in other trials.
Secondary outcomes
None of the included studies reported measurement of recurrence
of the condition after the end of the intervention period or the
time taken to cure.
Proportion of participants with clinical cure only
Three studies reported the proportion of patients achieving only
a clinical cure (Deng 2011; Gupta 2001; Khan 2011); two were
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new studies added in this update (Deng 2011; Khan 2011). We
did not pool the data from these studies because of significant
clinical heterogeneity, especially due to the various fungal types in
different studies.
Deng 2011 compared the effects of terbinafine for two weeks,
terbinafine for four weeks, and griseofulvin for treating partic-
ipants infected with T. violaceum (55.1%), A. vanbreuseghemi
(30.6%) and T. tonsurans (14.3%). Investigators found that the
clinical cure inweek 8was 85.2%(23/27) in the 2-week terbinafine
group and 84.2% (16/19) in the griseofulvin group (RR 1.01,
95% CI 0.79 to 1.30; Analysis 1.3). The corresponding rate was
78.3% (18/23) in the 4-week terbinafine group and 84.2% (16/
19) in the griseofulvin group (RR 0.93, 95% CI 0.70 to 1.24;
Analysis 1.3). When the follow-up was extended to one year, all
participants in the three groups achieved clinical cure.
Gupta 2001 reported that the proportion of participants with
clinical cure was determined at the end of treatment (week four for
terbinafine and week six for griseofulvin) showing better results in
the griseofulvin group (70%, 35/50) than in the terbinafine group
(40%, 20/50) (RR 0.57, 95% CI 0.39 to 0.84; Analysis 1.3).
Khan 2011 compared the effects of terbinafine for four weeks
and griseofulvin for treating patients infected with T. tonsurans
(75%) and M. canis (22%). The proportion of participants with
clinical cure only at week six seemed to be higher in the terbinafine
group than in the griseofulvin group, but the difference was not
statistically significant (70% versus 55%; RR 1.27, 95% CI 0.96
to 1.69; Analysis 1.3).
Percentage of drop-outs as a surrogate for participant
adherence
Four studies reported on the percentage of drop-outs as a surrogate
for participant adherence (Deng 2011; Fuller 2001; Gupta 2001;
Memisoglu 1999), including one new study added to this update
(Deng 2011). Deng 2011 reported no drop-outs in the terbinafine
group and one in the griseofulvin group (5.3%, 1/19) (RR 0.13,
95% CI 0.01 to 3.08; Analysis 1.4).
The percentage of drop-outs was 35.9% (37/103) versus 24.2%
(26/107) (RR 1.48, 95% CI 0.97 to 2.26 Fuller 2001); 4.0% (2/
50) versus 8.0% (4/50) (RR 0.50, 95% CI 0.10 to 2.61 Gupta
2001); 10.2% (4/39) versus 17.9% (7/39) (RR 0.57, 95% CI
0.18 to 1.80; Memisoglu 1999) in the terbinafine and griseofulvin
groups, respectively (see Analysis 1.4). Only one study reported
no drop-outs from either treatment arm (Haroon 1995).
2. Terbinafine (6 weeks) versus griseofulvin (6 weeks)
in Trichophyton infections; medium treatment
duration; 10 weeks follow-up
Primary outcomes
Complete cure, i.e. clinical and mycological cure
Two studies reported on complete cure (Elewski 2008; Lipozencic
2002), including one new study added to this update (Elewski
2008). This study included 1549 participants and compared
terbinafine (5 to 8 mg/kg for 6 weeks) with griseofulvin (10 to 20
mg/kg for 6 weeks) in children with tinea capitis. In this study,
49.3% of the participants were infected with T. tonsurans, 15.6%
were infected with T. violaceum, and 15.1% were infected withM.
canis.
Trichopyton tonsurans infections
In those infected with T. tonsurans, 52.1% (264/507) of partici-
pants in the terbinafine group versus 35.4% (91/257) in the grise-
ofulvin group achieved a complete cure (RR 1.47, 95%CI 1.22 to
1.77; N = 764; moderate quality evidence; Analysis 2.1; Summary
of findings for the main comparison).
Trichopyton violaceum infections
In those infected with T. violaceum, 41.3% (66/160) of partici-
pants in the terbinafine group versus 45.1% (37/82) in the grise-
ofulvin group achieved a complete cure (RR 0.91, 95% CI 0.68
to 1.24; N = 242; low quality evidence; Analysis 2.1; Summary of
findings for the main comparison).
The pooled data of participants infected with Trichophyton in-
dicated that there was no significant difference between the
terbinafine group and the griseofulvin group (49.5% versus
37.8%; RR 1.18, 95% CI 0.74 to 1.88; N = 1006; low qual-
ity evidence; Analysis 2.1; Summary of findings for the main
comparison).
Adverse events
Drug-related adverse events
Both Elewski 2008 and Lipozencic 2002 reported this outcome.
New evidence from Elewski 2008 indicated that 51.9% (541/
1042) of participants in the terbinafine group and 49.1% (249/
507) in the griseofulvin group reported an adverse effect dur-
ing the study (RR 1.06, 95% CI 0.95 to 1.18). A total of 9.2%
(96/1042) of participants in the terbinafine group and 8.3% (42/
507) in the griseofulvin group had adverse events attributed to the
study drugs (RR 1.11, 95% CI 0.79 to 1.57; N = 1549; mod-
erate quality evidence; Analysis 2.2; Summary of findings for the
main comparison). The most frequent adverse events, accounting
for more than 5% in any group, were nasopharyngitis, headache,
pyrexia, cough, and vomiting. These individual adverse events
were also similar between the two groups.
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In addition, Lipozencic 2002 reported “adverse events from18.4%
to 42.4% for the terbinafine treatment groups and 16.7% for the
griseofulvin group”. The most common adverse events, account-
ing for approximately 5% in any group, were fever, pharyngi-
tis, infections (parasitic, viral and upper respiratory tract) and in-
fluenza-like symptoms. Terbinafine was well tolerated in all treat-
ment groups, although two participants prematurely discontinued
treatment. One suffering from urticaria was in the terbinafine 6-
week group; and the other, suffering from asymptomatic and re-
versible neutropaenia, was in the terbinafine 10-week group. Both
events resolved without sequelae. Somnolence and gastrointestinal
disorders were also reported.
Severe adverse events
Severe adverse events were rare (0.6% in both groups; RR 0.97,
95% CI 0.24 to 3.88; N = 1549; moderate quality evidence;
Analysis 2.3; Summary of findings for the main comparison).
Secondary outcomes
None of the studies comparing terbinafine (six weeks) to griseoful-
vin (six weeks) for Trichophyton infection reported recurrence of
the condition after the end of the intervention period, percentage
of drop-outs as a surrogate for participant adherence or the time
taken to cure.
Proportion of participants with clinical cure only
One new study reported the proportion of patients with a clini-
cal cure only (Elewski 2008). In participants infected with T. ton-
surans, the proportion of participants with clinical cure only at
week 10 was 70% (355/507) in the terbinafine group and 57.2%
(147/257) in the griseofulvin group (RR 1.22, 95% CI 1.09 to
1.38; Analysis 2.4). In participants infected with T. violaceum, the
corresponding proportion was 65% (104/160) in the terbinafine
group and 64.6% (53/82) in the griseofulvin group (RR 1.01,
95% CI 0.83 to 1.22; Analysis 2.4).
3. Terbinafine (medium (6 to 8 weeks) and long term
(10 to 12 weeks) treatment versus griseofulvin in
Microsporum infections; 10-16 weeks follow-up
Primary outcome
Complete cure, i.e. clinical and mycological cure
Microsporum infections
We included two studies that reported data for participants in-
fected with Microsporum (Elewski 2008; Lipozencic 2002). In
Elewski 2008, a new study added in this update that included 1549
participants,15.1% were infected with M. canis. Of these, 27%
(41/152) of participants in the medium-term terbinafine group
versus 43.9% (36/82) in the griseofulvin group achieved complete
cure (Elewski 2008) (RR 0.61, 95% CI 0.43 to 0.88; Analysis
3.1).
Another open study, Lipozencic 2002, assessed medium- to long-
term treatment regimens of terbinafine versus griseofulvin. In this
study, 98.5% of the 165 included participants were infected with
M. canis, and the remainder were infected with M. audouini.
A lower proportion of participants treated with medium-term
terbinafine achieved complete cure (51.4%, 36/70) compared to
those treated with griseofulvin (70%, 21/30), but the difference
was not statistically significant (RR 0.73, 95% CI 0.53 to 1.02;
Analysis 3.1). Long-term duration of treatment (10 or 12 weeks)
resulted in the complete cure being higher in those in the griseo-
fulvin group (70%, 21/30) compared to those in the terbinafine
group (35%, 23/65) at 4 weeks after the end of treatment (RR
0.51, 95% CI 0.34 to 0.76; Analysis 3.1).
In participants infected with Microsporum, pooling the data from
two studies for medium-term treatment (six or eight weeks) re-
sulted in an increase in complete cure for those in the griseofulvin
group compared to those in the terbinafine group at four weeks
after the end of treatment (34.7% versus 50.9%; RR 0.68, 95%
CI 0.53 to 0.86; N = 334; moderate quality evidence; Analysis
3.1; Elewski 2008; Lipozencic 2002; Summary of findings for the
main comparison).
Adverse events
None of the studies (Elewski 2008; Lipozencic 2002) reported this
outcome.
Secondary outcomes
Neither of the included studies comparing short- or long-term
treatment with terbinafine versus griseofulvin forMicrosporum re-
ported on recurrence of the condition after the end of the inter-
vention period or the time taken to cure.
Proportion of participants with clinical cure only
Two studies reported the proportion of participants with a clinical
cure only (Elewski 2008; Lipozencic 2002), including one new
study added to this update (Elewski 2008). According to Elewski
2008, in participants infected with M. canis, the proportion of
participants with clinical cure only at week 10 was 39.5% (60/
152) in the terbinafine group and 57.3% (47/82) in the griseo-
fulvin group (RR 0.69, 95% CI 0.53 to 0.90; Analysis 3.2). In
Lipozencic 2002 at 16 weeks, the proportion of participants in-
fectedwithMicrosporumwith clinical cure onlywas 61.1%(22/36)
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and 70.5% (24/34) in the groups treatedwith terbinafine for 6 and
8 weeks, respectively, and 60.6% (20/33) and 50% (16/32) in the
groups treated with terbinafine for 10 and 12 weeks, respectively,
compared to 80% (24/30) in the griseofulvin group. The control
treatment (griseofulvin for 12 weeks) resulted in more cures com-
pared with medium-term terbinafine treatment duration (6 to 8
weeks) (RR 0.82, 95% CI 0.64 to 1.05; Analysis 3.2) and long-
term terbinafine treatment duration (10 to 12 weeks) (RR 0.69,
95% CI 0.52 to 0.92; Analysis 3.2), which was statistically signif-
icant in favour of griseofulvin. We pooled data from two studies
(Elewski 2008; Lipozencic 2002) in a meta-analysis. In partici-
pants infected with Microsporum, the proportion of participants
with clinical cure only was significantly lower in the medium-term
terbinafine treatment group than in the griseofulvin group (RR
0.76, 95% CI 0.63 to 0.91; N = 334; Analysis 3.2).
Percentage of drop-outs as a surrogate for participant
adherence
Lipozencic 2002 reported on drop-outs as a surrogate to measure
adherence. The percentage of drop-outs was 22.2% (8/36), 14.7%
(5/34), 18.18% (6/33), 34.2% (12/32), and 23.3% (7/30), in
the groups treated with terbinafine for 6, 8, 10, or 12 weeks and
griseofulvin, respectively.
4. Terbinafine short-term versus long-term for
treating Trichophyton and Microsporum infections;
12 to 20 weeks follow-up
Primary outcomes
Complete cure, i.e. clinical and mycological cure
One to two weeks versus four weeks
Four studies reported on complete cure (Friedlander 2002;
Haroon 1996; Kullavanijaya 1997; Talarico Filho 1998). Meta-
analysis showed that a four-week treatment duration of terbinafine
was significantly better than one to two weeks (65.1% versus
48.6%; RR 0.73, 95% CI 0.62 to 0.86; Analysis 4.1).
Medium term (6 to 8 weeks) versus long-term (10 to 12 weeks)
Medium-term (six to eight weeks) treatment duration of
terbinafine appeared to be better than long-term (10 to 12 weeks)
treatment duration, but the difference was not statistically sig-
nificant (51.4% versus 35.3%; RR 1.45, 95% CI 0.97 to 2.17;
Lipozencic 2002; Analysis 4.1).
Adverse events
Five studies reported on adverse events (Deng 2011; Friedlander
2002; Hamm 1999; Haroon 1996; Talarico Filho 1998), includ-
ing one study added to this update (Deng 2011).
Deng 2011 reported that none of the terbinafine treated patients
experienced adverse events.
Talarico Filho 1998 reported the following adverse events: mild
itching andmild constipation in the one-week arm;mild headache
and nausea in the two-week arm; mild urticaria, swelling of the
lips (labial oedema), mild constipation, moderate loss of appetite,
mild diarrhoea, mild nausea and moderate or partial loss of taste
(recovered within eight weeks) in the four-week arm.
Hamm 1999 reported: abdominal pain (mild to moderate), epis-
taxis (nose bleed), lack of appetite, headache, severe facial swelling,
coughing and fever (mild to moderate) in the one-week arm; ab-
dominal pain, fatigue, nausea, dyspepsia, headache and fever in
the two-week arm.One additional participant had lack of appetite
and gastroenteritis only during the additional four-week treatment
period.
In Friedlander 2002, around 44% of the participants experienced
mild to moderate adverse events, which were probably not related
to treatment. The most frequent adverse events were “upper res-
piratory tract infections, gastrointestinal upsets and other events
common in this patient population”. Authors did not report rele-
vant data but stated that the frequency of adverse events was sim-
ilar between groups.
Haroon 1996 compared three different regimens (at one, two and
four weeks), reporting a few adverse events: headache, raised hep-
atic enzymes, raised triglycerides, eosinophilia and leucocytosis in
the one-week arm; raised hepatic enzymes and eosinophilia in the
two-week arm and raised hepatic enzymes, raised triglycerides,
eosinophilia and leucocytosis in the four-week arm.
Secondary outcomes
None of the studies reported recurrence of the condition after the
end of the intervention period.
Proportion of participants with clinical cure only
Four studies reported on the proportion of participants achieving
a clinical cure only, all of which were also included in the orig-
inal review (Friedlander 2002; Haroon 1996; Lipozencic 2002;
Talarico Filho 1998).
One to two weeks versus four weeks
Meta-analysis of three included studies showed that a four-week
treatment duration of terbinafine seemed to be better than one-
to two-week treatment duration, but the difference was not sta-
tistically significant (75.1% versus 63.9%; RR 0.84, 95% 0.67
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to 1.06; Friedlander 2002; Haroon 1996; Talarico Filho 1998;
Analysis 4.2).
Medium term (6 to 8 weeks) versus long-term (10 to 12 weeks)
Data from Lipozencic 2002 showed that medium-term (6 to 8
weeks) treatment duration of terbinafine appeared to be better
than long-term (10 to 12 weeks), but the difference was also not
statistically significant (65.7% versus 55.4%; RR 1.19, 95% CI
0.90 to 1.56; Analysis 4.2).
Percentage of drop-outs as a surrogate for participant
adherence
Two studies reported drop-outs as a surrogate for adherence (Deng
2011; Friedlander 2002), including one new study added to this
update (Deng 2011).
Deng 2011 reported there were no drop-outs in the two-week or
four-week terbinafine groups.
In Friedlander 2002, the percentage of drop-outs in the one-, two-
and four-week arms were reported as 25% (14/56), 25.4%(15/59)
and 19.3% (12/62), respectively.
Time taken to cure
One study, also included in the original review, reported on time
taken to cure (Hamm1999). The time taken to cure was about two
weeks if the causative organism was a Trichophyton. Participants
infected with Microsporum only responded to an additional four-
week treatment course of terbinafine, i.e. two to three weeks after
an initial course of one or two weeks.
5. Terbinafine standard dose versus double dose in
Microsporum infections; 20 weeks follow-up
This update did not identify any new studies addressing the out-
comes for this comparison. Likewise, we did not find any studies
reporting on our primary outcome of adverse events or the sec-
ondary outcomes of proportion of participants with clinical cure
only; measurement of recurrence of the condition after the end of
the intervention period; or percentage of drop-outs as a surrogate
for participant adherence.
Primary outcomes
Complete cure, i.e. clinical and mycological cure
Ungpakorn 2004 reported on complete cure and assessed the effi-
cacy of the standard dose of terbinafine compared to double doses
of terbinafine after 20 weeks of follow-up. Both treatments were
given in a pulsed protocol (one week on, three weeks off ) for the
treatment of tinea capitis caused byMicrosporum species. The pro-
portion with complete cure for the standard dose group reached
60.8% (14/23) and was similar to 68.4% (13/19) in the double
dose group (RR 1.12, 95% CI 0.72 to 1.76; Analysis 5.1).
Secondary outcomes
Time taken to cure
Ungpakorn 2004 also reported time taken to cure: at week 20
all participants were cured with the exception of one who at the
beginning had moderately severe tinea capitis.
6. Itraconazole (six and two weeks) versus
griseofulvin (six weeks) in Trichophyton and
Microsporum infections
This update did not identify any new studies addressing the out-
comes for this comparison.
Primary outcomes
Complete cure, i.e. clinical and mycological cure
Two studies reported complete cure (Gupta 2001; López-Gómez
1994).
Gupta 2001 compared six weeks of griseofulvin versus two to three
weeks of itraconazole in 100 people, with the dose given according
to the participant’s weight. This study showed complete cure at
82% (41/50) for the itraconazole group and 92% (46/50) for the
griseofulvin group (RR 0.89, 95% CI 0.76 to 1.04; Analysis 6.1).
The main causative fungi were T. tonsurans and T. violaceum, al-
though investigators did not report the exact percentages. Accord-
ing to this trial, when Trichophyton species are the infecting fungi,
both griseofulvin and itraconazole reach high complete cure per-
centages, although griseofulvin tends to be more effective. How-
ever the disadvantage was that griseofulvin was administered for
six weeks treatment, while itraconazole was administered only for
two to three weeks.
In another study involving 34 participants, in whomM. canis was
the most common fungi, complete cure was the same for both
drugs at 88% (15/17 and 15/17) (López-Gómez 1994). This study
compared six weeks of treatment with ultra microsize griseoful-
vin 500 mg/d or itraconazole 100 mg/d with a follow-up of 14
weeks. According to this trial, in tinea capitis involving Microspo-
rum species, both itraconazole and griseofulvin reached high com-
plete cure percentages within a treatment period of six weeks (RR
1.00, 95% CI 0.78 to 1.28; Analysis 6.1).
We did not see a significant statistical difference between the dif-
ferent doses of itraconazole employed in the two studies and grise-
ofulvin in the pooled analysis (83.6% versus 91.0%; RR 0.92,
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95%CI 0.81 to 1.05; N = 134; very low quality evidence; Analysis
6.1; Summary of findings 2).
Adverse events
Two studies reported adverse events (Gupta 2001; López-Gómez
1994).
Authors did not report adverse events in the itraconazole group of
either of the trials. In those treated with griseofulvin, two partic-
ipants experienced nausea and intense stomach ache with severe
vomiting at weeks two and four of treatment, requiring discon-
tinuation of therapy (López-Gómez 1994). Gupta 2001 reported
three gastric problems and three cases of nausea in the griseofulvin
group. One of the participants who experienced nausea dropped
out of the study.
Secondary outcomes
None of the studies under this comparison reported recurrence of
the condition after the end of the intervention period or the time
taken to cure.
Proportion of participants with clinical cure only
Only one study reported this outcome (Gupta 2001). The propor-
tion of participants with clinical cure only at the end of treatment
reported in the study were 44% (22/50) and 70% (35/50) in the
itraconazole and in the griseofulvin groups, respectively (RR 0.63,
95% CI 0.44 t0 0.90; Analysis 6.2).
Percentage of drop-outs as a surrogate for participant
adherence
Two studies reported on drop-outs (Gupta 2001; López-Gómez
1994).
In Gupta 2001, the percentage of drop-outs was the same for both
treatment groups (8% versus 8%; RR 1.00, 95% CI 0.26 to 3.78;
Analysis 6.3). In López-Gómez 1994 the percentage of drop-outs
was 5.5% (1/18) in the itraconazole group and 11.7% (2/17) in
the griseofulvin group (RR 0.47, 95% CI 0.05 to 4.74; Analysis
6.3).
7. Itraconazole versus terbinafine (both two weeks) in
Trichophyton infections
This update did not identify any new studies addressing the out-
comes for this comparison.
Primary outcomes
Complete cure, i.e. clinical and mycological cure
Gupta 2001 and Jahangir 1998 reported on complete cure.
Jahangir 1998 had 60 participants and compared a two-week
course of itraconazole (50 to 200 mg/d based on weight) with
two weeks of terbinafine. T. violaceum was the causative fungus
in 82% to 89% of the participants. Twelve weeks after the start
of treatment, 53% (16/30) and 60% (18/30) of participants were
completely cured in the terbinafine and itraconazole groups, re-
spectively (RR 1.13, 95% CI 0.72 to 1.75; Analysis 7.1). Gupta
2001, where Trichophyton was the species of fungus, compared
itraconazole and terbinafine with a two- to three-week course of
therapy. At 12 weeks, 94% (47/50) in the terbinafine group had
a complete cure, compared to 82% (41/50) in the itraconazole
group (RR 0.87, 95% CI 0.75 to 1.01; Analysis 7.1).
In the pooled analyses, there was very little difference in the pro-
portion of participants achieving complete cure with itraconazole
and terbinafine (as treatment of Trichophyton species) when used
for periods of two to three weeks (73.8% versus 78.8%; RR 0.93,
95% CI 0.72 to 1.19; N = 160; low quality evidence; Analysis 7.1;
Summary of findings 3).
Adverse events
Only Jahangir 1998 reported adverse events. Two participants re-
ported urticaria in the itraconazole group. In the terbinafine group,
one participant experienced fever, body aches and vertigo, but no
participant showed any significant haematological or biochemical
change.
Secondary outcomes
No studies for this comparison reported recurrence of the condi-
tion after the end of the intervention period or the time taken to
cure.
Proportion of participants with clinical cure only
Only Gupta 2001 reported on the proportion of participants
achieving clinical cure at the end of the four-week treatment,
with similar results in both terbinafine and itraconazole treatment
groups: 40% (20/50) and 44% (22/50), respectively (RR 1.10,
95% CI 0.69 to 1.75; Analysis 7.2).
Percentage of drop-outs as a surrogate for participant
adherence
Gupta 2001 reported that the percentage of drop-outs was 8% (4/
50) for the itraconazole group and 4% (2/50) for the terbinafine
group (RR 2.00, 95% CI 0.38 to 10.43, Analysis 7.3).
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8. Ketoconazole versus griseofulvin (12 to 26 weeks)
in Trichophyton infections; 12 to 26weeks follow-up
This update did not identify any new studies addressing the out-
comes for this comparison.
Primary outcomes
Complete cure, i.e. clinical and mycological cure
Two studies reported complete cure, but because of the differences
in treatment durations between them, we did not pool the results
(Gan 1987; Tanz 1988).
Gan 1987 was an open study in 80 participants where Trichophy-
ton species predominated; investigators compared once-daily ke-
toconazole 5 mg/kg/d with once-daily griseofulvin 15 mg/kg/d.
The children were examined every two weeks while they were re-
ceiving therapy (and at least one follow-up after the end of ther-
apy). Treatment was stopped when there was either complete cure
or after six months had passed. At the end of 12 weeks of therapy,
73.5% (25/34) of participants treatedwith ketoconazole had com-
plete cure of their infection, compared with 96.4% (27/28) of the
participants given griseofulvin (RR 0.76, 95% CI 0.62 to 0.94; N
= 62; low quality evidence; Analysis 8.1; Summary of findings 4
).
Those who did not achieve a complete clinical cure within 12
weeks continued to take therapy and were assessed between 12
and 26 weeks of therapy, until they exhibited complete resolution
of clinical disease and negative hair sample cultures. During this
period, the one remaining griseofulvin participant and six of the
ketoconazole participants with continuing disease had complete
clearance of clinical and mycological disease.
Thus, by the end of 26 weeks, all of the participants in the griseo-
fulvin group were completely cured, and only three ketoconazole-
treated patients remained with persistent clinical disease and pos-
itive mycological cultures (i.e. 91.2% (31/34) participants receiv-
ing ketoconazole compared with 100% (28/28) in the griseoful-
vin group (RR 0.95, 95% CI 0.83 to 1.07; N = 62; low quality
evidence; Analysis 8.1; Summary of findings 4).
In Tanz 1988, participants randomly received ketoconazole or
griseofulvin for 12 weeks. The proportion of participants with
complete cure was similar at 48% (16/33) in the ketoconazole
group and 54% (25/46) in the griseofulvin group (RR 0.89, 95%
CI 0.57 to 1.39; N = 79; low quality evidence; Analysis 8.1;
Summary of findings 4).
Adverse events
Four studies reported adverse events (Gan 1987; Martínez-Roig
1988; Tanz 1985; Tanz 1988). Despite reports of liver disease
(Lewis 1984), we did not find any studies reporting this adverse
effect. Ketoconazole use was associated with two cases of abdom-
inal pain and one case of urticaria (Tanz 1985). Only one par-
ticipant from the ketoconazole group withdrew from the study
and reported to have nausea. Other than this, there were no se-
rious adverse reactions in any of the two groups (Tanz 1988).
No adverse events were reported in the ketoconazole group (Gan
1987; Martínez-Roig 1988). One griseofulvin-treated participant
showed a two-fold increase in serum alanine aminotransferase
and aspartate aminotransferase after three weeks of treatment, but
values returned to normal at the following weekly clinic visits
(Martínez-Roig 1988).
Secondary outcomes
Proportion of participants with clinical cure only
Only one study reported this outcome (Martínez-Roig 1988). The
proportion of participants with clinical cure evaluated at the end
of treatment were 100% (8/8) and 80% (4/5) in the ketoconazole
and griseofulvin groups, respectively (RR 1.26, 95% CI 0.77 to
2.05; Analysis 8.2).
Proportion of participants with recurrence of the condition
after the end of the intervention period
Gan1987 reported (page 48) that “three patients (two treatedwith
ketoconazole and one treated with griseofulvin) had a recurrence
of tinea capitis at four weeks (two patients) and at four months
(one patient) following discontinuation of therapy”.
Percentage of drop-outs as a surrogate for participant
adherence
Two studies reported this outcome (Tanz 1985; Tanz 1988).
In Tanz 1985, the percentage of drop-outs was 30% (3/10) and
41.6% (5/12) in the ketoconazole and griseofulvin groups, respec-
tively (RR 0.72, 95% CI 0.23 to 2.30, Analysis 8.3).
In Tanz 1988, the percentage of drop-outs was 66.6% (22/33)
and 56.5% (26/46) in the ketoconazole and griseofulvin groups,
respectively (RR 1.18, 95% CI 0.83 to 1.67; Analysis 8.3).
Time taken to cure
Two studies reported this outcome (Gan 1987; Martínez-Roig
1988).
In Gan 1987, the time needed to improve was 60 days and 108
days in the ketoconazole and griseofulvin groups, respectively.Hair
sample cultures took significantly longer to become negative (ster-
ile) in the ketoconazole group (median eight weeks) than in the
griseofulvin group (four weeks).
Martínez-Roig 1988 reported the mean time to clinical cure in
weeks: 4.2 weeks in the griseofulvin group and 5.0 weeks in the
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ketoconazole group. They also reported the mean time needed
to achieve negative cultures in weeks: 3.6 and 4.7 weeks in the
griseofulvin and ketoconazole groups, respectively.
9. Fluconazole (2 to 6 weeks) versus griseofulvin (6
weeks); 8-12 weeks follow-up
The study by Foster 2005 was new to this update.
Primary outcomes
Complete cure, i.e. clinical and mycological cure
Three studies reported this outcome (Dastghaib 2005; Foster
2005; Gupta 2001).
Dastghaib 2005 assessed 40 participants: 16 were infected with
T. violaceum, 16 with T. verrucosum and 8 with M. canis. The
children were treated with 5 mg/kg/d of fluconazole or 15 mg/kg/
d griseofulvin for four and six weeks, respectively. Complete cure
was reported for 79% (15/19) of the fluconazole arm and 76%
(16/21) of the griseofulvin arm (RR 1.04, 95% CI 0.74 to 1.45;
Analysis 9.1).
Foster 2005 included 880 participants: 86% were infected with
T. tonsurans and 11% with M. canis; 721 of them were included
in the analyses: 245 participants on short-term fluconazole, 246
participants on themedium-termfluconazole and230participants
in the griseofulvin group. As we stated in the ’Methods’ section,
for RCTs with multiple intervention groups, we split the shared
griseofulvin group (N = 230) in two (N = 115 each) to avoid
double-counting.
The children were randomly assigned to three groups and treated
with a short-term course of fluconazole (6 mg/kg/d for three
weeks; N = 245); medium-term use of fluconazole (6 mg/kg/d for
six weeks; N = 246); or griseofulvin (11 mg/kg/d for six weeks;
230), respectively. Complete cure was not significantly different
between the short-term fluconazole group and the griseofulvin
group (30.2% versus 31.3%; RR 0.96, 95% CI 0.69 to 1.34;
Analysis 9.1).
Gupta 2001 assessed 100 participants who were infected with
T. tonsurans and/or T. violaceum (the exact percentages were not
reported). They were treated with either fluconazole 6 mg/kg/d
for two to three weeks or with microsize griseofulvin 20 mg/kg/d
for six weeks. The proportion of participants with complete cure
were 82% (41/50) and 92% (46/50), respectively (RR 0.89, 95%
CI 0.76 to 1.04; Analysis 9.1).
Short-term (2-4 weeks) fluconazole
Meta-analysis of the three studies failed to show any significant
difference between short-term use of fluconazole and griseofulvin
for proportions of participants with complete cure i.e. clinical and
mycological cure (41.4% versus 52.7%; RR 0.92, 95% CI 0.81 to
1.05;N=615; moderate quality evidence; Analysis 9.1; Dastghaib
2005; Foster 2005; Gupta 2001; Summary of findings 5).
Medium-term (6 weeks) fluconazole
There is a single trial in this subgroup (N = 361; Foster 2005).
There was no clear difference between between the medium-
term fluconazole group and the griseofulvin group (34.1% versus
32.1%; RR 1.06, 95% CI 0.77 to 1.46; N = 361; low quality
evidence; Analysis 9.1; Summary of findings 5).
Adverse events
Three studies reported this outcome (Dastghaib 2005; Foster
2005; Gupta 2001).
Foster 2005 included 1063 patients for safety evaluation and re-
ported that the most frequent treatment-related adverse events
were abdominal pain (1.3%) and diarrhoea (0.7%) in the short-
term fluconazole group; headache (0.9%) and rash (0.6%) in the
medium-term fluconazole group; and headache (1.7%), abdomi-
nal pain (1.4%) and dyspepsia (1.0%) in the griseofulvin group.
There were no significant differences between the three groups
with regard to all causality and treatment-related adverse events.
Two studies reported nausea as an adverse effect in the griseofulvin
group (Dastghaib 2005; Gupta 2001).
Secondary outcomes
None of the studies in this comparison reported on recurrence of
the condition after the end of the intervention period or the time
taken to cure.
Proportion of participants with clinical cure only
Two studies reported this outcome (Foster 2005; Gupta 2001).
Foster 2005 reported that the proportions of participants with
clinical cure only at week 10 were 40% (98/245), 46% (112/246),
and 40% (92/230) in the short-term fluconazole, medium-term
fluconazole, and griseofulvin groups, respectively.
Gupta 2001 reported the proportions of participants with clinical
cure only at the end of treatment (week 4 for fluconazole and week
6 for griseofulvin) were 26% (13/50) and 70% (35/50) in the
fluconazole and griseofulvin groups, respectively (RR 0.37, 95%
CI 0.22 to 0.61; Analysis 9.2).
Percentage of drop-outs as a surrogate for participant
adherence
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Two studies reported this outcome (Foster 2005; Gupta 2001).
Foster 2005 reported that the percentages of drop-outs were 12%
(37/302), 7% (21/286), and 8% (24/292) in the short-term flu-
conazole, medium-term fluconazole and griseofulvin groups, re-
spectively.
The same percentage of drop-outs was reported for both groups
in Gupta 2001 (8% versus 8%, RR 1.00, 95% CI 0.26 to 3.78;
Analysis 9.3).
10. Fluconazole (2 to 3 weeks) versus terbinafine (2 to
3 weeks) in Trichophyton infections; 12 weeks follow-
up
This update did not identify any new studies addressing the out-
comes for this comparison. Moreover, none of the trials evaluating
this comparison reported on adverse events, recurrence of the con-
dition after the end of the intervention period or the time taken
to cure.
Primary outcome
Complete cure, i.e. clinical and mycological cure
Only one study reported this outcome (Gupta 2001). The effi-
cacy of fluconazole for two to three weeks was compared with
terbinafine, dosed according to weight for two to three weeks
in Trichophyton infections. The proportions of participants with
complete cure were 82% (41/50) for the fluconazole arm and 94%
(47/50) for the terbinafine arm (RR 0.87, 95%CI 0.75 to 1.01; N
= 100; low quality evidence; Analysis 10.1; Summary of findings
6).
Secondary outcomes
Proportion of participants with clinical cure only
Only one study reported this outcome (Gupta 2001). The pro-
portion of participants with clinical cure only at the end of treat-
ment (week 4 for terbinafine and fluconazole) was not significantly
different in the terbinafine group compared with the fluconazole
group ((40% versus 26%; RR 1.54, 95% CI 0.86 to 2.74).
Percentage of drop-outs as a surrogate for participant
adherence
Only one study reported this outcome (Gupta 2001). The percent-
age of drop-outs was 4% (2/50) and 8% (4/50) in the terbinafine
and fluconazole groups, respectively (RR 0.50, 95% CI 0.10 to
2.61).
11. Fluconazole (2 to 3 weeks) versus itraconazole (2
to 3 weeks) in Trichophyton infections; 12 weeks
follow-up
This update did not identify any new studies addressing the out-
comes for this comparison. Moreover, none of the trials evaluating
this comparison reported on adverse events, recurrence of the con-
dition after the end of the intervention period or the time taken
to cure.
Primary outcome
Complete cure, i.e. clinical and mycological cure
Only one study reported this outcome (Gupta 2001). When flu-
conazole treatmentwas comparedwith itraconazole in participants
with Trichophyton tinea capitis, in doses of 5 mg/kg/d daily for
two to three weeks, the proportion of participants with complete
cure was 82% (41/50 and 41/50) for both groups (RR 1.00, 95%
CI 0.83 to 1.20; N = 100; low quality evidence; Analysis 11.1;
Summary of findings 7).
Secondary outcome:
Proportion of participants with clinical cure only
Only one study reported this outcome (Gupta 2001). The propor-
tion of participants with clinical cure only at the end of treatment
(week four in itraconazole and fluconazole groups) was nearly dou-
ble in the itraconazole group: 44% (22/50) compared with 26%
(13/50) in the fluconazole group, but the difference was not statis-
tically significant (RR 1.69, 95% CI 0.96 to 2.97; Analysis 11.2).
Percentage of drop-outs as a surrogate for participant
adherence
Only one study reported this outcome (Gupta 2001). The same
percentage of drop-outs as a surrogate for participant adherence
was reported in both treatment groups (8%, 4/50; RR 1.00, 95%
CI 0.26 to 3.78; Analysis 11.3).
12. Fluconazole low dose versus higher dose (1.5, 3.0
and 6.0 mg/kg/d) in Trichophyton infections; 4 months
follow-up
This update did not identify any new studies addressing the out-
comes for this comparison. In fact, we found a single study for this
comparison, and it only reported on one primary outcome (com-
plete cure) and not on any of our secondary outcomes (Solomon
1997). We categorised data into three subgroups comprising 1.5
mg versus 3.0 mg; 1.5 mg versus 6.0 mg; and 3.0 mg versus 6.0
mg.
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Primary outcome
Complete cure, i.e. clinical and mycological cure
Solomon 1997 compared different doses of fluconazole: 1.5 mg/
kg/d, 3.0 mg/kg/d, and 6.0 mg/kg/d, for 20 days in a group of 41
participants with tinea capitis caused by the Trichophyton species.
Authors reported efficacy in only 27 participants and did not pro-
vide details on drop-outs by group. However, they reported the
total missing participants (34%) in the study. Thus, we assumed
that the same percentage was applied for the missing participants
in each group, being originally 12, 15 and 14 participants ran-
domly assigned in the 1.5 mg/kg/d, 3.0 mg/kg/d and 6.0 mg/kg/
d groups, respectively. Intention-to-treat efficacy rates in the 1.5
mg/kg/d, 3.0 mg/kg/d and 6.0 mg/kg/d groups were 17% (2/12),
40% (6/15) and 57% (8/14), respectively.
Although higher doses resulted in more cures than lower doses,
none of the comparisons reached statistical significance (3.0 mg
versus 1.5 mg: RR 2.40, 95% CI 0.59 to 9.82; Analysis 12.1; 6.0
mg versus 1.5 mg: RR 3.43, 95% CI 0.89 to 13.15; Analysis 12.1;
6.0 mg versus 3.0 mg: RR 1.43, 95% CI 0.66 to 3.08; Analysis
12.1).
13. Treatment durations of fluconazole (3 weeks
versus 6 weeks); 10 weeks follow-up
One new study added to this update evaluated this comparison,
but it did not report on adverse events, recurrence of the condition
after the end of the intervention period or the time taken to cure
(Foster 2005).
Primary outcome
Complete cure, i.e. clinical and mycological cure
Foster 2005 compared different treatment duration of fluconazole:
short-term use of fluconazole (6 mg/kg/d for three weeks) and
medium-term use of fluconazole (6 mg/kg/d for six weeks). At
week 10, there was no significant difference with regard to the
proportion of participants with complete cure for the short-term
and medium-term use of fluconazole in children infected with T.
tonsurans and M. canis (30.2%, 74/245 versus 34.1%, 84/246;
RR 0.88, 95% CI 0.68 to 1.14; N = 491; low quality evidence;
Analysis 13.1; Summary of findings 8).
Secondary outcomes
Proportion of participants with clinical cure only
Foster 2005 reported that short-term use of fluconazole and
medium-termuse of fluconazole had similar effects on clinical cure
(RR 0.88, 95% CI 0.72 to 1.08).
Percentage of drop-outs as a surrogate for participant
adherence
Foster 2005 reported the percentage of drop-outs was 12% (37/
302) and 7% (21/286) in the short-term and medium-term flu-
conazole groups, respectively (RR 1.67, 95% CI 1.00 to 2.78).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Itraconazole versus griseofulvin for children infected with Trichophyton and Microsporum
Patient or population: children infected with Trichophyton and Microsporum
Intervention: it raconazole (2-6 weeks durat ion)
Comparison: griseofulvin (6 weeks durat ion)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Griseofulvin Itraconazole
Proportion of participants
with complete cure
910 per 1000 838 per 1000
(737 to 956)
RR 0.92
(0.81 to 1.05)
134
(2 studies)
⊕©©©
Very lowa,b,c
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDowngraded one level because both studies were at unclear risk of bias.
bDowngraded one level because the treatment durat ion of it raconazole was signif icant ly heterogenous between the two
included studies.
cDowngraded one level because total number of events was less than 300.
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Itraconazole versus terbinafine in children infected with Trichophyton
Patient or population: children infected with Trichophyton
Intervention: it raconazole (2 weeks durat ion)
Comparison: terbinaf ine (2 weeks durat ion)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Terbinafine Itraconazole
Proportion of participants
with complete cure
788 per 1000 732 per 1000
(567 to 937)
RR 0.93
(0.72 to 1.19)
160
(2 studies)
⊕⊕©©
Lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDowngraded one level because both studies were at unclear risk to bias.
bDowngraded one level because total number of events was less than 300.
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Ketoconazole versus griseofulvin in children infected with Trichophyton
Patient or population: children infected with Trichophyton
Intervention: ketoconazole (12-26 weeks durat ion)
Comparison: griseofulvin (12-26 weeks durat ion)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Griseofulvin Ketoconazole
Proportion of partic-
ipants with complete
cure
Follow-up: 12 weeks
964 per 1000 733 per 1000
(598 to 906)
RR 0.76
(0.62 to 0.94
62
(1 study)
⊕⊕©©
Lowa,b
Ketocona-
zole (12 weeks) versus
griseofulvin (12 weeks)
Proportion of partic-
ipants with complete
cure
Follow-up: 26 weeks
1000 per 1000 920 per 1000
(810 to 1000)
RR 0.92
(0.81 to 1.03)
62
(1 study)
⊕⊕©©
Lowa,b
Ketoconazole (up to 26
weeks) versus griseo-
fulvin (up to 26 weeks)
Proportion of partic-
ipants with complete
cure
Follow-up: 12 weeks
543 per 1000 484 per 1000
(310 to 755)
RR 0.89
(0.57 to 1.39)
79
(1 study)
⊕⊕©©
Lowa,b
Ketocona-
zole (12 weeks) versus
griseofulvin (12 weeks)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.30
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aDowngraded one level because the study was at high risk of bias.
bDowngraded one level because total number of events was less than 300.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
3
1
S
y
ste
m
ic
a
n
tifu
n
g
a
l
th
e
ra
p
y
fo
r
tin
e
a
c
a
p
itis
in
c
h
ild
re
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Fluconazole versus griseofulvin in children with tinea capitis
Patient or population: children with t inea capit is
Intervention: f luconazole (for the f irst outcome: 2-4 weeks durat ion; for the second outcome: 6 weeks durat ion)
Comparison: griseofulvin (6 weeks durat ion)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Griseofulvin Fluconazole
Proportion of participants
with complete cure
Follow-up: 2-4 weeks
449 per 1000 413 per 1000
(368 to 466)
RR 0.92
(0.81 to 1.05)
615
(3 studies)
⊕⊕⊕©
Moderatea
Proportion of participants
with complete cure
Follow-up: 8-12 weeks
322 per 1000 341 per 1000
(248 to 470)
RR 1.06
(0.77 to 1.46)
361
(1 study)
⊕⊕©©
Lowb,c
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDowngraded one level because one of the three studies was at high risk of bias, the other two were at unclear risk of bias.
bDowngraded one level because the study was at unclear risk of bias.
cDowngraded one level because total number of events was less than 300.
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Fluconazole versus terbinafine for children infected with Trichophyton
Patient or population: children infected with Trichophyton
Intervention: f luconazole (2-3 weeks durat ion)
Comparison: terbinaf ine (2-3 weeks durat ion)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Terbinafine Fluconazole
The proportion of partici-
pants with complete cure
Follow-up: 12 weeks
940 per 1000 818 per 1000
(705 to 949)
RR 0.87
(0.75 to 1.01)
100
(1 study)
⊕⊕©©
Lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a Downgraded one level because the study was at unclear risk of bias.
bDowngraded one level because total number of events was less than 300.
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Fluconazole versus itraconazole in children infected with Trichophyton
Patient or population: children infected with Trichophyton
Intervention: f luconazole (2-3 weeks durat ion)
Comparison: it raconazole (2-3 weeks durat ion)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Itraconazole Fluconazole
Proportion of participants
with complete cure
Follow-up:12 weeks
820 per 1000 820 per 1000
(681 to 984)
RR 1.00
(0.83 to 1.20)
100
(1 study)
⊕⊕©©
Lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a Downgraded one level because the study was at unclear risk of bias.
bDowngraded one level because total number of events was less than 300.
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Different durations of fluconazole in children infected with T. tonsurans and M. canis
Patient or population: children infected with T. tonsurans and M. canis
Intervention: f luconazole (3 weeks durat ion)
Comparison: f luconazole (6 weeks durat ion)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Fluconazole ( 6 weeks du-
ration)
Fluconazole ( 3 weeks du-
ration)
Proportion of participants
with complete cure
Follow-up: 8-12 weeks
341 per 1000 300 per 1000
(232 to 389)
RR 0.88
(0.68 to 1.14)
491
(1 study)
⊕⊕©©
Lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a Downgraded one level because the study was at unclear risk of bias.
bDowngraded one level because the total number of events was less than 300.
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D I S C U S S I O N
Summary of main results
In this updated review,we included25 studies (comprising of 4449
participants), including 4 new studies (2637 participants) added
to this update. The data from the included studies produced 13
main comparisons of interventions.
Terbinafine versus griseofulvin
In our meta-analyses of terbinafine for 4 weeks versus griseofulvin
for 8 weeks assessed at 12 to 24 weeks of follow-up, the result
favoured neither terbinafine nor griseofulvin for Trichophyton in-
fections (RR 1.06, 95% CI 0.98 to 1.15; N = 328, 3 RCTs; low
quality evidence; Summary of findings for the main comparison)
for our primary outcome of complete cure.This was also the case
for mixedTrichophyton and Microsporum infections in two studies
and in a single study analysis of Microsporum infections.
New evidence from Elewski 2008 indicated that terbinafine (at
standard doses according to the participant’s weight for six weeks)
achieved a similar proportion with complete cure as griseoful-
vin (at standard doses according to the participant’s weight for
six weeks) in children infected with Trichophyton, when followed
up for 10 weeks (RR 1.18, 95% CI 0.74 to 1.88; N = 1006; 1
RCT; low quality evidence, Summary of findings for the main
comparison). Sub-group analysis assessing response to treatment
in children infected with T. tonsurans revealed that terbinafine is
better than griseofulvin. This new evidence resulted in a change in
the conclusions of this review. However, both of the two regimens
had similar effects in children with T. violaceum.
There is moderate quality evidence that griseofulvin (6 to 12
weeks) is better thanmedium-term (6 to8weeks) use of terbinafine
with respect to the proportion of participants achieving complete
cure (RR 0.68, 95% CI 0.53 to 0.86; N = 334; 2 RCTs; Summary
of findings for the main comparison).This evidence in favour of
the efficacy of griseofulvin in Microsporum infection was newly
added to this update (Elewski 2008).
Moderate quality evidence also confirmed that the adverse events
and severe adverse events are comparable between terbinafine and
griseofulvin, the adverse events being mild and reversible in most
cases (RR 1.11, 95%CI 0.79 to 1.57; N = 1549; 1 RCT; Summary
of findings for the main comparison).
Different dose regimens of terbinafine
We investigated a possible relationship between dose, duration
and response for terbinafine. A meta-analysis of four studies indi-
cated that a four-week treatment duration of terbinafine was sig-
nificantly better than one or two weeks of treatment with respect
to complete cure of Trichophyton andMicrosporum infections (RR
0.73, 95% CI 0.62 to 0.86; N = 552; 4 RCTs). There were no
differences in the proportion of participants who were completely
cured, or cured clinically, when comparing medium-term (6 to 8
weeks) versus long-term (10 to 12 weeks) terbinafine in a single-
study analysis. Comparisons of adverse events between the differ-
ent terms of treatment showed that the adverse events were mild
and comparable between the groups. A single-study comparison
of the standard dose of terbinafine compared to a double dose in
one study ofMicrosporum infections showed that the effectiveness
in completely curing the infection was comparable between regi-
mens when assessed at 20 weeks follow-up.
Itraconazole versus griseofulvin
A meta-analysis of two studies found no significant difference be-
tween itraconazole and griseofulvin for achieving a complete cure
in children with Trichophyton andMicrosporum (RR 0.92, CI 0.81
to 1.05; N = 134; 2 RCTs; very low quality evidence; Summary
of findings 2).
Itraconazole versus terbinafine
A meta-analysis of two studies indicated that there was no signif-
icant difference between itraconazole and griseofulvin for achiev-
ing a complete cure in children infected with Trichophyton (RR
0.93, CI 0.72 to 1.19; N = 160; 2 RCTs; low quality evidence;
Summary of findings 3).
Ketoconazole versus griseofulvin
Current evidence regarding ketoconazole versus griseofulvin was
limited. One study favoured griseofulvin, because ketoconazole
(for 12 weeks) appeared to be less effective in terms of complete
cure than griseofulvin for the same period (RR 0.76; 95% CI
0.62 to 0.94; Gan 1987). However, by the end of the study, when
the treatment duration was extended up to a maximum of 26
weeks in those who had not achieved a cure by 12 weeks, their
effects appeared to be similar (RR 0.95, 95% CI 0.83 to 1.07).
Another study indicated that the proportion with a complete cure
was similar in the ketoconazole (for 12 weeks) and griseofulvin
(for 12 weeks) groups (RR 0.89, 95% CI 0.57 to 1.39; Summary
of findings 4).
Fluconazole versus other therapies (griseofulvin or
terbinafine or fluconazole)
A meta-analysis of three studies indicated that fluconazole and
griseofulvin had similar effects for achieving complete cure either
in the short term of two to four weeks (RR 0.92, 95% CI 0.81
to 1.05; N = 500; 3 RCTs moderate quality evidence) or in the
medium term of six weeks (RR 1.06, 95% CI 0.77 to 1.46; N =
361; 1 RCT low quality evidence, Summary of findings 5).
A single study analysis of one small trial showed no differences
between either of the two interventions for the outcome of com-
plete cure when fluconazole was compared with terbinafine, both
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administered for two to three weeks (RR 0.87 CI 0.75 to 1.01; N
= 100; 1 RCT; low quality evidence; Summary of findings 6), or
when fluconazole was compared to itraconazole each administered
for two to three weeks, for Trichophyton infections (RR 1.00 CI
0.83 to 1.20; N = 100, 1 RCT low quality evidence, Summary of
findings 7).
Different dosages of fluconazole
The dosage of fluconazole was compared in one small single study
analysis, that is, 1.5, 3.0, and 6.0 mg/k/d in Trichophyton infec-
tions, with no significant differences between the groups, although
higher doses resulted in more cures in each comparison when fol-
lowed up at 4 months.
Different treatment duration of fluconazole
A further single study analysis of treatment duration of flucona-
zole treatment comparing short-term (3-week) versus medium-
term (6-week) treatment at 10 weeks follow-up, showed no sig-
nificant differences between the groups for children infected with
T. tonsurans and M. canis.
Overall completeness and applicability of
evidence
This review may help physicians worldwide weigh the advantages
and disadvantages of systemic antifungal agents and the options
when treating children with tinea capitis. It draws on detailed
information derived from clinical trials assessing the efficacy of
treatments for tinea capitis. However, caution is warranted when
interpreting the data, because the 25 included studies published
between 1987 to 2013 were conducted in different countries and
included people of different ethnicities. Furthermore, fungal types
varied from one trial to another. This means that our results may
not be directly clinically applicable to individual participants and
their specific situations.
Quality of the evidence
The quality of evidence in this review for each outcome, as pre-
sented in the ’Summary of findings’ tables, was very low to moder-
ate. The main reasons for downgrading the quality of the evidence
for these outcomes were imprecision due to low sample sizes and
risk of bias in the included studies.
Limitations in study design, execution, and reporting
The studies included in this review had several methodological
limitations: only four studies adequately described the method of
randomisation, and only two described adequate allocation con-
cealment. Blinding of participants and personnel and blinding of
outcome assessors was not adequate in any of the studies. Ten
studies were at high risk of bias from incomplete reporting of out-
come data (attrition bias), and although we judged that none was
at high risk of selective reporting bias, we did not actually have
access to the study protocols for comparison.
We detected other sources of bias, including failure to report dis-
ease severity or baseline comparability, but the extent to which
these factors may have introduced bias was unclear. It is therefore
important to emphasise that any conclusions that we have drawn
are reliant on primary studies with varying degrees of bias. Readers
should consider risk of bias when interpreting these results (Figure
3) and exercise caution with findings derived from studies with
high or unclear risk of bias.
Inconsistency of the results
Inconsistency refers to an unexplained heterogeneity of the results
across studies.
In this review, most of the comparisons were assessed in single
studies, so assessment of consistency of the results across studies
was not necessary. In outcomes for which the data were pooled,
inconsistency of effects was only identified for one outcome (com-
plete cure, terbinafine versus griseofulvin, Summary of findings
for the main comparison). In this outcome, we downgraded one
level because I2 of the pooled outcome was 85%, which indicated
substantial heterogeneity.One source of heterogeneity in this anal-
ysis of Trichophyton infections may be that the analysis included
bothT. tonsurans and T. violaceum infections; however, the extent
to which this clinical heterogeneity contributed to the observed
statistical heterogeneity is unclear.
Imprecision of the results
Results are considered imprecise when studies include relatively
few patients and few effects. In this review, imprecision was iden-
tified in some comparisons, and the reason for imprecision was
that total number of effects was less than 300 as recommended by
the GRADE handbook (Schünemann 2013).
Indirectness of the evidence
The majority of the 4449 participants with fungal infections in
the 25 included studies were aged 2 to 16 years, so the evidence
we found directly relates to the disease population of interest. In
this review, patient-reported outcomes (PROs), such as quality
of life, were rarely reported in the included studies. PROs are
important for evidence-based clinical decision making and need
to be addressed in future studies.
Publication bias
It was impossible to perform a funnel plot analysis to assess po-
tential publication bias for any of our outcomes because of the
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limited number of trials; there were only one to three studies for
each comparison.
Potential biases in the review process
Our assessment of the included studies was based on the published
manuscripts; therefore, the results were inevitably influenced by
the reporting quality of these studies. Undoubtedly, poor reporting
quality influences the accuracy of the assessments, and we were
unable to obtain further information from the trial investigators
we contacted. Pather 2006 was a conference paper that appeared
to meet the inclusion criteria, but as we could not obtain further
information, we could not include or exclude it. This may be a
source of potential bias, as the conclusions of the review could
change once that study has been assessed.We attempted to conduct
a comprehensive search for studies, but theoretically, there might
be somemissing studies because we did not search all local medical
databases around the world.
In addition, clinical heterogeneity between included studies is in-
evitable because each study had participants with different ethnic-
ities, types of fungal infection, severity of disease, dosages of drugs,
and durations of treatment and follow-up. Clinical heterogeneity
could introduce bias when we combined the results of different
studies by meta-analysis.
Agreements and disagreements with other
studies or reviews
Griseofulvin
In this review, griseofulvin was employed as a standard therapy for
the evaluation of any newer treatments for tinea capitis.
An earlier meta-analysis found that griseofulvin was an effective
therapy for tinea capitis (Gupta 2008). This conclusion is sup-
ported by the findings of our review: in our meta-analyses of grise-
ofulvin versus terbinafine (two to four weeks), griseofulvin (six to
eight weeks) was at least as effective as terbinafine forTrichophyton,
Microsporum and mixedTrichophyton and Microsporum infections
for our primary outcome of complete cure.
Tey 2011, another meta-analysis, concluded that “griseofulvin is
more efficacious than terbinafine in treating tinea capitis caused
by Microsporum species”. Additionally, Gupta 2013 performed a
further meta-analysis of randomised controlled trials and found
no differences in the overall efficacy of the two drugs at the
doses specified, but differences were observed based on the infec-
tious species, i.e. griseofulvin was superior for Microsporum spp.,
whereas terbinafine was superior for Trichophyton spp. The recent
guideline from the British Association of Dermatologists (BAD)
also recommended griseofulvin as the first-line treatment for tinea
capitis in children, especially in those infected with Microsporum
spp. (Fuller 2014). This update of the review also provides new,
moderate quality evidence that for Microsporum infections, grise-
ofulvin is better than terbinafine with respect to the proportion of
participants achieving complete cure (Summary of findings for the
main comparison), which is in agreement with previous reviews
and guidelines.
In our other comparisons of griseofulvin with triazole antifungal
agents (itraconazole, fluconazole and ketoconazole) we found no
evidence that griseofulvin was superior in efficacy for the outcome
of complete cure, but these were small trials, and the quality of
the evidence was moderate at best.
We found only limited evidence about the most suitable doses,
duration and formulations of griseofulvin. Dosage recommenda-
tions for griseofulvin vary due to different formulations (Higgins
2000), and taking griseofulvin with fatty food improves its absorp-
tion and bioavailability. Some trials recommended higher doses for
microsized griseofulvin but not for ultra-microsized griseofulvin,
although up to 25 mg/kg may be necessary (Higgins 2000). We
found no evidence that directly compared different formulations
of griseofulvin.
The main disadvantage of griseofulvin is perceived to be long du-
ration of treatment required, which may lead to reduced adher-
ence. The European Society for Pediatric Dermatology (ESPD)
recommended, “The treatment decision between griseofulvin and
newer antifungal agents for children with Trichophyton spp. for
tinea capitis can be based on an individual patient on the balance
between duration of treatment adherence and economic consid-
erations” (Kakourou 2010). It is still unclear if there is a difference
in terms of adherence between four weeks of terbinafine versus
eight weeks of griseofulvin, as in this review we did not find any
evidence to support the hypothesis that adherence improves with
shorter courses of treatment. It could be argued, though, that long
courses of griseofulvin versus shorter courses of terbinafine for ex-
ample, already incorporate any reduced adherence simply because
of the longer duration of the former.
We included two studies that reported data on duration of treat-
ment for participants infected with Microsporum (Elewski 2008;
Lipozencic 2002). A lower proportion of participants treated with
six to eight weeks of terbinafine inM. canis andM. audouini infec-
tions achieved complete cure compared to those treated with grise-
ofulvin (not statistically significant). Long-term duration of treat-
ment (10 or 12 weeks) resulted in a higher proportion of partici-
pants achieving complete cure in the griseofulvin group than in the
terbinafine group (Summary of findings for themain comparison).
However, in the absence of further direct comparisons of duration
or formulations, we cannot comment further on the optimal reg-
imens for treating tinea capitis in children with griseofulvin.
Griseofulvin is reported to be a safe drug, although it commonly
causes side effects such as headaches and gastrointestinal upsets
(Bennassar 2010). Despite the assumption that gastrointestinal
disturbance is a major drawback of the older drugs like griseo-
fulvin, we did not find reports of gastrointestinal disturbance as-
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sociated with use of griseofulvin in our included studies. We ac-
knowledge that while RCTs may not always provide a platform
for reporting rare side effects, they are a reasonable method of de-
tecting common ones. We included common adverse events as an
outcome in our review; however, the included studies registered
some infrequent adverse events that may or may not be related to
griseofulvin treatment. We did find evidence that when they oc-
cur, severe adverse events are comparable between terbinafine and
griseofulvin. In most cases, though, adverse events were mild and
reversible. These included elevated serum liver enzymes, triglyc-
erides and uric acid; anaemia, eosinophilia; leucocytosis and gran-
ulocytopenia. Although few observed adverse events were labelled
as severe, periodic monitoring every month of organ system func-
tions, including hepatic, renal and haematopoietic (blood) systems
is advisable in those taking griseofulvin for more than eight weeks
(Möhrenschlager 2005).
Griseofulvin has traditionally been the most widely used systemic
treatment for tinea capitis, and its advantages are that it is inexpen-
sive, there is extensive experience of its use, the suspension dosage
form allows for accurate dosing in children, and it is licensed in
most countries. However, griseofulvin is no longer available in
New Zealand and other countries including Canada (Bortolussi
2016), as it has been superseded by newer antifungal drugs.
Terbinafine
The original version of this review found that terbinafine was at
least as effective as griseofulvin for the treatment of Trichophyton
infections of the scalp. In this update, we added some new ev-
idence to support this finding. We found that for T. tonsurans,
terbinafine is better than griseofulvin, while the two regimens had
similar effects in children with T. violaceum. This finding also
agrees with that of a previous meta-analysis comparing terbinafine
against griseofulvin (Fleece 2004).
The efficacy of terbinafine treatment may vary according to the
fungal species isolated. New evidence in this update shows that
terbinafine has a poorer effect on complete cure in participants
withMicrosporum infections. This finding correlates with the 2014
BAD guideline (Fuller 2014), which concluded that terbinafine
was more effective against Trichophyton species; whereas griseoful-
vin was more effective against Microsporum species.
We found no evidence about formulations of terbinafine. While
tablets may be preferred by some children (age five years and older
perhaps), they may not allow for dosage individualisation (gen-
erally calculated by body weight, therefore smaller doses may be
required than that provided by tablet formations). Drops or syrups
are preferable to tablets for dosage individualisation in children,
and there is a granule formation of terbinafine to be sprinkled on
food (Fuller 2014).
The duration of terbinafine therapy may be important. Limited
evidence from observational studies suggests that longer therapeu-
tic regimens of terbinafine may improve complete cure for those
infected with Microsporum species (Aste 2004; Commens 2003;
Devliotou 2004). In our meta-analysis of four studies that directly
compared two weeks versus four weeks duration of terbinafine,
a longer treatment duration was significantly better than a short
duration for a complete cure.
Itraconazole
Itraconazole is currently the preferred agent in most European
countries, although it is not licensed in some countries (e.g. the
United Kingdom) for treating tinea capitis in children aged 12
years or younger (Fuller 2014). However, in this review, we only
identified limited evidence based on small trials suggesting that
oral itraconazole at weight-adjusted doses was effective and safe for
tinea capitis caused by T. violaceum (two weeks of treatment) and
M. canis (six weeks of treatment). More well-designed RCTs with
large sample sizes are needed to confirm the safety, efficacy and
optimal treatment regimens of itraconazole for paediatric tinea
capitis patients.
Fluconazole
In this update, we included a large RCT that compared short-
term use of fluconazole (6mg/kg/d for three weeks) withmedium-
term use of fluconazole (6 mg/kg/d for six weeks) (Foster 2005).
According to this study, short-term and medium-term use of flu-
conazole had a similar effect on complete cure. In the 2014 BAD
guideline (Fuller 2014), fluconazole was recommended as an al-
ternative to terbinafine for tinea capitis in children. However, the
optimal regimen of fluconazole for treating paediatric tinea capitis
remains unclear. Based on Fuller 2014 and the findings of this
review, short-term duration of fluconazole may be a useful treat-
ment regimen.
Ketoconazole
This review identified low quality evidence that indicated that ke-
toconazole appeared to have similar efficacy with griseofulvin for
tinea capitis in children, although it appears to be less effective
than griseofulvin for children with tinea capitis caused by Tri-
chophyton species (Gan 1987). However, ketoconazole is not rec-
ommended for use in children because of potential adverse events,
especially hepatotoxicity (Elewski 2000), and oral ketoconazole
was withdrawn from use in the United Kingdom and Europe in
2013 (Fuller 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is very low to moderate quality evidence to support the
use of griseofulvin to treat tinea capitis in children, caused by T.
tonsurans, M. canis, T. mentagrophytes and T. violaceum. Overall
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griseofulvin is considered to be safe in children. On the basis of the
studies described, the recommendeddosage regimen for children is
continuous therapy for six to eightweekswith tablets or suspension
including microsized and ultra-microsized preparations, adjusted
according to the child’s weight.
This review supports the idea that although griseofulvin will con-
tinue to remain the first-line choice in tinea capitis, terbinafine
may constitute another first-line drug that is well tolerated and
has few side effects. Long-term (more than six weeks) terbinafine
therapy cannot be recommended on the basis of this review. How-
ever, new evidence of moderate quality in this update indicates
that terbinafine (at standard doses for six weeks) may be a better
choice than griseofulvin (at standard doses for six weeks) in chil-
dren infected with T. tonsurans. However, the two regimens have
similar effects in children with T. violaceum. In addition, in the
case of M. canis, griseofulvin may be a better choice.
We included trials on various other drugs. Limited evidence indi-
cates that terbinafine, itraconazole and fluconazole may have sim-
ilar effects for children with tinea capitis caused by Trichophyton
species. Ketoconazole appears to be less effective for children in-
fected with Trichophyton species, but limited data prevents us from
making any firm conclusions about their relative efficacy.
Some evidence based on a few studies shows that oral itraconazole
at doses according to the child’s weight for two to six weeks is
effective and safe for tinea capitis caused by T. violaceum (two
weeks of treatment) and M. canis (six weeks of treatment). In
addition, evidence of moderate quality shows that two to four
weeks of fluconazole are comparable to six weeks of griseofulvin,
especially with tinea capitis caused by Trichophyton species.
The adverse events of terbinafine, griseofulvin, itraconazole, ke-
toconazole, and fluconazole were all mild and reversible, and the
adverse events and severe adverse events are comparable between
terbinafine and griseofulvin.
Implications for research
The majority of the literature about systemic antifungal treatment
for tinea capitis is on griseofulvin. There need to be more studies
on any advantages of the newer and relatively expensive antifun-
gals such as ketoconazole,terbinafine, itraconazole and flucona-
zole, both in comparison to each other and to griseofulvin.
Any studies would need to be of adequate sample size, involving
different treatment doses and duration of treatment to determine
the clinical effectiveness and any adverse events. Importantly, fur-
ther research is also required regarding the impact on mode of
administration and adherence to treatment (which may be needed
over several weeks) in children. Patient-reported outcomes such as
quality of life are important for evidence-based clinical decisions
and need to be addressed in future studies.
In order to ensure the reporting quality of any clinical trials un-
dertaken, they must conform to the Consolidated Standards of
Reporting Trials (CONSORT) 2010 statement (Schulz 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cáceres-Ríos 2000
Methods Triple-blind, parallel group RCT for 12 weeks
Participants • Lima (Perú)
• N = 50 (23 males, 27 females) participants
• Aged 1-14
• Inclusion criteria: clinical and mycologic diagnosis of non-inflammatory tinea
capitis; weight > 10 kg; normal baseline laboratory evaluation (complete blood cell
count, erythrocyte sedimentation rate, liver function tests and urinalysis)
• Exclusion criteria: antimycotic therapy during the month before consultation;
bacterial superinfection, systemic illness or unknown intolerance or allergy to
terbinafine or griseofulvin
• Fungi isolated
◦ T. tonsurans: 74%
◦ M. canis: 26%
• No mention of adherence assessment
Interventions • Group 1: griseofulvin (microsize) tablet, 10-20 kg: 125 mg/d; 20-40 kg: 250 mg/
d; > 40 kg: 500 mg/d, for 8 weeks (N = 25)
• Group 2: terbinafine tablet, 10-20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d; > 40 kg:
250 mg/d, once a day for 4 weeks plus 4 weeks of placebo (N = 25)
No co-treatment
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only at 12 weeks
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
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Cáceres-Ríos 2000 (Continued)
All outcomes was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There was only one drop-out
(2%, 1/50). Although which group this
drop-out belonged to was unclear and ITT
analysis was not performed, the propor-
tion of missing outcomes compared with
the observed event risk seemed to be not
enough to have a clinically relevant impact
on the intervention effect estimate
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection:
griseofulvin group: black dot 32% (8/25);
white-greyish hair 68% (17/25);
terbinafine group: black dot 8% (2/25);
white-greyish hair 92% (23/25)
◦ Age: griseofulvin group: 6.72;
terbinafine group: 6.84
◦ Sex: griseofulvin group: males:
10; females: 15; terbinafine group: males:
13; females: 12
◦ Duration of complaint: from 1
week to 4 years
Dastghaib 2005
Methods Single-blind, parallel group RCT for 8 weeks
Participants • Iran
• N = 40
• Aged between from 1 to 16; 80% were boys and 20% girls
• Inclusion criteria: clinical and mycologic diagnosis of non-inflammatory tinea
capitis
• Exclusion criteria: a history of allergy to imidazoles; use of oral antifungals within
8 weeks or use of topical antifungals within 4 weeks before screening; a history of
congenital or acquired immunodeficiency or disorders affecting kidney or liver
function; concurrent therapy with other drugs; and systemic illness
• Fungi isolated
◦ T. verrucosum: fluconazole: 26.3%; griseofulvin: 52.4%; total: 40%
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Dastghaib 2005 (Continued)
◦ T. violaceum: fluconazole: 52.6%; griseofulvin: 28.6%; total: 40%
◦ M. canis: fluconazole: 21.1%; griseofulvin: 19%; total: 20%
Interventions • Group 1: griseofulvin 15 mg/kg/d for 6 weeks (N = 21)
• Group 2: fluconazole 5 mg/kg/d for 4 weeks (N = 19)
Outcomes • The proportion of participants with complete cure after 8 weeks
• The frequency and type of adverse events
• Mycologic cure at the end of treatment
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Participants were not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Investigators were blinded, but
the method of blinding was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 5 participants (12.5%, 5/40)
were lost to follow-up. It was unclear which
group these drop-outs belonged to. ITT
analysis was not performed. The reason for
drop-outs was not clear
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: not
mentioned
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability:
◦ Mean age: griseofulvin (8.66);
fluconazole (7.71)
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Dastghaib 2005 (Continued)
◦ Sex: griseofulvin (males: 17;
females: 4), fluconazole (males: 15;
females: 4)
◦ Mean weight (kg): griseofulvin
(23.61); fluconazole (21.60)
◦ Severity of disease: similar in
both groups at first examination
Deng 2011
Methods 3-arm, parallel group RCT for 1 year
Participants • China (Kashgar)
• N = 88
• Aged 2-14 years old. The mean ages were 8.42, 7.69, and 9.13 in the 3 groups,
respectively.
• 78.3% males
• Inclusion criteria: “Children with age older than two years old, weight more than
10 kg, no apparent other diseases, not using any steroids, not taking antifungal drugs
for 4 weeks, and renal functions were normal.”
• Exlcusion criteria: “Children who did not return for observation on time, those
who took other antifungal drugs locally and/or orally during treatment, and those who
discontinued treatment due to side effects.”
• Fungi isolated
◦ T. violaceum: 55.1%
◦ A. vanbreuseghemi: 30.6%
◦ T. tonsurans: 14.3%
• Adherence assessment: not mentioned
Interventions • Group 1: griseofulvin, doses of 20mg/kg/d, for 4 consecutive weeks (N = 19)
• Group 2: terbinafine, doses depend on weight:< 20 kg, 62.5 mg/d; 20-40 kg, 125
mg/d; and > 40 kg, 250 mg/d, for 2 consecutive weeks (N = 27)
• Group 3: terbinafine, doses depend on weight:< 20 kg, 62.5 mg/d; 20-40 kg, 125
mg/d; and > 40 kg, 250 mg/d, for 4 consecutive weeks (N = 23)
No co-treatment
Outcomes • Clinical cure rates at 2, 4, 8 weeks, and 1 year after therapy
• Clinical effectiveness rates at 2, 4, 8 weeks, and 1 year after therapy
• Mycological cure rates at 2, 4, 8 weeks, and 1 year after therapy
• The frequency and type of adverse events
• Percentage of drop-outs as a surrogate for participant adherence
One of the primary outcomes of interest in this review (complete cure rate) was not
reported in this study
Notes • The enrolled: 88 participants were randomised, 70 participants were evaluated for
adverse events, 69 participants were evaluated for clinical results
• Funding: Novartis Pharmaceutica
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Deng 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on the
method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Whether the participants and per-
sonnel were blinded was not stated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: Investigators were not blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 12.5% (11/88) participants lost to
follow-up. It was unclear which group these
drop-outs belonged to. ITT analysis was not
performed
Selective reporting (reporting bias) Low risk Comment: The publication reported findings
on all outcomes listed in the Methods section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved: yes
• Baseline comparability: yes, there were no
significant differences regarding to gender,
weight, age, and severity of signs and
symptoms
Elewski 2008
Methods Multicentre, single-blind, parallel group RCT for 10 weeks
Participants • USA, Peru, UK, Egypt, Russia, and Sourth Africa
• N = 1549
• The mean age was 6.8 years (ranged from 4-12 years). 62.2% males.
• Inclusion criteria: “Children were included if they were between 4 and 12 years of
age and had a clinical diagnosis of tinea capitis confirmed by positive potassium
hydroxide (KOH) microscopy at baseline.”
• Exclusion criteria: “Patients with protocol-defined clinically significant
biochemistry and hematologic abnormalities were excluded from the study as were
those with kerions requiring immediate treatment or treatment with systemic
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Elewski 2008 (Continued)
corticosteroids and/or systemic antibiotics, those with a condition or treatment that
could interfere with evaluation of drug effect, or those with current or past liver disease.
Other criteria for exclusion from study were presence of serious gastrointestinal disease,
hypersensitivity to study agents, and history of systemic lupus erythematosus. Patients
with systemic antifungal treatment or history of use of any other investigational agent
within 2 months before screening; use of immunosuppressant, cytostatic, or radiation
therapy within 1 month before screening; or topical treatment of the scalp within 1
week before baseline visit were also excluded from study participation.”
• Fungi isolated
◦ T. tonsurans 49.3%
◦ T. violaceum 15.6%
◦ M. canis 15.1%
◦ M. audouini 1.5%
◦ M. vanbreuseghemi 0.3%
◦ T. mentagrophytes 0.2%
◦ T. rubrum 0.2%
◦ M. gypseum 0.1%
◦ Other 6.5%
◦ Negative 17.0%
• Adherence assessment: not mentioned
Interventions • Group 1: terbinafine, doses of 5-8 mg/kg for 6 weeks (N = 1040)
• Group 2: griseofulvin, doses of 10-20 mg/kg for 6 weeks (N = 509)
No co-treatment
Outcomes • Complete cure rate at 10 weeks
• Clinical cure rate at 10 weeks
• Mycologic cure rate at 10 weeks
• The frequency and severity of adverse events
Notes This article included 2 RCTs, but the results of the 2 RCTs were reported together
Funding: Novartis Pharmaceuticals Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 43): “Eligible patients were
randomized in a 2:1 ratio to terbinafine
and griseofulvin treatment arms, respec-
tively (Fig 1). Patients were randomized to
the lowest available randomization number
at each site based on treatment allocation
cards received by a pharmacist or designee
at the site after they had fulfilled the inclu-
sion/exclusion criteria”
Comment: Standared randomisation
method was applied
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Elewski 2008 (Continued)
Allocation concealment (selection bias) Low risk Quote (page 43): “Randomization data
were accessible only to the dispenser of
medication and were kept confidential un-
til database lock.”
Comment: Themethod for allocation con-
cealment seemed to be adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 45): “Investigators and others
performing assessments, recording data, or
analysing data were blinded to treatment
identity from the time of randomisation
until database lock.”
Comment: The method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 45): “Investigators and others
performing assessments, recording data, or
analysing data were blinded to treatment
identity from the time of randomisation
until database lock.”
Comment: The method of blinding was
not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 3.6% (56/1549) participants
lost to follow-up. Among them, 40 partic-
ipants were in the terbinafine group and
16 participants in the griseofulvin group.
ITT analyses were performed. The propor-
tion of missing outcomes compared with
the observed event risk didn’t seem to be
enough to have a clinically relevant impact
on the intervention effect estimate
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: yes
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability: yes, there
were no significant differences with regard
to baseline demographic and disease
characteristics, including infection severity
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Foster 2005
Methods Multicentre, single-blind, parallel group RCT for 10 weeks
Participants • USA, Guatemala, Chile, Costa Rica and India
• N = 880
• Most participants (71%, 72%, and 73% in the 3 groups, respectively) were black
• Aged 3-12 years old.
• Inclusion criteria: “male or female between the ages of 3 and 12 years, a potassium
hydroxide preparation positive for fungal elements on direct microscopy, a clinical
diagnosis of tinea capitis, a guardian capable of providing informed consent who was
able to be actively involved in the care and evaluation of the subject, a negative baseline
urine pregnancy test if applicable, and otherwise healthy.”
• Exclusion criteria: participants with any of the following conditions were
excluded: “a negative baseline potassium hydroxide preparation; a kerion requiring
immediate treatment with systemic corticosteroids or antibiotics; previous treatment
with topical or systemic antifungal therapy within the past 48 hours or 30 days,
respectively; elevations in the blood levels of alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase,g-glutamyl transferase, or total bilirubin higher
than two times the upper limit of normal; history of active liver disease; previous
treatment with any other investigational agent within eight weeks before enrolment in
this study; a disease or condition that could impair absorption from the gastrointestinal
tract; underlying liver, kidney, or other organ disease that could result in abnormalities
in the absorption or metabolism of griseofulvin, fluconazole, or their metabolites;
allergies to the aforementioned drugs, pregnant females or those at risk of becoming
such; those currently taking any substance known to inhibit cytochrome P-450; those
with concurrent skin disease that could obscure the diagnosis and treatment of tinea
capitis; an immunocompromised state; or an enrolled family member.”
• Fungi isolated
◦ T.tonsurans 86%
◦ M. canis 11%
• Adherence assessment: not mentioned
Interventions • Group 1: fluconazole, dose of 6 mg/kg for 3 weeks followed by 3 weeks of placebo
(N = 302)
• Group 2: fluconazole, dose of 6 mg/kg for 6 weeks (N = 286)
• Group 3: griseofulvin, dose of 11 mg/kg for 6 weeks (N = 292)
No co-treatment
Outcomes • Clinical outcomes
◦ Clinical cure rate at 3, 6, and 10 weeks
◦ Clincial improvement rate at 3, 6, and 10 weeks
◦ Clinical failure rate at 3, 6, and 10 weeks
• Combined outcomes
◦ Success rate at 3, 6, and 10 weeks
◦ Partial success rate at 3, 6, and 10 weeks
◦ Failure rate at 3, 6, and 10 weeks
• Mycological outcome
◦ The percentage of participants with negative cultures
• Safety outcomes
◦ The incidence of all causality and treatment-related adverse events
◦ The frequency and type of adverse event
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Foster 2005 (Continued)
One of the primary outcomes of interest in this review (complete cure rate) was not
reported in this study
Notes Main data of this article were from 2 identical studies. The safety data from this article
were from 3 studies. Overall, 90% of participants were from USA
Funding: Prifzer, Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Low risk Quote (page 799): “Sealed envelopes con-
taining randomly assigned treatments”
were applied
Comment: A standard method of location
concealment was done.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Whether the participants and
personnel were blinded was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Investigators were blinded, but
the method of blinding was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 9.3% (82/880) participants lost
to follow-up. Among them, 37 participants
were in the fluconazole 3 weeks group;
24 participants were in the fluconazole 6
weeks group; and 21 participants were in
the griseofulvin group. ITT analyses were
performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: yes
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability: yes. There
was no significant difference between
groups regarding age, gender, weight or
height. However, baseline information
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Foster 2005 (Continued)
about severity of infection was not stated.
Friedlander 2002
Methods Triple-blind, parallel group RCT for 12 weeks
Participants • North America
• N = 177 (78% were black; 57.2% males)
• Age was 4 years or older (98% participants < 18 years old; mean age, 7.4 years
old), only 3 adults
• Inclusion criteria: male and female participants aged 4 years or older, with
clinically diagnosed tinea capitis caused by Trichophyton spp.
• Exclusion criteria: any systemic treatment for tinea capitis in the month before
enrolment. Kerions that required immediate treatment, concurrent seborrhoeic
dermatitis, or other scalp conditions such as scabies, head lice, psoriasis, or atopic
dermatitis. Immunocompromised participants or a history of malignancy within 5
years. Chronic or active liver disease. Serious gastrointestinal disease. Hypersensibility
to terbinafine or placebo. Treatment with any other investigative agent within the
previous 8 weeks. Pregnancy or lactation.
• Fungi isolated
◦ T. tonsurans: 98.74%
◦ T. soudanense: 0.63%
◦ T. verrucosum: 0.63%
• Adherence assessed by asking participants to return unused medication at each
visit
Interventions • Group 1: oral terbinafine 3-6 mg/kg/d for 1 week (N = 56)
• Group 2: oral terbinafine 3-6 mg/kg/d for 2 weeks (N = 59)
• Group 3: oral terbinafine 3-6 mg/kg/d for 4 weeks (N = 62)
Followed by placebo to complete 4 weeks when needed
Co-treatment: non-medicated shampoo twice weekly
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only at 12 weeks
• Percentage of drop-outs as a surrogate for participant adherence
• The time taken to cure
• Mycological cure at 12 weeks
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
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Friedlander 2002 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 23.2% (41/177) participants
lost to follow-up. Among them, 14 patents
were in the terbinafine for 1 week group;
15 participants were in the terbinafine for
2 weeks group; 12 participants were in the
terbinafine for 4 weeks group. ITT analyses
were performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type fungi involved: yes
• Baseline comparability
◦ Severity of infection: not stated
◦ Age: terbinafine for 1 week: 7.1
years; terbinafine for 2 weeks: 8.5 years;
terbinafine for 4 weeks: 6.6 years
◦ Sex: terbinafine for 1 week
(males 28, females 28); terbinafine for 2
weeks: (males 32, females 27); terbinafine
for 4 weeks: (males 31, females 31)
Fuller 2001
Methods Open-label, parallel group RCT for 24 weeks
Participants • UK
• N = 210
• Aged 2-16 years
• Inclusion criteria: children aged 2-16 years old with clinical diagnosis of tinea
capitis
• Exclusion criteria: immunocompromised children and those receiving any topical
antifungal agents within 7 days or systematic antifungal agents within 6 weeks prior to
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Fuller 2001 (Continued)
the start of the treatment
• Fungi isolated
◦ Microsporum audouini: 13% (13/103) in the terbinafine group and 11.4%
(12/107) in the griseofulvin group
◦ M. canis: 1.3% (1/103) in the terbinafine group and 1.4% (2/107) in the
griseofulvin group
◦ M.rivalieri: 0% in the terbinafine group and 1.4% (2/107) in the
griseofulvin group
◦ Trichophyton tonsurans: 64.9% (67/103) in the terbinafine group and 72.9%
(78/107) in the griseofulvin group
◦ T. soudanense: 10.4% (11/103) in the terbinafine group and 4.3% (5/107) in
the griseofulvin group
◦ T. violaceum: 2.6% (3/103) in the terbinafine group and 0% in the
griseofulvin group
◦ Trichophyton species unknown: 2.6% (3/103) in the terbinafine group and
0% in the griseofulvin group
• Adherence assessed by direct questioning.
Interventions • Group 1: griseofulvin suspension, 10 mg/kg/d, for 8 weeks (N = 107)
• Group 2: terbinafine tablet, < 20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d ; > 40 kg:
250 mg/d, for 4 weeks (N = 103)
Co-treatment: selenium sulphide shampoo, twiceweekly for the first 2weeks of treatment
Outcomes • Proportion of participants with complete cure at 24 weeks
• Frequency and type of adverse events
• Percentage of drop-outs as a surrogate for participant adherence: terbinafine group
• Mycological cure at 24 weeks
Notes Funding: Novartis Pharmaceuticals UK Ltd (Terbinafine).
The report of the study stated that “T. tonsurans accounted for 77% of the terbinafine
group and 88% of the griseofulvin group. Microsporum species accounted for 14% of
both groups” (i.e. 88% plus 14% = 102%). We used the data from this paper’s tables
(which seemed to be reliable)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 323): “Computer generated”,
“participants randomised in blocks of four”
Comment: standard methods of randomi-
sation performed
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding
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Fuller 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 54.8% (115/210) participants
lost to follow-up. Among them, 62 par-
ticipants were in the terbinafine group; 53
participants were in the griseofulvin group.
ITT analyses were performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: yes
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not
reported
◦ Age: group terbinafine: 5.6;
group griseofulvin: 6
◦ Sex: group terbinafine: males:
69%, females: 31%; group griseofulvin:
males:64%, females: 36%
◦ Duration of complaint:
unknown
Gan 1987
Methods Open-label, parallel group RCT for 26 weeks
Participants • USA (Dallas)
• N = 80
• Age 2.1-11.0 years (mean age 5.2 years).
• The remaining children after the drop-outs were 63; 55% were female
• Inclusion criteria: children with tinea capitis were eligible for the study
• Exclusion criteria: presence of kerion; if their parents were unable to make a
commitment for follow-up visits, or if there was a history of hepatocellular dysfunction
or finally if they had received a systemic antifungal agent in the preceding 6 weeks
• Fungi isolates (94% of the participants had positive fungal cultures)
• ◦ T. tonsurans: 70%.
◦ M. canis: 11.6%.
◦ T. mentagrophytes: 1.6%.
◦ T. violaceum: 1.6%.
◦ Uncertain classification: 15%.
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• Adherence assessed by history and by quantifying the amount of residual
medication brought in by the parents.
Interventions • Group 1: griseofulvin tablet or suspension, 15 mg/kg/d, single daily dose; 2 to 12-
26 weeks (depending on the participant’s clinical response to therapy) (N = 40)
• Group 2: ketoconazole tablet or crushed tablets suspended in sucrose syrup, 5 mg/
kg/d, single daily dose 2-26 weeks depending on the participant’s clinical response to
the therapy (N = 40)
No co-treatment
Outcomes • The proportion of participants with complete cure at 12 and 26 weeks
• Percentage of drop-outs as a surrogate for participant adherence
• The time taken to cure (scalp clearing)
One of the primary outcomes of interest in the review (adverse events) was not reported
in this study
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 47): “Table of random num-
bers” was used.
Comment: A standardmethodof randomi-
sation was performed.
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 21.3%(17/80) participants lost
to follow-up. Among them, 11 participants
were in the griseofulvin group, whereas 6
were in the ketoconazole group. ITT anal-
ysis was not performed
Selective reporting (reporting bias) Low risk Comment: publication reported findings
on all outcomes listed in the Methods sec-
tion
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Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria : yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not
reported
◦ Age (in months): griseofulvin
group (63); ketoconazole group (62)
◦ Sex: griseofulvin group (males:
13, females: 15); ketoconazole group
(males: 16, females: 20)
◦ Duration of complaint (in
weeks): griseofulvin group (5.6);
ketoconazole group (5.8)
Gupta 2001
Methods Multicentre, double-blind, parallel group RCT for 12 weeks
Participants • Canada and South Africa
• N = 200
• Inclusion criteria: children aged 6 months or older, with clinical signs and
symptoms of tinea capitis with mycology that was positive for Trichophyton spp.
• Exclusion criteria: those who had been or were on topical or oral antifungal agents
for 2 or 4 weeks, respectively, prior to the starting therapy
• Fungi isolated
◦ griseofulvin group: T. tonsurans: 39/50 and T. violaceum: 11/50
◦ terbinafine group: T. tonsurans: 37/50 and T. violaceum: 13/50
◦ itraconazole group: T. tonsurans: 35/50 and T. violaceum: 15/50
◦ fluconazole group: T. tonsurans: 44/50 and T. violaceum: 6/50
• No mention of adherence assessment
Interventions • Group 1: microsize griseofulvin 20 mg/kg/d for 6 weeks (N = 50)
• Group 2: terbinafine < 20 kg: 62.5 mg; 20-40 kg: 125 mg; > 40 kg: 250 mg for 2-
3 weeks (N = 50)
• Group 3: itraconazole 5 mg/kg/d for 2-3 weeks (N = 50)
• Group 4: gluconazole 6 mg/kg/d for 2-3 weeks. (N = 50)
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only at the end of treatment
• Percentage of drop-outs as a surrogate for participant adherence
• Mycologic cure at 12 weeks
• Effective therapy (mycologic cure with clinical cure or few residual symptoms) at
12 weeks
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Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Clinicians were blinded, but
the method of blinding was not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 7% (14/200) participants lost
to follow-up. Among them, 4 were in the
griseofulvin group, 2were in the terbinafine
group, 4 were in the itraconazole group, 4
were in the fluconazole group. ITT analy-
sis was not performed. The proportion of
missing outcomes compared with the ob-
served event risk seemed to be not enough
to have a clinically relevant impact on the
intervention effect estimate
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes (only culture
positive)
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection
⋄ Mild: griseofulvin group:
18; terbinafine group: 20; itraconazole
group: 9; fluconazole group: 9
⋄ Moderate: griseofulvin
group: 28; terbinafine group: 27;
itraconazole group: 36; fluconazole group:
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28
⋄ Severe: griseofulvin group:
4; terbinafine group: 2; itraconazole
group: 4; fluconazole group: 11
⋄ Kerion: griseofulvin
group: 0; terbinafine group: 1:
itraconazole group: 1; fluconazole group:
2
◦ Age: griseofulvin group: 5.9;
terbinafine group: 5.6; itraconazole group:
5.2; fluconazole group: 5.9
◦ Sex: griseofulvin group: males:
38, females: 12; terbinafine group: males:
37, females: 13; itraconazole group: males:
27, females: 23; fluconazole group: males:
32, females: 18
◦ Duration of complaint: not
mentioned
Hamm 1999
Methods Triple-blind, parallel group RCT for 12 weeks
Participants • Germany
• N = 35 (16 males and 19 females)
• The mean age was 9.3 years for males and 7.8 for females
• Inclusion criteria: mycologically proven scalp infection
• Fungi isolated
◦ M. canis: terbinafine for 1 week: 43.7%; terbinafine for 2 weeks: 26.3%
◦ T. tonsurans: terbinafine for 1 week: 37.5%; terbinafine for 2 weeks: 31.5%
◦ T. violaceum: terbinafine for 1 week: 6.25%; terbinafine for 2 weeks: 26.3%
◦ T. mentagrophytes: terbinafine for 1 week: 12.5%; terbinafine for 2 weeks: 5.
3%
◦ T. verrucosum: terbinafine for 2 weeks: 5.3%
• No mention of adherence assessment
Interventions • Group 1: terbinafine 10-20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d; > 40 kg: 250
mg/d once daily for 1 week (N = 16)
• Group 2: terbinafine same dose for 2 weeks (N = 19)
No co-treatment
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The time taken to cure
Notes Participants were observed for 12 weeks. After 4 weeks, non-responders were offered an
additional 4 weeks of treatment followed by a second observation period
Funding: Novartis (terbinafine)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no drop-outs reported
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: no
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not stated
◦ Age: we are unaware of the
mean age for each group
◦ Sex: we are unaware of the
number of females and males in each
group
◦ Duration of complaint: not
stated
Haroon 1995
Methods Parallel group RCT for 12 weeks
Participants • Pakistan
• N = 105 (49 males, 56 females)
• Aged 2-65; 94 were < 12 years
• Inclusion criteria: clinical evidence of dermatophytosis of the scalp; participant of
any age that weighed more than 10 kg
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• Exclusion criteria: concomitant treatment with systemic or X-ray therapy; topical
antifungal therapy within 2 weeks or oral antifungal within 4 weeks of entering the
study
• Fungi isolated included
◦ T. violaceum: 87.6% (92/105)
◦ T. tonsurans: 38% (4/105)
◦ T. rubrum: 0.95% (1/105)
◦ T. verrucosum: 6.6% (7/105)
◦ M. audouinii: 0.95% (1/105)
• No mention of adherence assessment
Interventions • Group 1: terbinafine 62.5-250 mg for 4 weeks, plus 4 weeks of placebo (N = 56)
• Group 2; griseofulvin 125-500 mg for 8 weeks (N = 49)
Outcomes • Proportion of participants with complete cure at 12 weeks
• Frequency and type of adverse events
• Mycological cure at 12 weeks
Notes Funding: Sandoz
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on the
method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient information although stated
to be a “double-blind comparative study of
terbinafine and griseofulvin in tinea capitis”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient information although stated
to be a “double-blind comparative study of
terbinafine and griseofulvin in tinea capitis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no drop-outs
Selective reporting (reporting bias) Low risk Comment: The publication reported findings on all
outcomes listed in the Methods section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved: yes
• Baseline comparability
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◦ Severity of infection: not known
◦ Age: terbinafine: 8.6; griseofulvin: 9.1
◦ Sex: terbinafine: male: 24, female: 32;
griseofulvin: male: 25, female: 24
◦ Duration of complaint: not known
Haroon 1996
Methods Triple-blind, parallel group RCT for 12 weeks
Participants • Pakistan
• N = 161 (90 males, 71 females; 156 were children below 12)
• Aged 3-13
• Inclusion criteria: clinical and mycological evidence of dermatophytosis of the
scalp; participants of any age that weighed more than 10 kg
• Exclusion criteria: concomitant treatment with systemic or X-ray therapy; topical
antifungal therapy within 2 weeks or oral antifungal within 4 weeks of entering the
study
• Fungi isolated
◦ T. violaceum: 71.5%
◦ T. tonsurans: 14.9%
◦ T. verrucosum: 4.3%
◦ M. audouinii: 4.3%
◦ M. canis: 2.5%
◦ T. schoenleinii: 1.9%
◦ T. mentagrophytes: 0.6%
• No mention of adherence assessment
Interventions • Group 1: terbinafine, 10-20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d ; > 40 kg: 250
mg/d, once daily for 1 week plus 3 weeks of placebo (N = 53)
• Group 2: terbinafine same dose for 2 weeks plus 2 weeks of placebo (N = 51)
• Group 3: terbinafine same dose for 4 weeks (N = 57)
No co-treatment
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only at 12 weeks
Notes Funding: Sandoz (terbinafine)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
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Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no drop-outs reported
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not
mentioned
◦ Age: we are unaware of the
mean age in each group
◦ Sex: we are unaware of the
number of females and males in each
group, only the total stated
◦ Duration of complaint: not
stated
Jahangir 1998
Methods Triple-blind, parallel group RCT for 12 weeks
Participants • Pakistan
• N = 55
• Inclusion criteria: subjects of either sex or any age, weighing 10 kg or more and
suffering from mycologically confirmed tinea capitis
• Exclusion criteria: history of allergy to imidazoles or allylamines, use of oral
antifungals within 8 weeks or topical antifungals within 4 weeks before screening,
concurrent therapy with rifampicin, phenytoin, digoxin, oral anticoagulants,
cyclosporin, astemizole and terfenadine, psoriasis of the scalp, history of any systemic
illness or abnormal liver and renal function tests
• Fungi isolated
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Jahangir 1998 (Continued)
◦ T. violaceum: itraconazole group: 82.1%; terbinafine group: 88.9%
◦ T. tonsurans: itraconazole group: 7.1%; terbinafine group: 3.7%
◦ T. mentagrophytes: itraconazole group: 7.1%; terbinafine group:3.7%
◦ T. verrucosum: itraconazole group: 3.7%; terbinafine group: 3.7%
• No mention of adherence assessment
Interventions • Group 1: itraconazole: < 20 kg: 50 mg; 20-40 kg: 100 mg; > 40 kg: 200 mg -
supposed daily - for 2 weeks (N = 28)
• Group 2: terbinafine: < 20 kg: 62.5 mg; 20-40 kg: 125 mg; > 40 kg: 200-250 mg
- supposed daily - for 2 weeks (N = 27)
No co-treatment
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• Mycological cure at 12 weeks
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no drop-outs
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not
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declared
◦ Age: itraconazole group: 7.9 ±
4.58; terbinafine group: 7.8 ± 4.58.
◦ Sex: male to female ratio
itraconazole group: 1:1; terbinafine group:
1:1.3
◦ Duration of complaint: not
stated
Khan 2011
Methods Triple-blind, parallel group RCT for 6 weeks (although the author stated this was a “third
party blind” study in the abstract, it was unclear whether they applied blinding method
or not)
Participants • Peshawar (Pakistan)
• N = 120
• Aged 3-12 years
• 75% participants were males
• Inclusion criteria: “Males and females between the ages of 3 and 12 years with
potassium hydroxide preparation positive for fungal elements on direct microscopy
were included in the study.”
• Exclusion criteria: “Patients with negative baseline KOH preparation, patients
having kerion and those having treatment with topical antifungal agents within past 2
weeks or systemic antifungal agents within past 30 days”; “patients with elevated liver
enzymes and history of active liver disease”
• Fungi isolated
◦ T. tonsurans 75%
◦ M. canis 22%
Interventions • Group 1: terbinafine, <20 kg 62.5 mg; 20-40 kg 125 mg, for 4 weeks (N = 60)
• Group 2: griseofulvin, 15 mg/kg, for 4 weeks (N = 60)
Co-treatment: not mentioned
Outcomes • Clinical cure rate at 2, 4, and 6 weeks
• Mycological cure rate at 2, 4, and 6 weeks
• The type of adverse events
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: unclear, although the author
stated this was a “third party blind” study
in the abstract
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: unclear, although the author
stated this was a “third party blind” study
in the abstract
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no drop-outs
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: yes
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability: not
mentioned
Kullavanijaya 1997
Methods Single-blind, parallel group RCT for 20 weeks
Participants • Bangkok (Thailand)
• N = 82
• All participants were children 7 years or older, except for 3 adults, all living in an
orphanage
• Fungi isolated: T. tonsurans and M. ferrugineum; proportions not stated
• No mention of adherence assessment
Interventions • Group 1: terbinafine 62.5-250 mg according to body weight - supposed once
daily - for 1 week. N = 27 completed the study
• Group 2: terbinafine same dose for 2 weeks. N = 28 completed the study
• Group 3: terbinafine same dose for 4 weeks. N = 27 completed the study
Outcomes • The proportion of participants with complete cure at 12 weeks
One of the primary outcomes of interest in this review (adverse events) was not reported
in this study
Notes The proportions and percentages were done including the adults, because we are unaware
which group they belonged to
Funding: Sandoz (terbinafine)
Risk of bias
68Systemic antifungal therapy for tinea capitis in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kullavanijaya 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: study was described as “single
blind and open trial study” but no mention
ofwhich one (participant or observers), and
the method of blinding was not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: study was described as “single
blind and open trial study” but no mention
ofwhich one (participant or observers), and
the method of blinding was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 8.5% (7/82) participants lost
to follow-up. It was unclear which group
these lost participants belonged to. ITT
analysis was not performed. The propor-
tion of missing outcomes compared with
the observed event risk seemed insufficient
to have a clinically relevant impact on the
intervention effect estimate
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: very poor
• Exclusion criteria: not mentioned
• Reporting of type of fungi involved:
yes
• Baseline comparability: yes, though
no statistical differences were noted either
reported, among the 3 groups with regard
to age, weight and sex ratio
Lipozencic 2002
Methods Multicentre, triple-blind, parallel group RCT for 16 weeks
Participants • Europe and South America (22 centres)
• N = 165
• The majority of participants were white (77%); 63% were males and the mean
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age was 7.7 years, only 3 adults were enrolled in the study; 67% weighed between 20
and 40 kg.
• Inclusion criteria: male or female aged ≥ 4, with tinea capitis confirmed by
positive culture of Microsporum spp., who were otherwise healthy outpatients and able
to swallow the study drug tablets
• Exclusion criteria: participants with conditions that could interfere with
gastrointestinal absorption of terbinafine, with confirmed liver or renal impairment,
with kerion or any severe concurrent disease of the scalp. Those using any antifungal
therapy, radiotherapy, systemic therapy with cytostatic or immunosuppressive drugs
within 1 month prior to the start of the study, and known intolerance or allergy to
drugs used in the study
• In addition, participants receiving griseofulvin treatment in this study were
subject to exclusion according to the label instruction of that drug
• Fungi isolated
◦ M. canis: 98.5%
◦ Only 2 participants were infected with M. audouinii
• No mention of adherence assessment
Interventions • Group 1: terbinafine tablets < 20 kg: 62.5 mg/d; 20-40 kg: 125 mg/d; > 40 kg:
250 mg/d for 6 weeks, followed by placebo to complete the 12 week double-blind
treatment phase (N = 36)
• Group 2: terbinafine same dose for 8 weeks, followed by placebo to complete the
12 week double-blind treatment phase (N = 34)
• Group 3: terbinafine same dose for 10 weeks, followed by placebo to complete the
12 week double-blind treatment phase (N = 33)
• Group 4: terbinafine same dose for 12 weeks, followed by placebo to complete the
12 week double-blind treatment phase (N = 32)
• Group 5: griseofulvin oral suspension 20 mg/kg/d for 12 weeks (open label) (N =
30)
Participants were provided with baby-shampoo to clean the scalp
Outcomes • The proportion of participants with complete cure at 16 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only at 16 weeks
• Percentage of drop-outs as a surrogate for participant adherence
• The time taken to cure
• Mycological cure at 16 weeks
Notes Funding: Novartis Pharma AG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Participants, clinicians and out-
come assessors blinded, except for the arm
taking griseofulvin, where both partici-
pants and investigators were informed from
day 1”
Comment: The method of blinding was
not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Participants, clinicians and out-
come assessors blinded, except for the arm
taking griseofulvin, where both partici-
pants and investigators were informed from
day 1”
Comment: The method of blinding was
not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 21.8% (36/165) participants
lost to follow-up. Among them, 7 were in
the terbinafine for 6 weeks group, 4 were
in the terbinafine for 8 weeks group, 6 were
in the terbinafine for 10 weeks group, 12
were in the terbinafine for 12 weeks group,
7 were in the griseofulvin group. ITT anal-
yses were performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: yes
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not
reported
◦ Age: terbinafine for 6 weeks: 9.
5; terbinafine for 8 weeks: 7; terbinafine
for 10 weeks: 6.8; terbinafine for 12
weeks: 8.8; griseofulvin group: 6.3
◦ Sex: % of males: terbinafine for
6 weeks: 66%; terbinafine for 8 weeks:
73%; terbinafine for 10 weeks: 70%;
terbinafine for 12 weeks: 53%;
griseofulvin group: 50%
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Methods Triple-blind, parallel group RCT for 12 weeks
Participants • Madrid (Spain)
• N = 35 (23 males and 12 females)
• All participants were children younger than 12 years old, except for 1 adult who
was 60 years old
• Inclusion criteria: the presence of dermatophytes
• Fungi isolated
◦ T. tonsurans: itraconazole group: 5.5%
◦ M. canis: itraconazole group: 88.8%; griseofulvin group: 94.1%
◦ T. mentagrophytes: itraconazole group: 5.5%
◦ T. violaceum: griseofulvin group: 5.9%
• No mention of adherence assessment
Interventions • Group 1: itraconazole 100 mg/d for 6 weeks (N = 18, including 1 adult)
• Group 2: griseofulvin (ultra microsize) 500 mg/d for 6 weeks (N = 17)
• No co-treatment
Outcomes • The proportion of participants with complete cure at 14 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only at 14 weeks
• Percentage of drop-outs as a surrogate for participant adherence
Notes Funding: Janssen (itraconazole)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 8.6% (3/35) participants lost
to follow-up. Among them, 1 was in the
itraconazole group, 2 were in the griseoful-
vin group. ITT analysis was not performed.
The proportion of missing outcomes com-
pared with the observed event risk seemed
72Systemic antifungal therapy for tinea capitis in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
López-Gómez 1994 (Continued)
to be not enough to have a clinically rele-
vant impact on the intervention effect esti-
mate
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: not mentioned
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not
reported
◦ Age: itraconazole group: 2 to
11; griseofulvin group: 2 to 10
◦ Sex: itraconazole group: males:
12, females: 6; griseofulvin group: males:
11, females: 6
◦ Duration of complaint: not
reported
Martínez-Roig 1988
Methods Triple-blind, parallel group RCT for 6 weeks
Participants • Barcelona (Spain)
• N = 13
• Children aged 2-16
• Sex distribution not reported
• Inclusion criteria: children suffering from dermatophytic lesions
• Exclusion criteria: not to have received previous antifungal therapy
• Fungi isolated: T. mentagrophytes,M. canis and Epidermophyton floccosum
• Adherence assessed
Interventions • Group 1: ketoconazole tablet, 100 mg/d at 12-hourly intervals for 6 weeks (N = 8)
• Group 2: griseofulvin tablet, 350 mg/d, at 12-hourly intervals for 6 weeks (N = 5)
Co-treatment: manual depilation in cases of inflammatory tinea capitis
Outcomes • The frequency and type of adverse events
• The proportion of participants with clinical cure only at the end of treatment
• Measurement of recurrence of the condition after the end of the intervention
period
• The time taken to cure
One of the primary outcomes of interest in this review (complete cure rate) was not
reported in this study
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Martínez-Roig 1988 (Continued)
Notes Tinea corporis and tinea capitis study, information poorly stated
It needs to be taken into account that the study talks about 47 participants, which is the
total, tinea capitis and tinea corporis participants, but for the purpose of our review we
have only used the results of the 13 tinea capitis participants
Funding: Laboratories Dr Esteve (ketoconazole)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 38): “Computer generated
random number table”
Comment: A standardmethodof randomi-
sation was done.
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no drop-outs
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability: not reported
Memisoglu 1999
Methods Triple-blind, parallel group RCT for 12 weeks
Participants • Turkey
• N = 78
• Children aged 2-13 years
• Inclusion criteria: participants with clinically suspected tinea capitis, provisionally
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Memisoglu 1999 (Continued)
confirmed by detection of fungal hyphae in KOH.
• Exclusion criteria: evidence of concomitant candida or bacterial infection
• Fungi isolated
◦ T. violaceum: griseofulvin group: 11.4% (4/35); terbinafine group: 15.6%
(5/32)
◦ T. rubrum: griseofulvin group: 22.8% (8/35); terbinafine group: 15.6%(5/
32)
◦ M. canis: griseofulvin group: 48.5% (17/35); terbinafine group: 46.8%(15/
32)
◦ T. tonsurans: griseofulvin group: 5.7% (2/35); terbinafine group: 6.25% (2/
32)
◦ T. mentagrophytes: griseofulvin group: 5.7% (2/35); terbinafine group: 3.1%
(1/32)
◦ T. verrucosum: griseofulvin group: 5.7% (2/35); terbinafine group: 3.1% (1/
32)
◦ M. audouinii: terbinafine group: 3.1% (1/32)
◦ Unidentified: terbinafine group: 6.25% (2/32)
• No mention of adherence assessment
Interventions • Group 1: microsize griseofulvin 20 mg/kg/d for 6 weeks (N = 50)
• Group 2: terbinafine < 20 kg: 62.5 mg; 20 to 40 kg: 125 mg; > 40 kg: 250 mg for
2-3 weeks (N = 50)
• Group 3: itraconazole 5 mg/kg/d for 2-3 weeks (N = 50)
• Group 4: gluconazole 6 mg/kg/d for 2-3 weeks (N = 50)
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only was scored at 12 weeks
• Percentage of drop-outs as a surrogate for participant adherence
• Mycological cure at 12 weeks
Notes At the beginning there were 39 participants in each group, after the drop-outs there were
32 and 35 left, and so the percentages do not match:
• T. violaceum: 13.4%
• T. rubrum: 19.4%
• M. canis: 47.7%
• T. tonsurans: 5.9%
• T. mentagrophytes:4.5%
• T. verrucosum: 4.5%
• M. audouinii : 1.5%
• Unidentified: 3%
These fungi percentages are the total over 67, not over 78 participants
Funding: not mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
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Memisoglu 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 14.1%(11/78) participants lost
to follow-up. Among them, 7 were in the
griseofulvin group, whereas 4 were in the
terbinafine group. ITT analysis was not
performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not stated
◦ Age: griseofulvin group: 6.6;
terbinafine group: 7
◦ Sex: griseofulvin group: males
26, females 9 ; terbinafine group: males
21, females 11
◦ Duration of complaint: not
stated
Rademaker 1998
Methods Open-label, parallel group RCT for 12 weeks
Participants • New Zealand
• N = 24
• 16 male and 8 female
• Age ranged between 2 and 15 years old
• Inclusion criteria: paediatric participants under 16 years old with culture positive
tinea capitis
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Rademaker 1998 (Continued)
• Fungi isolated
◦ M. canis 71%
◦ T. verrucosum 29%
• No mention of adherence assessment
Interventions • Group 1: griseofulvin 10 mg/kg/d for 8 weeks (N = 14)
• Group 2: terbinafine < 20 kg: 62.5 mg/d; 20 to 40 kg: 125 mg/d; > 40 kg: 250
mg/d for 4 weeks (N = 10)
Co-treatment: ketoconazole shampoo twice a week and econazole cream nightly was
recommended
Outcomes • The frequency and type of adverse events
• The proportion of participants with clinical cure only
• Measurement of recurrence of the condition after the end of the intervention
period
One of the primary outcomes of interest in this review (complete cure rate) was not
reported in this study
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: not mentioned
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: no
• Reporting of type of fungi involved:
yes
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Rademaker 1998 (Continued)
• Baseline comparability
◦ Severity of infection: only total
stated
◦ Age: only total stated
◦ Sex: only total stated
◦ Duration of complaint: not
stated
Solomon 1997
Methods Double-blind, parallel group RCT for 16 weeks
Participants • New York (USA)
• N = 27
• 15 females and 13 males aged 2-15 years
• Inclusion criteria: mycologic confirmation of infection before initiation of
therapy; children from 2 to 15 years of age; normal complete blood cell count with
differential, liver function test, and SMA-7; and parental consent
• Exclusion criteria: participants who had received antimycotic therapy within 2
weeks of initial visit; a history of kidney or liver disease; participants with history of
hypersensitivity reaction to any of the ingredients of fluconazole; participants receiving
interactive medications within preceding 30 days; participants with coexisting
immunosuppressive disease; and participants with inflammatory tinea capitis
• Fungi isolated: T. tonsurans 100%
• No mention of adherence assessment
Interventions • Group 1: fluconazole tablets or suspension 1.5 mg/kg/d for 20 days, N = 8
completed the study
• Group 2: fluconazole tablets or suspension 3 mg/kg/d for 20 days, N = 10
completed the study
• Group 3: fluconazole tablets or suspension 6 mg/kg/d for 20 days, N = 9
completed the study
No co-treatment
Outcomes • Proportion of participants with complete cure at 6 to 16 weeks
• Proportion of participants with clinical cure only
• Measurement of recurrence of the condition after the end of the intervention
period
One of the primary outcomes of interest in this review (adverse events) was not reported
in this study
Notes Funding: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
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Solomon 1997 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants were not blinded,
but the outcomes were unlikely to be in-
fluenced; clinicians were blinded, but the
method of blinding was not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 51.8%(14/27) participants lost
to follow-up. It was unclear which group
these lost participants belonged to. ITT
analysis was not performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: not
reported
◦ Age: not reported
◦ Sex: not reported
◦ Duration of complaint: not
reported
Talarico Filho 1998
Methods Single-blind, parallel group RCT for 12 weeks
Participants • Brazil
• N = 132 (63 females and 69 males)
• Aged 1-14 years
• Inclusion criteria: children of both sexes with tinea capitis, aged 1-14 years,
weighing ≥ 20 kg
• Exclusion criteria: use of any systemic antifungal therapy within 1 month or
topical antifungal therapy within 2 weeks prior to the start of the study or both;
conditions that could interfere with gastrointestinal absorption of terbinafine;
confirmed liver/renal impairment, haematological disorders; radiotherapy, systemic
therapy with cytostatic or immunosuppressive drugs, or therapy with antibacterial,
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Talarico Filho 1998 (Continued)
antiviral or antihelmintic drugs, either currently or during the 2 weeks preceding the
beginning of the study
• Fungi isolated
◦ T. tonsurans: terbinafine for 1 week: 88.6% (3/35); terbinafine for 2 weeks:
18.5% (7/38); terbinafine for 4 weeks: 26.5% (9/34)
◦ T. mentagrophytes: terbinafine for 1 week: 2.8% (1/35); terbinafine for 4
weeks: 5.9% (2/34)
◦ M. canis: terbinafine for 1 week: 77.1% (27/35); terbinafine for 2 weeks: 73.
3% (28/38); terbinafine for 4 weeks: 55.9% (19/34)
◦ T. rubrum: terbinafine for 1 week: 8.6% (3/35); terbinafine for 2 weeks: 7.
9% (3/38); terbinafine for 4 weeks: 5.9% (2/34)
◦ T. schoenleini: terbinafine for 1 week: 2.8% (1/35); terbinafine for 4 weeks:
2.9% (1/34)
◦ M. gypseum: terbinafine for 4 weeks: 2.9% (1/34)
• No mention of adherence assessment
Interventions • Group 1: terbinafine 10 to 20 kg: 62.5 mg/d; 20 to 40 kg: 125 mg/d; > 40 kg:
250 mg/d once daily for 1 week plus 3 weeks of placebo (N = 42)
• Group 2: terbinafine same dose for 2 weeks plus 2 weeks of placebo (N = 44)
• Group 3: terbinafine same dose for 4 weeks same dose (N = 46)
No co-treatment
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure only at 12 weeks
• Percentage of drop-outs as a surrogate for participant adherence
Notes Funding: Sandoz (terbinafine)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Only participants blinded, but
themethod of blinding was not stated. The
outcomes were likely to be influenced if the
clinicians were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: Outcome assessors were not
blinded.
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Talarico Filho 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 18.2% (24/132) participants
lost to follow-up. Among them, 6 were in
the terbinafine for 1 week group, 6 were in
the terbinafine for 2 weeks group, and 12
were in the terbinafine for 4 weeks group.
ITT analyses were performed. The reasons
for drop-outs were not clear
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
◦ Severity of infection: studied
but not shown
◦ Age: terbinafine for 1 week: 6.5
years; terbinafine for 2 weeks: 6.5 years;
terbinafine for 4 weeks: 6.1 years
◦ Sex: terbinafine for 1 week:
males 26, females 16; terbinafine for 2
weeks: males 17, females 27; terbinafine
for 4 weeks: males 26, females 20
◦ Duration of complaint: studied
but not shown
Tanz 1985
Methods Triple-blind, parallel group RCT for 6 weeks
Participants • Chicago (USA)
• N = 22
• Inclusion criteria: children 2-16 years old were eligible if they had clinically
diagnosed or mycologically proven tinea capitis
• Exclusion criteria: those that had received systemic antimycotic therapy within 1
month of enrolment, if griseofulvin therapy was contraindicated; if they had a serious
concurrent disease or a history of hepatitis; if they were taking warfarin-like
anticoagulants or barbiturates, or if they were pregnant
• Fungi isolated
◦ T. tonsurans: 50% (11/22)
◦ Scopulariopsis spp. : 4.5% (1/22)
◦ Penicillium spp. :4.5% (1/22)
◦ Unidentified fungus: 4.5% (1/22)
• Adherence assessed
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Tanz 1985 (Continued)
Interventions • Group 1: griseofulvin tablet, 500 mg/d, plus ’ketoconazole’ placebo tablet
(participants < 40 kg: half tablet) for 6 weeks (N = 12)
• Group 2: ketoconazole tablet, 200 mg/d, plus ’griseofulvin’ placebo tablet
(participants weighing < 40 kg: half tablet) for 6 weeks (N = 10)
Co-treatment: antiseborrhoeic shampoo
Outcomes • The frequency and type of adverse events
• Percentage of drop-outs as a surrogate for participant adherence
• Mycological cure at 12 weeks
One of the primary outcomes of interest in this review (complete cure rate) was not
reported in this study
Notes Funding: Janssen (ketoconazole)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 36.4% (8/22) participants lost
to follow-up. Among them, 3 were in the
griseofulvin group, whereas 5 were in the
ketoconazole group. ITT analysis was not
performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability
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Tanz 1985 (Continued)
◦ Severity of infection:
(minimum score = 0, maximum score =
21): griseofulvin group: 9.3; ketoconazole
group: 8.3
◦ Age: griseofulvin group: 6.4;
ketoconazole group: 5.7
◦ Sex: (male: female): griseofulvin
group: 0:7; ketoconazole group: 2:5
◦ Duration of complaint: (weeks)
: griseofulvin group: 16.5; ketoconazole
group: 24
Tanz 1988
Methods Triple-blind, parallel group RCT for 12 weeks
Participants • Chicago (USA)
• N = 79 (65% female)
• 92% black
• Inclusion criteria: children aged 2-16 years old, with tinea capitis or mycologic
evidence of dermatophyte infection of the scalp
• Exclusion criteria: participants receiving systemic antimycotic therapy within 30
days of the initial visit; if they had a history of porphyria, liver disease, or
immunodeficiency; if they were pregnant or if they were receiving warfarin-like
anticoagulants or barbiturates
• Fungi isolated
◦ T. tonsurans: 64% of the enrolled participants and 74% of the evaluable
participants
◦ M. canis: 12% of the enrolled participants and 13% of evaluable participants
• Adherence not assessed
Interventions • Group 1: griseofulvin (microsize) 250 mg tablet ( 10 to 20 mg/kg/d) plus
’ketoconazole’ placebo tablet, single daily dose, for 12 weeks (N = 46)
• Group 2: ketoconazole 200 mg tablet (3.3 to 6.6 mg/kg/d) plus ’griseofulvin’
placebo tablet in a single daily dose for 12 weeks (N = 33)
Co-treatment: antiseborrhoeic shampoos
Outcomes • The proportion of participants with complete cure at 12 weeks
• The frequency and type of adverse events
• The proportion of participants with clinical cure at 12 weeks
• Percentage of drop-outs as a surrogate for participant adherence
• Mycological cure at 12 weeks
Notes Not much information given apart from the total cured results
The enrolled : 79 were randomised, 46 were evaluable
Funding: Janssen (ketoconazole)
Risk of bias
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Tanz 1988 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 39.2%(31/79) participants lost
to follow-up. Among them, 20 were in the
griseofulvin group, whereas 11 were in the
ketoconazole group. ITT analysis was not
performed
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: no
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability: taken into
account but not reported
There were no statistically significant dif-
ferences between the groups in terms of age,
sex, weight or duration of infection
Ungpakorn 2004
Methods Triple-blind, parallel group RCT for 20 weeks
Participants • Thailand
• N = 42
• Inclusion criteria: not to have received any topical or systemic antifungal therapy
in the preceding 2 or 4 weeks, respectively
• Fungi isolated: Microsporum spp.:
◦ M. ferrugineum 50% (21/42)
◦ M. canis 47.6% (20/42)
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Ungpakorn 2004 (Continued)
◦ M. gypseum 2.3% (81/42)
Interventions • Group 1: oral terbinafine 10 to 20 kg: 62.5 mg/d; 20 to 40 kg: 125 mg/d; over 40
kg: 250 mg/d, in a pulsed regimen (N = 23)
• Group 2: oral terbinafine at double dose, in a similar pulsed regimen (N = 19)
Outcomes • Proportion of participants with complete cure at 20 weeks
• Mycological cure at 20 weeks.
One of the primary outcomes of interest in this review (adverse events) was not reported
in this study
Notes Funding: Institute of Dermatology Research Funds and Novartis (Thailand)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: There was no information on
the method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: There was no information on
the method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Participants and clinicians were
blinded, but the method of blinding was
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Outcome assessors
were blinded, but the method of blinding
was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no drop-outs
Selective reporting (reporting bias) Low risk Comment: The publication reported find-
ings on all outcomes listed in the Methods
section
Other bias Unclear risk • Sample size calculation declared: yes
• Inclusion criteria: yes
• Exclusion criteria: yes
• Reporting of type of fungi involved:
yes
• Baseline comparability: not
mentioned
ITT: intention-to-treat; KOH: potassium hydroxide; RCT: randomised controlled trial.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ginsburg 1987 Excluded because this study evaluated the therapy for inflammatory lesions caused by tinea capitis.
The main aim of this study was to analyse the treatment of kerions in tinea capitis, combining
the tinea capitis treatment of griseofulvin plus intralesional corticosteroid to try to reduce the
inflammation
Honig 1994 Excluded because this study evaluated the therapy for inflammatory lesions caused by tinea capitis.
It combined griseofulvin for the tinea capitis with steroids to modulate the immune-mediated
inflammation, hasten resolution of kerions and minimise scar formation
Hussain 1999 Excluded because this study evaluated the therapy for inflammatory lesions caused by tinea capitis.
It combined griseofulvin treatment and griseofulvin treatment plus prednisolone, a glucocorticoid
Koumantaki-Mathioudaki 2005 Excluded because this study was not a RCT
Shemer 2013 Excluded because this study was not a RCT
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Pather 2006
Methods Single-blinded, randomised controlled trial
Participants 64 children with tinea capitis aged 4-12 years randomised to 3 treatment groups. 5 participants lost to follow-up
Interventions 1. Group 1: griseofulvin (10 mg/kg; daily dose for 6 weeks)
2. Group 2: griseofulvin (50 mg/kg; 2 doses 1 month apart)
3. Group 3: griseofulvin (50 mg/kg; weekly dose for 6 weeks)
Outcomes Primary outcome: mycological cure rate at week 6
Secondary outcomes: clinical improvement according to clinical symptom score; mycological cure rate at month 6;
the type and frequency of adverse events
Notes -
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D A T A A N D A N A L Y S E S
Comparison 1. Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment duration; 6-24 weeks
follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
5 477 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.94, 1.24]
1.1 Trichophyton infections 3 328 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.98, 1.15]
1.2 Microsporum infections 1 21 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.15, 1.35]
1.3 Mixed
Trichophyton/Microsporum
infections
2 128 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.64, 2.42]
2 Primary outcome: adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Drug-related adverse
events
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Secondary outcome: proportion
of participants with clinical
cure only
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 2-week terbinafine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 4-week terbinafine 3 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Secondary outcome: percentage
of drop-outs as a surrogate for
participant adherence
4 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections; medium treatment
duration; 10 weeks follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
1 1006 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.74, 1.88]
1.1 T. tonsurans infections 1 764 Risk Ratio (M-H, Random, 95% CI) 1.47 [1.22, 1.77]
1.2 T. violaceum infections 1 242 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.68, 1.24]
2 Primary outcome: drug-related
adverse events
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Primary outcome: severe adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Secondary outcomes: proportion
of participants with clinical
cure only
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 T. tonsurans infections 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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4.2 T. violaceum infections 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Terbinafine, medium- (6-8 weeks) and long-term (10-12 weeks) treatment versus griseofulvin in
Microsporum infections; 10-16 weeks follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Medium terbinafine
treatment duration (6-8 weeks)
2 334 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.53, 0.86]
1.2 Long terbinafine
treatment duration (10-12
weeks)
1 95 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.34, 0.76]
2 Secondary outcome: clinical cure
only
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Medium terbinafine
treatment duration (6-8 weeks)
2 334 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.63, 0.91]
2.2 Long terbinafine
treatment duration (10-12
weeks)
1 95 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.52, 0.92]
Comparison 4. Terbinafine, short-term versus long-term for treating Trichophyton and Microsporum infections;
12-20 weeks follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 1-2 weeks versus 4 weeks 4 552 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.62, 0.86]
1.2 Medium term (6-8 weeks)
versus long term (10-12 weeks)
1 135 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.97, 2.17]
2 Secondary outcome: clinical cure
only
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 1-2 weeks versus 4 weeks 3 470 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.67, 1.06]
2.2 Medium term (6-8 weeks)
versus long term (10-12 weeks)
1 135 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.90, 1.56]
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Comparison 5. Terbinafine standard dose versus double dose in Microsporum infections; 20 weeks follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 6. Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in Trichophyton and Microsporum
infections
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
2 134 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.81, 1.05]
2 Secondary outcome: proportion
of participants with clinical
cure only
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Secondary outcome: percentage
of drop-outs as a surrogate for
participant adherence
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 7. Itraconazole versus terbinafine (both 2 weeks) in Trichophyton infections
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
2 160 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.72, 1.19]
2 Secondary outcome: clinical cure
only
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Secondary outcome: percentage
of drop-outs as a surrogate for
participant adherence
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Comparison 8. Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in Trichophyton infections; 12-26
weeks follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Ketoconazole (12 weeks)
versus griseofulvin (12 weeks)
assessed at 12 weeks
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Ketoconazole (up to 26
weeks) versus griseofulvin (up
to 26 weeks) assessed at 26
weeks
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Ketoconazole (12 weeks)
versus griseofulvin (12 weeks)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Secondary outcome: proportion
of participants with clinical
cure only
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Secondary outcome: percentage
of drop-outs as a surrogate for
participant adherence
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 9. Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Short-term (2-4 weeks)
fluconazole
3 500 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.81, 1.05]
1.2 Medium-term (6 weeks)
fluconazole
1 361 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.77, 1.46]
2 Secondary outcome: proportion
of participants with clinical
cure only
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Secondary outcome: percentage
of drop-outs as a surrogate for
participant adherence
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Comparison 10. Fluconazole (2-3 weeks) versus terbinafine (2-3 weeks) in Trichophyton infections; 12 weeks
follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 11. Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in Trichophyton infections; 12 weeks
follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Secondary outcome: proportion
of participants with clinical
cure only
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Secondary outcome: percentage
of drop-outs as a surrogate for
participant adherence
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 12. Fluconazole low dose versus higher dose (1.5, 3.0 and 6.0 mg/kg/d) in Trichophyton infections;
4 months follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 1.5 mg versus 3.0 mg 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 1.5 mg versus 6.0 mg 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 3.0 mg versus 6.0 mg 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 13. Fluconazole 3 weeks versus 6 weeks; 10 weeks follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: complete cure,
i.e. clinical and mycological
cure
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment
duration; 6-24 weeks follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment duration; 6-24 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup Terbinafine Griseofulvin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Trichophyton infections
Haroon 1995 52/56 39/49 29.3 % 1.17 [ 0.99, 1.37 ]
Fuller 2001 45/65 39/58 19.3 % 1.03 [ 0.81, 1.31 ]
Gupta 2001 47/50 46/50 37.5 % 1.02 [ 0.92, 1.14 ]
Subtotal (95% CI) 171 157 86.1 % 1.06 [ 0.98, 1.15 ]
Total events: 144 (Terbinafine), 124 (Griseofulvin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.95, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Microsporum infections
Fuller 2001 3/11 6/10 1.5 % 0.45 [ 0.15, 1.35 ]
Subtotal (95% CI) 11 10 1.5 % 0.45 [ 0.15, 1.35 ]
Total events: 3 (Terbinafine), 6 (Griseofulvin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
3 Mixed Trichophyton/Microsporum infections
Memisoglu 1999 15/39 17/39 5.8 % 0.88 [ 0.52, 1.50 ]
C ceres-R os 2000 19/25 11/25 6.6 % 1.73 [ 1.05, 2.83 ]
Subtotal (95% CI) 64 64 12.4 % 1.24 [ 0.64, 2.42 ]
Total events: 34 (Terbinafine), 28 (Griseofulvin)
Heterogeneity: Tau2 = 0.16; Chi2 = 3.33, df = 1 (P = 0.07); I2 =70%
0.1 0.2 0.5 1 2 5 10
Favours griseofulvin Favours terbinafine
(Continued . . . )
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(. . . Continued)
Study or subgroup Terbinafine Griseofulvin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.65 (P = 0.52)
Total (95% CI) 246 231 100.0 % 1.08 [ 0.94, 1.24 ]
Total events: 181 (Terbinafine), 158 (Griseofulvin)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.43, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 2.54, df = 2 (P = 0.28), I2 =21%
0.1 0.2 0.5 1 2 5 10
Favours griseofulvin Favours terbinafine
Analysis 1.2. Comparison 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment
duration; 6-24 weeks follow-up, Outcome 2 Primary outcome: adverse events.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment duration; 6-24 weeks follow-up
Outcome: 2 Primary outcome: adverse events
Study or subgroup Terbinafine Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Drug-related adverse events
Fuller 2001 26/77 17/70 1.39 [ 0.83, 2.34 ]
0.01 0.1 1 10 100
Favours terbinafine Favours griseofulvin
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Analysis 1.3. Comparison 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment
duration; 6-24 weeks follow-up, Outcome 3 Secondary outcome: proportion of participants with clinical cure
only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment duration; 6-24 weeks follow-up
Outcome: 3 Secondary outcome: proportion of participants with clinical cure only
Study or subgroup Terbinafine Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2-week terbinafine
Deng 2011 23/27 16/19 1.01 [ 0.79, 1.30 ]
2 4-week terbinafine
Deng 2011 18/23 16/19 0.93 [ 0.70, 1.24 ]
Gupta 2001 20/50 35/50 0.57 [ 0.39, 0.84 ]
Khan 2011 42/60 33/60 1.27 [ 0.96, 1.69 ]
0.01 0.1 1 10 100
Favours griseofulvin Favours terbinafine
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Analysis 1.4. Comparison 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment
duration; 6-24 weeks follow-up, Outcome 4 Secondary outcome: percentage of drop-outs as a surrogate for
participant adherence.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 1 Terbinafine (2-4 weeks) versus griseofulvin (6-8 weeks); short treatment duration; 6-24 weeks follow-up
Outcome: 4 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence
Study or subgroup Terbinafine Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Deng 2011 0/50 1/19 0.13 [ 0.01, 3.08 ]
Fuller 2001 37/103 26/107 1.48 [ 0.97, 2.26 ]
Gupta 2001 2/50 4/50 0.50 [ 0.10, 2.61 ]
Memisoglu 1999 4/39 7/39 0.57 [ 0.18, 1.80 ]
0.005 0.1 1 10 200
Favours terbinafine Favours griseofulvin
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Analysis 2.1. Comparison 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections;
medium treatment duration; 10 weeks follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical
and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections; medium treatment duration; 10 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup Terbinafine Griseofulvin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 T. tonsurans infections
Elewski 2008 264/507 91/257 53.3 % 1.47 [ 1.22, 1.77 ]
Subtotal (95% CI) 507 257 53.3 % 1.47 [ 1.22, 1.77 ]
Total events: 264 (Terbinafine), 91 (Griseofulvin)
Heterogeneity: not applicable
Test for overall effect: Z = 4.08 (P = 0.000044)
2 T. violaceum infections
Elewski 2008 66/160 37/82 46.7 % 0.91 [ 0.68, 1.24 ]
Subtotal (95% CI) 160 82 46.7 % 0.91 [ 0.68, 1.24 ]
Total events: 66 (Terbinafine), 37 (Griseofulvin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 667 339 100.0 % 1.18 [ 0.74, 1.88 ]
Total events: 330 (Terbinafine), 128 (Griseofulvin)
Heterogeneity: Tau2 = 0.10; Chi2 = 6.95, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 6.92, df = 1 (P = 0.01), I2 =86%
0.02 0.1 1 10 50
Favours griseofulvin Favours terbinafine
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Analysis 2.2. Comparison 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections;
medium treatment duration; 10 weeks follow-up, Outcome 2 Primary outcome: drug-related adverse events.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections; medium treatment duration; 10 weeks follow-up
Outcome: 2 Primary outcome: drug-related adverse events
Study or subgroup Terbinafine Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elewski 2008 96/1042 42/507 1.11 [ 0.79, 1.57 ]
0.01 0.1 1 10 100
Favours terbinafine Favours griseofulvin
Analysis 2.3. Comparison 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections;
medium treatment duration; 10 weeks follow-up, Outcome 3 Primary outcome: severe adverse events.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections; medium treatment duration; 10 weeks follow-up
Outcome: 3 Primary outcome: severe adverse events
Study or subgroup Terbinafine Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elewski 2008 6/1042 3/507 0.97 [ 0.24, 3.88 ]
0.01 0.1 1 10 100
Favours terbinafine Favours griseofulvin
97Systemic antifungal therapy for tinea capitis in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.4. Comparison 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections;
medium treatment duration; 10 weeks follow-up, Outcome 4 Secondary outcomes: proportion of participants
with clinical cure only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 2 Terbinafine (6 weeks) versus griseofulvin (6 weeks) in Trichophyton infections; medium treatment duration; 10 weeks follow-up
Outcome: 4 Secondary outcomes: proportion of participants with clinical cure only
Study or subgroup Terbinafine Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 T. tonsurans infections
Elewski 2008 355/507 147/257 1.22 [ 1.09, 1.38 ]
2 T. violaceum infections
Elewski 2008 104/160 53/82 1.01 [ 0.83, 1.22 ]
0.01 0.1 1 10 100
Favours griseofulvin Favours terbinafine
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Analysis 3.1. Comparison 3 Terbinafine, medium- (6-8 weeks) and long-term (10-12 weeks) treatment
versus griseofulvin in Microsporum infections; 10-16 weeks follow-up, Outcome 1 Primary outcome: complete
cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 3 Terbinafine, medium- (6-8 weeks) and long-term (10-12 weeks) treatment versus griseofulvin inMicrosporum infections; 10-16 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup Terbinafine Griseofulvin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium terbinafine treatment duration (6-8 weeks)
Elewski 2008 41/152 36/82 45.4 % 0.61 [ 0.43, 0.88 ]
Lipozencic 2002 36/70 21/30 54.6 % 0.73 [ 0.53, 1.02 ]
Subtotal (95% CI) 222 112 100.0 % 0.68 [ 0.53, 0.86 ]
Total events: 77 (Terbinafine), 57 (Griseofulvin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 Long terbinafine treatment duration (10-12 weeks)
Lipozencic 2002 23/65 21/30 100.0 % 0.51 [ 0.34, 0.76 ]
Subtotal (95% CI) 65 30 100.0 % 0.51 [ 0.34, 0.76 ]
Total events: 23 (Terbinafine), 21 (Griseofulvin)
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00092)
0.1 0.2 0.5 1 2 5 10
Favours griseofulvin Favours terbinafine
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Analysis 3.2. Comparison 3 Terbinafine, medium- (6-8 weeks) and long-term (10-12 weeks) treatment
versus griseofulvin in Microsporum infections; 10-16 weeks follow-up, Outcome 2 Secondary outcome: clinical
cure only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 3 Terbinafine, medium- (6-8 weeks) and long-term (10-12 weeks) treatment versus griseofulvin inMicrosporum infections; 10-16 weeks follow-up
Outcome: 2 Secondary outcome: clinical cure only
Study or subgroup Terbinafine Griseofulvin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium terbinafine treatment duration (6-8 weeks)
Elewski 2008 60/152 47/82 45.2 % 0.69 [ 0.53, 0.90 ]
Lipozencic 2002 46/70 24/30 54.8 % 0.82 [ 0.64, 1.05 ]
Subtotal (95% CI) 222 112 100.0 % 0.76 [ 0.63, 0.91 ]
Total events: 106 (Terbinafine), 71 (Griseofulvin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.97 (P = 0.0030)
2 Long terbinafine treatment duration (10-12 weeks)
Lipozencic 2002 36/65 24/30 100.0 % 0.69 [ 0.52, 0.92 ]
Subtotal (95% CI) 65 30 100.0 % 0.69 [ 0.52, 0.92 ]
Total events: 36 (Terbinafine), 24 (Griseofulvin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
0.1 0.2 0.5 1 2 5 10
Favours griseofulvin Favours terbinafine
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Analysis 4.1. Comparison 4 Terbinafine, short-term versus long-term for treating Trichophyton and
Microsporum infections; 12-20 weeks follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical and
mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 4 Terbinafine, short-term versus long-term for treating Trichophyton and Microsporum infections; 12-20 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup Shorter terbinafine Longer terbinafine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1-2 weeks versus 4 weeks
Haroon 1996 57/104 38/57 31.1 % 0.82 [ 0.64, 1.06 ]
Kullavanijaya 1997 28/55 21/27 20.3 % 0.65 [ 0.47, 0.91 ]
Talarico Filho 1998 42/86 36/46 29.0 % 0.62 [ 0.48, 0.81 ]
Friedlander 2002 48/115 30/62 19.6 % 0.86 [ 0.62, 1.21 ]
Subtotal (95% CI) 360 192 100.0 % 0.73 [ 0.62, 0.86 ]
Total events: 175 (Shorter terbinafine), 125 (Longer terbinafine)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.64, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 Medium term (6-8 weeks) versus long term (10-12 weeks)
Lipozencic 2002 36/70 23/65 100.0 % 1.45 [ 0.97, 2.17 ]
Subtotal (95% CI) 70 65 100.0 % 1.45 [ 0.97, 2.17 ]
Total events: 36 (Shorter terbinafine), 23 (Longer terbinafine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
0.1 0.2 0.5 1 2 5 10
Favours longer Favours shorter
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Analysis 4.2. Comparison 4 Terbinafine, short-term versus long-term for treating Trichophyton and
Microsporum infections; 12-20 weeks follow-up, Outcome 2 Secondary outcome: clinical cure only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 4 Terbinafine, short-term versus long-term for treating Trichophyton and Microsporum infections; 12-20 weeks follow-up
Outcome: 2 Secondary outcome: clinical cure only
Study or subgroup shorter terbinafine longer terbinafine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1-2 weeks versus 4 weeks
Haroon 1996 87/104 49/57 39.8 % 0.97 [ 0.85, 1.11 ]
Talarico Filho 1998 50/86 39/46 32.7 % 0.69 [ 0.55, 0.85 ]
Friedlander 2002 58/115 36/62 27.6 % 0.87 [ 0.66, 1.15 ]
Subtotal (95% CI) 305 165 100.0 % 0.84 [ 0.67, 1.06 ]
Total events: 195 (shorter terbinafine), 124 (longer terbinafine)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.58, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Medium term (6-8 weeks) versus long term (10-12 weeks)
Lipozencic 2002 46/70 36/65 100.0 % 1.19 [ 0.90, 1.56 ]
Subtotal (95% CI) 70 65 100.0 % 1.19 [ 0.90, 1.56 ]
Total events: 46 (shorter terbinafine), 36 (longer terbinafine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.22)
0.1 0.2 0.5 1 2 5 10
Favours longer Favours shorter
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Analysis 5.1. Comparison 5 Terbinafine standard dose versus double dose in Microsporum infections; 20
weeks follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 5 Terbinafine standard dose versus double dose in Microsporum infections; 20 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup double dose standard dose Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ungpakorn 2004 13/19 14/23 1.12 [ 0.72, 1.76 ]
0.01 0.1 1 10 100
Favours standard Favours double
Analysis 6.1. Comparison 6 Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in Trichophyton and
Microsporum infections, Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 6 Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in Trichophyton and Microsporum infections
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup itraconazole griseofulvin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 41/50 46/50 71.9 % 0.89 [ 0.76, 1.04 ]
L pez-G mez 1994 15/17 15/17 28.1 % 1.00 [ 0.78, 1.28 ]
Total (95% CI) 67 67 100.0 % 0.92 [ 0.81, 1.05 ]
Total events: 56 (itraconazole), 61 (griseofulvin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours griseofulvin Favours itraconazole
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Analysis 6.2. Comparison 6 Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in Trichophyton and
Microsporum infections, Outcome 2 Secondary outcome: proportion of participants with clinical cure only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 6 Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in Trichophyton and Microsporum infections
Outcome: 2 Secondary outcome: proportion of participants with clinical cure only
Study or subgroup itraconazole griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 22/50 35/50 0.63 [ 0.44, 0.90 ]
0.01 0.1 1 10 100
Favours griseofulvin Favours itraconazole
Analysis 6.3. Comparison 6 Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in Trichophyton and
Microsporum infections, Outcome 3 Secondary outcome: percentage of drop-outs as a surrogate for
participant adherence.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 6 Itraconazole (6 and 2 weeks) versus griseofulvin (6 weeks) in Trichophyton and Microsporum infections
Outcome: 3 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence
Study or subgroup itraconazole griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 4/50 4/50 1.00 [ 0.26, 3.78 ]
L pez-G mez 1994 1/18 2/17 0.47 [ 0.05, 4.74 ]
0.01 0.1 1 10 100
Favours itraconazole Favours griseofulvin
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Analysis 7.1. Comparison 7 Itraconazole versus terbinafine (both 2 weeks) in Trichophyton infections,
Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 7 Itraconazole versus terbinafine (both 2 weeks) in Trichophyton infections
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup itraconazole terbinafine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jahangir 1998 18/30 16/30 24.0 % 1.13 [ 0.72, 1.75 ]
Gupta 2001 41/50 47/50 76.0 % 0.87 [ 0.75, 1.01 ]
Total (95% CI) 80 80 100.0 % 0.93 [ 0.72, 1.19 ]
Total events: 59 (itraconazole), 63 (terbinafine)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours terbinafine Favours itraconazole
Analysis 7.2. Comparison 7 Itraconazole versus terbinafine (both 2 weeks) in Trichophyton infections,
Outcome 2 Secondary outcome: clinical cure only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 7 Itraconazole versus terbinafine (both 2 weeks) in Trichophyton infections
Outcome: 2 Secondary outcome: clinical cure only
Study or subgroup itraconazole terbinafine Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 22/50 20/50 1.10 [ 0.69, 1.75 ]
0.1 0.2 0.5 1 2 5 10
Favours terbinafine Favours itraconazole
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Analysis 7.3. Comparison 7 Itraconazole versus terbinafine (both 2 weeks) in Trichophyton infections,
Outcome 3 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 7 Itraconazole versus terbinafine (both 2 weeks) in Trichophyton infections
Outcome: 3 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence
Study or subgroup itraconazole terbinafine Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 4/50 2/50 2.00 [ 0.38, 10.43 ]
0.01 0.1 1 10 100
Favours itraconazole Favours tervinafine
Analysis 8.1. Comparison 8 Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in Trichophyton
infections; 12-26 weeks follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological
cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 8 Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in Trichophyton infections; 12-26 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup Ketoconazole Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ketoconazole (12 weeks) versus griseofulvin (12 weeks) assessed at 12 weeks
Gan 1987 25/34 27/28 0.76 [ 0.62, 0.94 ]
2 Ketoconazole (up to 26 weeks) versus griseofulvin (up to 26 weeks) assessed at 26 weeks
Gan 1987 31/34 28/28 0.92 [ 0.81, 1.03 ]
3 Ketoconazole (12 weeks) versus griseofulvin (12 weeks)
Tanz 1988 16/33 25/46 0.89 [ 0.57, 1.39 ]
0.5 0.7 1 1.5 2
Favours griseofulvin Favours ketoconazole
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Analysis 8.2. Comparison 8 Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in Trichophyton
infections; 12-26 weeks follow-up, Outcome 2 Secondary outcome: proportion of participants with clinical cure
only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 8 Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in Trichophyton infections; 12-26 weeks follow-up
Outcome: 2 Secondary outcome: proportion of participants with clinical cure only
Study or subgroup Ketoconazole Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mart nez-Roig 1988 8/8 4/5 1.26 [ 0.77, 2.05 ]
0.01 0.1 1 10 100
Favours griseofulvin Favours ketoconazole
Analysis 8.3. Comparison 8 Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in Trichophyton
infections; 12-26 weeks follow-up, Outcome 3 Secondary outcome: percentage of drop-outs as a surrogate for
participant adherence.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 8 Ketoconazole (2-26 weeks) versus griseofulvin (2 to 26 weeks) in Trichophyton infections; 12-26 weeks follow-up
Outcome: 3 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence
Study or subgroup Ketoconazole Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tanz 1985 3/10 5/12 0.72 [ 0.23, 2.30 ]
Tanz 1988 22/33 26/46 1.18 [ 0.83, 1.67 ]
0.01 0.1 1 10 100
Favours ketoconazole Favours griseofulvin
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Analysis 9.1. Comparison 9 Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up,
Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 9 Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup Fluconazole Griseofulvin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term (2-4 weeks) fluconazole
Dastghaib 2005 15/19 16/21 14.9 % 1.04 [ 0.74, 1.45 ]
Foster 2005 74/245 36/115 15.1 % 0.96 [ 0.69, 1.34 ]
Gupta 2001 41/50 46/50 70.1 % 0.89 [ 0.76, 1.04 ]
Subtotal (95% CI) 314 186 100.0 % 0.92 [ 0.81, 1.05 ]
Total events: 130 (Fluconazole), 98 (Griseofulvin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Medium-term (6 weeks) fluconazole
Foster 2005 84/246 37/115 100.0 % 1.06 [ 0.77, 1.46 ]
Subtotal (95% CI) 246 115 100.0 % 1.06 [ 0.77, 1.46 ]
Total events: 84 (Fluconazole), 37 (Griseofulvin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours griseofulvin Favours fluconazole
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Analysis 9.2. Comparison 9 Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up,
Outcome 2 Secondary outcome: proportion of participants with clinical cure only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 9 Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up
Outcome: 2 Secondary outcome: proportion of participants with clinical cure only
Study or subgroup Fluconazole Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 13/50 35/50 0.37 [ 0.22, 0.61 ]
0.01 0.1 1 10 100
Favours griseofulvin Favours fluconazole
Analysis 9.3. Comparison 9 Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up,
Outcome 3 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 9 Fluconazole (2-6 weeks) versus griseofulvin (6 weeks); 8-12 weeks follow-up
Outcome: 3 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence
Study or subgroup Fluconazole Griseofulvin Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 4/50 4/50 1.00 [ 0.26, 3.78 ]
0.01 0.1 1 10 100
Favours fluconazole Favours griseofulvin
109Systemic antifungal therapy for tinea capitis in children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.1. Comparison 10 Fluconazole (2-3 weeks) versus terbinafine (2-3 weeks) in Trichophyton
infections; 12 weeks follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 10 Fluconazole (2-3 weeks) versus terbinafine (2-3 weeks) in Trichophyton infections; 12 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup fluconazole terbinafine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 41/50 47/50 0.87 [ 0.75, 1.01 ]
0.1 0.2 0.5 1 2 5 10
Favours terbinafine Favours fluconazole
Analysis 11.1. Comparison 11 Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in Trichophyton
infections; 12 weeks follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 11 Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in Trichophyton infections; 12 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup fluconazole itraconazole Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 41/50 41/50 1.00 [ 0.83, 1.20 ]
0.1 0.2 0.5 1 2 5 10
Favours itraconazole Favours fluconazole
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Analysis 11.2. Comparison 11 Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in Trichophyton
infections; 12 weeks follow-up, Outcome 2 Secondary outcome: proportion of participants with clinical cure
only.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 11 Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in Trichophyton infections; 12 weeks follow-up
Outcome: 2 Secondary outcome: proportion of participants with clinical cure only
Study or subgroup itraconazole fluconazole Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 22/50 13/50 1.69 [ 0.96, 2.97 ]
0.01 0.1 1 10 100
Favours fluconazole Favours itraconazole
Analysis 11.3. Comparison 11 Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in Trichophyton
infections; 12 weeks follow-up, Outcome 3 Secondary outcome: percentage of drop-outs as a surrogate for
participant adherence.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 11 Fluconazole (2-3 weeks) versus itraconazole (2-3 weeks) in Trichophyton infections; 12 weeks follow-up
Outcome: 3 Secondary outcome: percentage of drop-outs as a surrogate for participant adherence
Study or subgroup fluconazole itraconazole Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2001 4/50 4/50 1.00 [ 0.26, 3.78 ]
0.01 0.1 1 10 100
Favours fluconazole Favours itraconazole
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Analysis 12.1. Comparison 12 Fluconazole low dose versus higher dose (1.5, 3.0 and 6.0 mg/kg/d) in
Trichophyton infections; 4 months follow-up, Outcome 1 Primary outcome: complete cure, i.e. clinical and
mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 12 Fluconazole low dose versus higher dose (1.5, 3.0 and 6.0 mg/kg/d) in Trichophyton infections; 4 months follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup high dose low dose Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 1.5 mg versus 3.0 mg
Solomon 1997 6/15 2/12 2.40 [ 0.59, 9.82 ]
2 1.5 mg versus 6.0 mg
Solomon 1997 8/14 2/12 3.43 [ 0.89, 13.15 ]
3 3.0 mg versus 6.0 mg
Solomon 1997 8/14 6/15 1.43 [ 0.66, 3.08 ]
0.005 0.1 1 10 200
Favours low dose Favours high dose
Analysis 13.1. Comparison 13 Fluconazole 3 weeks versus 6 weeks; 10 weeks follow-up, Outcome 1 Primary
outcome: complete cure, i.e. clinical and mycological cure.
Review: Systemic antifungal therapy for tinea capitis in children
Comparison: 13 Fluconazole 3 weeks versus 6 weeks; 10 weeks follow-up
Outcome: 1 Primary outcome: complete cure, i.e. clinical and mycological cure
Study or subgroup 3 weeks 6 weeks Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Foster 2005 74/245 84/246 0.88 [ 0.68, 1.14 ]
0.01 0.1 1 10 100
Favours 6 weeks regimen Favours 3 weeks regimen
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A P P E N D I C E S
Appendix 1. Cochrane Skin Group Specialized Register (CRS) search strategy
(tinea and (capitis or tonsurans)) or kerion or (ringworm near (hair or scalp or head))
Appendix 2. CENTRAL (Cochrane Library) search strategy
#1 MeSH descriptor: [Tinea Capitis] explode all trees
#2 tinea tonsurans:ti,ab,kw
#3 (ringworm near/3 (hair or scalp or head))
#4 tinea capitis:ti,ab,kw
#5 herpes tonsurans:ti,ab,kw
#6 kerion:ti,ab,kw
#7 {or #1-#6}
#8 MeSH descriptor: [Antifungal Agents] explode all trees
#9 MeSH descriptor: [Griseofulvin] explode all trees
#10 MeSH descriptor: [Itraconazole] explode all trees
#11 MeSH descriptor: [Fluconazole] explode all trees
#12 (griseofulvin or terbinafine or itraconazole or fluconazole):ti,ab,kw
#13 {or #8-#12}
#14 #7 and #13
Appendix 3. MEDLINE (Ovid) search strategy
1. tinea tonsurans.mp.
2. exp Tinea Capitis/
3. (ringworm adj3 (hair or scalp or head)).mp.
4. tinea capitis.mp.
5. herpes tonsurans.mp.
6. kerion.mp.
7. or/1-6
8. Antifungal Agents/
9. Griseofulvin/
10. Itraconazole/
11. Fluconazole/
12. (griseofulvin or terbinafine or itraconazole or fluconazole).mp.
13. or/8-12
14. randomized controlled trial.pt.
15. controlled clinical trial.pt.
16. randomized.ab.
17. placebo.ab.
18. clinical trials as topic.sh.
19. randomly.ab.
20. trial.ti.
21. 14 or 15 or 16 or 17 or 18 or 19 or 20
22. exp animals/ not humans.sh.
23. 21 not 22
24. 7 and 13 and 23
[Lines 14-23: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-
maximizing version (2008 revision)]
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Appendix 4. Embase (Ovid) search strategy
1. tinea capitis/
2. tinea tonsurans.mp.
3. (ringworm adj3 (head or hair or scalp)).mp.
4. tinea capitis.mp.
5. herpes tonsurans.mp.
6. kerion/
7. kerion.mp.
8. or/1-7
9. antifungal agent/
10. griseofulvin/
11. itraconazole/
12. fluconazole/
13. terbinafine/
14. (griseofulvin or terbinafine or itraconazole or fluconazole).mp.
15. or/9-14
16. crossover procedure.sh.
17. double-blind procedure.sh.
18. single-blind procedure.sh.
19. (crossover$ or cross over$).tw.
20. placebo$.tw.
21. (doubl$ adj blind$).tw.
22. allocat$.tw.
23. trial.ti.
24. randomized controlled trial.sh.
25. random$.tw.
26. or/16-25
27. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
28. human/ or normal human/
29. 27 and 28
30. 27 not 29
31. 26 not 30
32. 8 and 15 and 31
Appendix 5. LILACS search strategy
((tinea or tina) and (capitis or tonsurans or tonsurante)) or kerion or querion or (ringworm near (hair or scalp or head))
These terms were combined with the Controlled clinical trials topic-specific query filter in the LILACS database.
Appendix 6. CINAHL (EBSCO) search strategy
S1 TI ( (tinea and (capitis or tonsurans)) or kerion or (ringworm near3 (hair or scalp or head)) ) OR AB ( (tinea and (capitis or
tonsurans)) or kerion or (ringworm near3 (hair or scalp or head)) )
S2 (MH “Clinical Trials+”)
S3 PT clinical trial
S4 TX (clinic* n1 trial*)
S5 (MH “Random Assignment”)
S6 TX random* allocat*
S7 TX placebo*
S8 (MH “Placebos”)
S9 (MH “Quantitative Studies”)
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S10 TX allocat* random*
S11 “randomi#ed control* trial*”
S12 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S13 S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12
S14 S1 AND S13
[Lines S2-S13 are the SIGN filter for RCTs adapted for CINAHL via EBSCO].
Appendix 7. Trials registers search strategy
((tinea or tina) and (capitis or tonsurans or tonsurante)) or kerion or querion or (ringworm and (hair or scalp or head))
WH A T ’ S N E W
Last assessed as up-to-date: 23 November 2015.
Date Event Description
4 May 2016 New search has been performed We included 4 new randomised controlled trials in this up-
date, which changed some of the main results
4 May 2016 New citation required and conclusions have changed The conclusions of the previous version of the review have
been altered
H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 4, 2007
Date Event Description
21 July 2008 Amended Converted to new review format
22 August 2007 New citation required and conclusions have changed Substantive amendment
30 May 2007 New search has been performed Minor update
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S O U R C E S O F S U P P O R T
Internal sources
• Spanish Society of Dermato-Epidemiology and Evidence-based Dermatology (SEDE-DBE) and Clínica Plató, Barcelona, Spain.
External sources
• Cochrane Child Health Field. Alberta Research Centre for Child Health Evidence, University of Alberta, Canada.
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Background: We updated and revised the text in the ’Description of the intervention and ’How the intervention might work’ sections
of the Background.
Types of interventions: In the protocol we planned to look at doses of drugs. We omitted this from the review and update because
the doses and formulations of drugs varied significantly across studies, and it was impossible and not clinically important to merge the
relevant results from different studies.
Types of outcome measures: In the protocol, resolution of hair loss was one of the primary outcome measures of clinical cure. We
omitted this from the original review and update, as hair loss is a clinical sign of tinea capitis, and the improvement of hair loss is
usually considered a sign of our primary outcome of clinical cure.
We removed the secondary outcome from the protocol, “proportion of participants with partial clinical improvement” in this update
because it is hard to define “partial clinical improvement”.
Search methods: We changed the databases that we planned to search in the protocol, because of lack of access to some of the databases
we originally planned to search and changes to standard search routines. We did not update the adverse events search undertaken in
2005.
Data collection and analysis: We updated the format of the review and used the pre-set subheadings available in Revman 2014.
We organised our information about methods into the headings of: Measures of treatment effect; Unit of analysis issues; Dealing
with missing data; Assessment of heterogeneity; Assessment of reporting biases; Data synthesis; Subgroup analysis and investigation of
heterogeneity; and Sensitivity analysis.
Data synthesis: In the original protocol, we failed to specify the acceptable window for the timing of the primary outcome assessment.
We decided during the course of the review to combine studies that recorded primary outcomes at between 12 to 20 weeks on the basis
that these are the range of time periods that best reflect clinical decision-making in practice.
Subgroup analysis and investigation of heterogeneity: there were too few studies in each comparison or outcome to perform subgroup
analysis as planned in the protocol.
Sensitivity analysis: In the protocol we planned to conduct sensitivity analyses but there too few studies in each comparison or outcome
to perform sensitivity analyses.
In this update we have produced ’Summary of findings’ tables for the primary outcomes/comparisons, which were not a requirement
when the protocol and review were published.
In this update, we modified the ’Risk of bias’ tables for all included studies based on the new Cochrane ’Risk of bias’ assessment tool
and included details of how we assessed risk of bias in the ’Methods’ section.
We modified our methods for analysing cross-over trials and trials with more than one treatment arm. We did not consider internally
controlled trials, such as those with cross-over andwithin-participant designs, because evenwith awashout period, they are inappropriate
designs for systemic treatment (because effects of antifungal therapy may endure over the washout period as most patients would
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experience a cure or at least some improvement in the first period of a cross-over study). For RCTs with multiple intervention groups,
we combined groups to a single pair-wise comparison as recommended by Cochrane (Higgins 2011).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antifungal Agents [∗therapeutic use]; Fluconazole [therapeutic use]; Griseofulvin [therapeutic use]; Itraconazole [therapeutic use];
Naphthalenes [therapeutic use]; Randomized Controlled Trials as Topic; Tinea Capitis [∗drug therapy]
MeSH check words
Child; Humans
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